Novel Analgesics and the Impact of Route of Administration in the Horse

by

Heather Ayn Davis

A dissertation submitted to the Graduate Faculty of Auburn University in partial fulfillment of the requirements for the Degree of Doctor of Philosophy

Auburn, Alabama December 14, 2019

Keywords: Absorption, Cannabinoid, Equine, Firocoxib, Pharmacokinetics, Peritonitis

Copyright 2019 by Heather A. Davis

Approved by

Dr. Dawn Merton Boothe, Chair, Professor, Anatomy, Physiology Pharmacology
Dr. Reid Hanson, Professor, Clinical Sciences
Dr. Robert Judd, Professor, Anatomy, Physiology, Pharmacology
Dr. John Schumacher, Professor Emeritus, Clinical Sciences
Dr. Jennifer Taintor, Associate Professor, Clinical Sciences
# Table of Contents

Acknowledgments......................................................................................................................... 8

Abstract........................................................................................................................................ 9

List of Figures.................................................................................................................................. 12

Chapter 1. Clinical Pharmacology and Drug Movement in the Equine Patient ...................... 16

Absorption....................................................................................................................................... 17

*Equine Anatomy*............................................................................................................................. 17

*Physiochemical Factors Affecting Oral Drug Absorption* ............................................................... 25

*Formulation Effects on Oral Drug Absorption*................................................................................. 27

*Physiological Factors Governing Oral Drug Absorption* ................................................................. 28

*Rectal Absorption in the Equine Patient* ......................................................................................... 32

Modeling Oral Drug Absorption in the Horse ................................................................................. 35

Modeling Rectal Drug Absorption in the Horse ............................................................................... 39

Distribution...................................................................................................................................... 43

Metabolism....................................................................................................................................... 46

Elimination........................................................................................................................................ 49


Effects of Pain................................................................................................................................... 52

Somatic Pain.................................................................................................................................... 56

*Pathway and Transmission*............................................................................................................... 56
Chapter 3. Pilot Study: Non-septic, transient, peritonitis model for use in evaluating drug movement in the equine patient

Abstract

Introduction

Materials and Methods

Animals

Peritonitis Induction Model

Evaluation of Peritonitis Induction Model

Statistical Analysis

Results

Discussion

Chapter 4. Impact of Route, Volume, and Fed/Fasted State on Acetaminophen Disposition after Oral Administration in the Horse

Abstract

Introduction

Materials and Methods

Animals
Materials & Methods ........................................................................................................ 132

Animals ................................................................................................................................ 132

Drug Administration .......................................................................................................... 132

Sample Collection ............................................................................................................... 133

Sample Analysis ................................................................................................................ 134

Pharmacokinetic Analysis ................................................................................................. 134

Results .................................................................................................................................. 136

Discussion .......................................................................................................................... 140

Chapter 7. Cannabinoid Pharmacology .......................................................................... 142

Cannabinoid Receptor ........................................................................................................ 142

Cannabinoid Ligands .......................................................................................................... 146

Pharmacokinetics of Cannabinoids .................................................................................. 150

Absorption ........................................................................................................................ 150

Distribution ........................................................................................................................ 155

Metabolism ........................................................................................................................ 157

Elimination ........................................................................................................................ 159

Pharmacodynamic Effects on People ............................................................................... 161

Pharmacodynamic Effects on Dogs ................................................................................. 163

Chapter 8. Pharmacokinetic and pharmacodynamics characterization of a CBD oil in the horse after oral and transmucosal administration ................................................. 164
Abstract .................................................................................................................................................. 164

Introduction ............................................................................................................................................... 165

Materials & Methods ................................................................................................................................. 167

Pilot Study .................................................................................................................................................. 167

Animals ...................................................................................................................................................... 168

Sample Collection ...................................................................................................................................... 168

Pharmacodynamic Assessment .................................................................................................................. 169

Sample Analysis ......................................................................................................................................... 170

Pharmacokinetic Analysis .......................................................................................................................... 172

Results ....................................................................................................................................................... 173

Discussion .................................................................................................................................................. 179

Potential Therapeutic Targets of Cannabinoids .......................................................................................... 184

Central Nervous System .............................................................................................................................. 184

Cancer ....................................................................................................................................................... 186

Ocular ......................................................................................................................................................... 187

Chapter 9. Conclusion Chapter and Potential Therapeutic Topics .............................................................. 188

Novel Development - Peritonitis Model ...................................................................................................... 188

Impact of Route and Volume on Drug Absorption in the Equine Patient .................................................... 190

Formulation Effect on Drug Absorption ...................................................................................................... 192

Comparison of Oral to Rectal Administration ........................................................................................... 194
Further Advances in Equine Pain Management ................................................................. 197

References ............................................................................................................................. 202
Acknowledgments

This manuscript is in honor of my grandparents, Byron “Whitey” and Helyn Madeline Davis, who taught me the importance of forgiveness, compassion, being kind to animals, and the value of a dollar. Without your continued guidance and support, I would not have been able to accomplish all of my dreams.

To the ≥3.75 legged guardian angels who weathered this journey by my side (Jude, Challenge, Anna May, Firebomb, Eis Vogel, Clarice Starling, and Hannibal Lector). Thank you for being larger than life personalities, steadfast companions, and giving me a reason to fight.

Drs. Jennifer Taintor and Amanda Crouthamel, Crisanta Cruz-Espindola, Roy Harmon, as well as the AU LAC Teaching Horses, without your organization, determination, and cooperation none of the work within this dissertation would have been possible.

Finally, my sincerest gratitude to the patience of my committee – this has been a very long, sometimes tortuous road, and there are not words to truly express how thankful I am for your continued faith in my ability to accomplish this goal.
Abstract

The primary goal of this dissertation was to describe the disposition of novel analgesics and the impact of their administration on the equine patient. In order to support this aim, a novel, non-septic, transient model of peritonitis was characterized for use in evaluating drug movement in an inflamed abdomen. Using acetaminophen as a marker of oral drug absorption, the impacts of both route (nasogastric tube administration vs. syringe) and volume (1.5 L vs. 100 mL) administered on drug disposition were compared. From this, placement of a nasogastric tube and larger volumes of water used for dissolution improved absorption of acetaminophen. Firocoxib was used to evaluate formulation effect on oral absorption. From this, it was determined that both the canine chewable tablet and equine paste were found to be equally bioavailable. Zonisamide was evaluated in a simple crossover study to assess both oral and rectal administration of the anti-epileptic drug. A pharmacokinetic profile was generated for oral route; however, the active ingredient did not prove to be rectally absorbed. Finally, two cannabidiol products were profiled after both oral and transmucosal administration. Consistent with human and canine studies, it appears transmucosal administration improves absorption of the product and lends itself for further work. Overall, this dissertation demonstrates the importance of scientifically studying both route and formulation prior to administration to the equine patient rather than making assumptions of drug movement based on work performed in other species.
List of Tables

Chapter 3. Pilot Study: Non-septic, transient, peritonitis model for use in evaluating drug movement in the equine patient .......................................................... 71

Results ........................................................................................................... 78

Table 3.1. Subjective abnormal abdominal ultrasound findings of horses after being treated with intraabominal infusion of autologous plasma, crystalloid solution and heparin, and whole blood (n=7). ........................................................................................................ 79

Table 3.2. Peritoneal nucleated cell counts for each treatment group for each time point post treatment (n=13). ........................................................................................................ 81

Table 3.3. Peritoneal total protein values for each treatment group for each time point post treatment (n=13). ........................................................................................................ 84

Chapter 4. Impact of Route, Volume, and Fed/Fasted State on Acetaminophen Disposition after Oral Administration in the Horse ........................................................................ 91

Materials and Methods .................................................................................. 94

Table 4.1. Treatment group descriptions and paired comparisons (n=6) horses per grouping. ........................................................................................................ 94

Results ........................................................................................................... 98

Table 4.2. Mean pharmacokinetic parameters for acetaminophen when administered in apparently healthy horses (n=6) ........................................................................................................ 99

Chapter 5. Clinical Application of Firocoxib Canine Chews in Equine Practice .............. 109

Results ........................................................................................................... 118
Table 5.1. Mean pharmacokinetic parameters for firocoxib when administered as either canine chews or equine paste in apparently healthy horses (n=8) ............................................. 120

Table 5.2. Percent difference between firocoxib concentrations after being stored in either glass or plastic tubes for 60 hours. .................................................................................. 122

Chapter 6. Pilot Study: Pharmacokinetics of the Antiepileptic Drug Zonisamide after Oral and Rectal Administration in the Horse .............................................................................. 128

Results .................................................................................................................................................................. 136

Table 6.1. Combined pharmacokinetic parameters after oral administration of 10 and 20 mg/kg n of zonisamide in apparently healthy horses (n=8) .......................................................... 137

Chapter 7. Cannabinoid Pharmacology ........................................................................................................... 142

Table 7.1. Cannabinoid and receptor relationships with corresponding response. .............. 149

Chapter 8. Pharmacokinetic and pharmacodynamics characterization of a CBD oil in the horse after oral and transmucosal administration ........................................................................... 164

Results .................................................................................................................................................................. 173

Table 8.1. Mean pharmacokinetic parameters for CBD when administered in apparently healthy horses (n=10). ........................................................................................................ 174

Table 8.2. Evaluation of sedation for horses (n=13) over the first 24 hours after administration ........................................................................................................................... 177
List of Figures

Chapter 3. Pilot Study: Non-septic, transient, peritonitis model for use in evaluating drug movement in the equine patient

Results

Figure 3.1. Peritoneal nucleated cell counts comparing treatment groups abdominocentesis (n=1), whole blood with heparin (n = 2), and whole blood only (n= 6).

Figure 3.2. Peritoneal nucleated cell counts comparing treatment groups crystalloid fluid infusion (n=1), crystalloid fluid with heparin (n = 2), and autologous plasma (n= 1).

Figure 3.3. Peritoneal total protein comparing treatment groups abdominocentesis (n=1), whole blood with heparin (n = 2), and whole blood only (n= 6).

Figure 3.4. Peritoneal total protein comparing treatment groups crystalloid fluid infusion (n=1), crystalloid fluid with heparin (n = 2), and autologous plasma (n= 1).

Chapter 4. Impact of Route, Volume, and Fed/Fasted State on Acetaminophen Disposition after Oral Administration in the Horse

Results

Figure 4.1. Serum acetaminophen concentrations comparing route of administration between Group 1 (SYR 100 mL) to Group 2 (NGT 100 mL) (n= 6).

Figure 4.2. Serum acetaminophen concentrations comparing volume of administration Group 2 (NGT 100 mL) to Group 3 (NGT 1.5 L) (n = 6).

Figure 4.3. Serum acetaminophen concentrations comparing treatment Group 3 (NGT 1.5L) to Group 4 (NF NGT 1.5L) (n=6).
Chapter 5. Clinical Application of Firocoxib Canine Chews in Equine Practice

Results

Figure 5.1. Firocoxib mean plasma drug concentrations (with SE) versus time in 8 apparently healthy horses when administered at 0.3 mg/ kg as three different formulations.

Chapter 6. Pilot Study: Pharmacokinetics of the Antiepileptic Drug Zonisamide after Oral and Rectal Administration in the Horse

Results

Figure 6.1. Combined oral dosing (10 and 20 mg/kg) of serum zonisamide concentrations plotted against time course of study (n=8).

Figure 6.2. Serum zonisamide concentrations plotted against time in apparently normal horses receiving zonisamide at either 10 mg/kg (n= 4) or 20 mg/kg (n= 4).

Chapter 8. Pharmacokinetic and pharmacodynamics characterization of a CBD oil in the horse after oral and transmucosal administration

Results

Figure 8.1. Serum equine cannabinoid concentrations (CBD and Δ9 THC) with corresponding standard deviations over the time course of the study (n=13).

Figure 8.2. Evaluation of sedation and serum CBD concentration for horses (n=13) over the first 24 hours after administration in graphical form.
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>ANOVA</td>
<td>Analysis of Variance</td>
</tr>
<tr>
<td>AUC</td>
<td>Area Under the Curve</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt;</td>
<td>Maximum Plasma/Serum Drug Concentration</td>
</tr>
<tr>
<td>C&lt;sub&gt;0&lt;/sub&gt;</td>
<td>Maximum Plasma/Serum Drug Concentration after Intravenous Administration</td>
</tr>
<tr>
<td>°C</td>
<td>Degrees Celsius</td>
</tr>
<tr>
<td>CL</td>
<td>Clearance</td>
</tr>
<tr>
<td>F</td>
<td>Absolute Bioavailability</td>
</tr>
<tr>
<td>°F</td>
<td>Degrees Fahrenheit</td>
</tr>
<tr>
<td>g</td>
<td>Gravity</td>
</tr>
<tr>
<td>h</td>
<td>Hour</td>
</tr>
<tr>
<td>HPLC</td>
<td>High Pressure Liquid Chromatography</td>
</tr>
<tr>
<td>L</td>
<td>Liters</td>
</tr>
<tr>
<td>MAT</td>
<td>Mean Absorption Time</td>
</tr>
<tr>
<td>mg</td>
<td>Milligrams</td>
</tr>
<tr>
<td>mL</td>
<td>Milliliters</td>
</tr>
<tr>
<td>MAT</td>
<td>Mean Absorbance Time</td>
</tr>
<tr>
<td>MRT</td>
<td>Mean Residence Time</td>
</tr>
<tr>
<td>Abbreviation</td>
<td>Definition</td>
</tr>
<tr>
<td>-------------</td>
<td>------------------------------------------------</td>
</tr>
<tr>
<td>NF</td>
<td>Non Fasted</td>
</tr>
<tr>
<td>ng</td>
<td>Nanograms</td>
</tr>
<tr>
<td>nm</td>
<td>Nanometers</td>
</tr>
<tr>
<td>NSAID</td>
<td>Non Steroidal Anti-Inflammatory Drug</td>
</tr>
<tr>
<td>NGT</td>
<td>Nasogastric Tube</td>
</tr>
<tr>
<td>PO</td>
<td>Per os</td>
</tr>
<tr>
<td>PR</td>
<td>Per rectum</td>
</tr>
<tr>
<td>rpm</td>
<td>Revolutions per Minute</td>
</tr>
<tr>
<td>r²</td>
<td>Coefficient of Variation</td>
</tr>
<tr>
<td>RSD</td>
<td>Relative Measurement of Uncertainty</td>
</tr>
<tr>
<td>SPE</td>
<td>Solid Phase Extraction</td>
</tr>
<tr>
<td>SYR</td>
<td>Syringe</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt;</td>
<td>Time to Maximum Plasma/Serum Drug Concentration</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt;</td>
<td>Elimination Half-Life</td>
</tr>
<tr>
<td>UV</td>
<td>Ultraviolet</td>
</tr>
</tbody>
</table>
Chapter 1. Clinical Pharmacology and Drug Movement in the Equine Patient

“I wanted to be a pharmacologist the day I stood in the ICU,
my patient was on more drugs than I could count,
and we had no idea how they would work together/against one another”

-Dr. Dawn Boothe

In order to achieve a desired clinical effect, such as management of pain in the equine patient, plasma drug concentrations of the therapeutic agent used for intervention must reach suitable levels to drive response. Plasma drug concentrations reflect the sum effect of four simultaneous drug movements: absorption, distribution, metabolism, and excretion. Alterations in physiology secondary to pathology plays a large role in how drugs move within the body and jeopardize effectiveness of the drug molecule being administered. Also, use of multiple drugs within a patient may enhance or inhibit the movement and ultimate effectiveness of a drug molecule within the patient. As a clinician, understanding the fundamentals of drug movement is critical to selecting the appropriate therapy in both acute as well as chronic conditions.
Absorption

In the eyes of people unfamiliar with medicine or pharmacology, when patients (two or four legged) receive a medication, once in the body, the drug works “magic” to treat the pathology of disease. However, the body, human or animal, is not a black box where pharmacology “magic” occurs. Instead, once a drug formulation is administered to a patient, a series of very important steps must occur in order for the active ingredient to be effective at the site of pathology. Similar to life where two things are for certain (death and taxes), a drug product will undergo all or a portion of four major components of drug movement: absorption, distribution, metabolism, and excretion.

Depending on how the drug is administer to the patient, there are often multiple steps required prior to reaching the target tissue for treating pathologies. The first step along this path is absorption of the formulation itself. Absorption is defined as the movement of the drug from the site of administration into the blood (Boothe; Riviere). In this dissertation, four routes of administration have been evaluated as they relate to modulators of pain management in the equine patient: oral, transmucosal, rectal, and intravenous and the focus of the enclosed chapter will be focused on characterizing drug movement as it relates to these routes of delivery.

Equine Anatomy

In order to understand oral and rectal absorption, one must first understand the anatomic configuration as well as function of each of the organs within the equine gastrointestinal tract and their contributing factors to the digestion and absorption of a drug.

The gastrointestinal tract is unique in that it serves as a protective barrier from the external environment while also serving to facilitate the absorption of nutrients from the ingested
food particulate. No matter if the substance is nutritional, supportive, or a drug, if administered orally, the molecule must be processed by the gastrointestinal tract prior to absorption into the blood stream. In so doing, the molecule must be able to withstand the intraluminal gastrointestinal environment (Florence).

All organs of the gastrointestinal tract are composed of four layers. Extending from the lumen outward are: the mucosa, submucosa, muscularis mucosa, and serosa. The structure of the innermost mucosal layer has configurations and cellular components which are organ specific. The muscularis mucosa is composed of a thin inner lamella and an outer, thicker lamella that have specific roles in gastrointestinal motility. Finally, the serosal layer is the primary protectant layer of the gastrointestinal tract (Auer J.A.).

After oral ingestion and transport through the esophagus, the first gastrointestinal organ a drug encounters are the stomach, which has a capacity of storing 5-15L of ingesta in the equine patient. The cardia of the equine stomach is attached to the diaphragm by the gastrophrenic ligament, the fundus lies adjacent to the 14th and 15th rib spaces, and the pylorus being position on the right side of midline. The equine stomach’s primary arterial blood supply is the celiac artery and drainage occurs through the gastric veins which feeds primarily into the portal vein (Auer J.A.).

There are four regions of the equine stomach: cardiac epithelium, non-glandular stratified squamous epithelium, proper gastric mucosa (glandular mucosa), and pyloric mucosa. In the equine stomach, approximately half of the mucosal surface area is composed of stratified, squamous epithelium. This area of the stomach lacks secretory ability, does not frequently come into contact with the ingesta contents, and may serve as a protective mechanism from abrasion by roughage consumed by the horse. Unique to the horse, there is a distinct division between the
secretory and non-secretory portion of the stomach. This line, the margo plicatus, indicates an abrupt change from the stratified squamous epithelium to the glandular mucosa. The glandular mucosa of the equine stomach is composed of a variety of cells responsible for secreting critical substances necessary for digestion. Within the gastric mucosa, parietal cells secrete hydrochloric acid and enterochromaffin cells secrete histamine. Within the pyloric region, G-cells secrete gastrin which enhances gastric acid secretion and D cells secrete somatostatin which is a negative feedback chemical to decrease gastric acid secretion. The glandular portion of the stomach is protected from back diffusion of hydrogen ions from the hydrochloric acid by tight connections between the mucosal lining (high transepithelial electrical resistance) as well as secretion of mucous and bicarbonate (Auer J.A.). Along the luminal aspect of the cellular lining of the stomach is a layer of surface mucous which serves as a protective barrier protecting the self-digestion secondary to exposure of acid and enzyme secretions (Boothe; Riviere).

Following the stomach is the small intestine which is composed of the duodenum, jejunum, and the ileum, and varies from 10-30 m in length. The duodenum, approximately one meter in length, extends from the pylorus right of midline along the right dorsal abdomen to a point caudal the root of the mesentery. Blood flow to the duodenum is split with the cranial half being supplied by the celiac artery and the caudal half being fed by a branch off of the cranial mesenteric artery. Despite horses lacking a gall bladder, they are similar to other mammalian species by having both a major and minor papilla which serve as an opening for the bile as well as primary and accessory pancreatic ducting (Auer J.A.).

The jejunum, approximately 17-28 m in length, can be found in the left dorsal quadrant of the abdomen between loops of the small colon. Nutrient digestion as well as the large portion of drug absorption takes place within the cranial half of the small intestine. In order to facilitate
this, the arterial blood supply to the jejunum is extensive. The arterial supply originates from the cranial mesenteric artery and the subsequent vascular arcades consists of a major jejunal vessel with several branching vasa recta that pass from the arcuate vessels into the intestinal wall.

Running parallel beside the extensive arterial supply to the jejunum is the venous network, which enter the portal vein to provide venous drainage from the small intestine (Auer J.A.).

The small intestine is the most important site of absorption in the mammalian body. The entire lining of the small intestine surface has fingerlike projections, known as villi, which extend into the lumen of the small intestine. From these villi are secondary projections known as microvilli, or the brush border, which also represent the final large increase in surface area of the small intestine. Ninety percent of the brush border is composed of columnar, enterocyte epithelium capable of absorption. Of these cells, only the upper third are capable of surface digestion of nutrients and active transport of digestive products. These enterocytes undergo a process known as restitution, where within two to three days (or two cell divisions) cells migrate from the villous crypts to the villi tip. The apical surface of the enterocytes is also coated with weakly acidic sulfated mucopolysaccharides which serve as a relatively impermeable barrier to bacteria and other foreign materials; however, these substrates do contribute to digestion of carbohydrates, proteins, as well as transport of molecules (Boothe; Florence; Riviere).

The entire lining of the small intestine is a continuous sheet of epithelial cells (enterocytes, mucous producing goblet cells, enteroendocrine and Paneth cells), held together at their base via tight junctions basal plasma membrane. These epithelial cells are equipped with metabolizing enzymes that can break down drug products at first exposure, resulting in a decreased amount of drug to be available to the blood stream (Boothe; Riviere).
The tight junctions between enterocytes minimize transmucosal flux of large molecules but are permeable to water as well as low molecular weight molecules. These tight junctions and intracellular space form a paracellular channel, which expand during water absorption. Beneath the basal membrane is the lamina propria. The lamina propria serves as a connective tissue structure that has a variety of cell types including blood and lymph vessels as well as nerve fibers. Once a drug molecule has reached this area, it may diffuse through the capillary membrane and enter systemic circulation, or it may penetrate the central lacteal and enter into the lymph. Central lacteals, a cavernous opening in the villi itself that feeds into the lymphatic system, are important for the absorption of triglycerides or emulsified fats in the forms of chylomicrons (larger than 0.5 micron in diameter). Most drugs reach the blood stream through the capillaries in the villi due to their large number since the area is highly and rapidly perfused by the blood stream. The capillary membranes themselves are more substantial barrier than those seen in the lymphatic system. Molecules that have extremely large oil/water partition coefficients (> $10^5$) such as drugs and insecticides will enter the systemic circulation through the lymph flow. In cases where there is decreased blood flow to the gastrointestinal tract, drug absorption through the lymphatic system may become more important (Auer J.A.; Boothe; Florence; Riviere).

The final mucosal layer, the muscularis mucosa, is comprised of smooth muscle layers three to ten cells thick. As ingesta moves into an area, both muscular layers relax to accommodate the bolus. Working together, the inner, circular layer contracts around the bolus while the outer, longitudinal muscle layer propulses the ingesta along the gastrointestinal tract. The rhythmic segmentation in the circular smooth muscle followed by the synchronous
shortening of the longitudinal muscle layer creates the peristaltic movement that moves the food bolus in an aboral direction (Auer J.A.; Florence).

Below the muscularis mucosa lies the lamina propria, which is composed of connective tissue, blood and lymph vessels as well as nerve fibers. All of the blood, lymph, and nervous intervention servicing a particular area of the gastrointestinal tract must pass through the lamina propria to reach their designated area (Auer J.A.).

Control of motility of the gastrointestinal tract is mediated by hormonal, neuronal, and mechanical processes. Coordinated release of both excitatory and inhibitory neurotransmitters coordinate the peristaltic reflex responsible for propulsive activity. The gastrointestinal tract receives neuronal stimulation from the vagus nerve, components of the sympathetic nervous system, and the enteric nervous system. The enteric nervous system is composed of both the myenteric and submucosa plexus. The myenteric plexus, also known as the Auerbach’s plexus, is the main source of longitudinal muscle innervation and the outer lamella of circular muscle. The submucosal plexus, Messner’s plexus, innervates the inner lamella of circular muscle contributing to contraction (Auer J.A.).

Myoelectric activity is based on both slow wave and spike potential wave neurotransmission that results in the contraction of both circular as well as longitudinal muscle layers contributing to gastrointestinal motility. Within the longitudinal layers of smooth muscle are the interstitial cells of cajal, these are the pacemakers of the cell and help create a rhythm of peristalsis. The rhythmicity of contractions is mediated by the slow wave oscillations generated by these cells. The slow wave potentials are greater at the duodenum, and less at the ileum. The frequencies of the slow waves determine the maximal frequency of the action potentials. If the smooth muscle slow wave oscillation drops below a threshold (amount), there is a rapid
depolarization, leading to intestinal contractions. Spike potentials can be initiated through mechanical stretch, neural, or hormonal stimuli (Auer J.A.).

Migrating motor complex (MMC) is consistently present during the interdigestive state between meals to facilitate movement of ingesta as well as minimize colonization of the small intestine. There are three phases of the MMC that facilitate peristalsis. In Phase One, there are no action potentials or spiking activity and slow wave movements are the only stimulation present. During Phase Two, there are intermittent or irregular spiking activity (ISA) where the slow waves are continually present but there are intermittent action potentials. Finally, during Phase Three, there is regular spiking activity where there is an action potential for every slow wave. This results in intense, sustained contractions. By using Phases Two and Three, most of a meal is moved through the small intestine. Motilin, a neurotransmitter released during fasting, acts on smooth muscle to regulate interdigestive MMC (Auer J.A.).

When a horse is orally dosed, movement of a solid dosage form out into the small intestine is dependent upon the stomach’s MMC phase at the time of dosing. The gastric residence time, the amount of time the dosage form stays in the stomach, will vary from minutes to hours depending on what stage the stomach is in when the form enters. This variability in residence time may help to explain some of the intersubjective variation in absorption profiles. For liquid dosage forms, the migrating motor complex does not apply as most of them are able to empty during all phases of the complex (Florence).

Mixing movements are a result of smooth muscle contractions which narrow the lumen of the intestine to facilitate the contact of ingesta with intestinal secretions as well as with the surface epithelium where there is increased surface area to facilitate absorption. The mixing
movements will increase the contact area between drug and membrane, causing an increase in rate of absorption (Auer J.A.; Florence).

After a meal, these peristaltic waves are increased as a result of the gastroenteric reflex initiated by the distention of the stomach. This movement determines intestinal transit time and pharmacologically dictates the drug residence time in the intestine. Residence time in the gastrointestinal tract is important because it determines how long the drug formulation has in order to release the active ingredient from the formulation state. Thus, the shorter the amount of time it takes to move through the gastrointestinal tract, the less time the drug has to release. Shortened transit time will significantly alter absorption of drugs that are poorly water soluble, enteric or polymer coated dosage forms and sustained release forms.

The last portion of the small intestine, the ileum, is approximately 0.7 m long and is marked by an ileocecal fold that attaches its antimesenteric side to the dorsal band of the cecum. The arterial supply of the ileum is provided by the ileocecal artery which is a branch from the cranial mesenteric artery. In horses, the primary responsibility of the cecum and large colon is to absorb water and electrolytes as well as serving as the primary site of microbial digestion. In microbial digestion, soluble and insoluble dietary carbohydrates are digested by microbial enzymes with the production of volatile fatty acids. In contrast to humans, the colon is thought to provide a good environment for drug absorption due to its mild pH, little enzymatic activity, and long residence time. However, limitations of the colon include small surface area, relatively viscous fluid like environment, and large colonies of bacteria (Auer J.A.; Florence).

Finally, the equine rectum, approximately 20-30 cm long, stretches from the pelvic inlet to the anus. It has been found to be shorter in young horses and those with little body fat. Venous drainage of the orad portion occurs via the caudal mesenteric vessels which directly
empty into the portal circulation. The distal portion of the rectum is drained by the internal iliac or pudendal veins which flow into the caudal vena cava. After administration, drugs may be absorbed across the epithelial cells (transcellular) or through the tight junctions that connect the mucosal cells (paracellular). In humans, there is a risk of the drug formulation diffusing up from the rectum into the small colon with an increased amount of fluid volume used in infusion. In horses, however, this is less of a concern due to the increased physical length and size of the rectal vault (Auer J.A.; Broome T.A.; d. B. van Hoogdalem E.J.).

**Physiochemical Factors Affecting Oral Drug Absorption**

Physiochemical characteristics involve the interaction between the dosage form and anything that would alter the solubility, dissolution, or chemical stability within the gastrointestinal tract. A drug must possess some aqueous solubility and membrane permeability in order to enter the systemic circulation and exert a therapeutic effect on the patient. Biologic membranes act as a lipid barrier to most drugs and allow lipid soluble drug molecules to be absorbed by passive diffusion and lipid-insoluble substances to diffuse only with difficulty or not at all. The primary properties influencing passive absorption across biological membranes are its oil:water partition coefficient, pH of the fluid that it is dissolved in, and the active ingredient’s molecular weight (Ansel; Boothe; Florence).

The oil:water partition coefficient is the measure of a molecule’s lipophilic character. With the exception of small, polar molecules, most compounds pass biological membranes through the lipid membranes. The ability of the compound to traverse the membrane is based on the atomic and molecular forces. The ability of a compound to move through a lipid and water portions of the lipid membrane is based on the forces interacting with the solute in each area. If
the solute-water interaction is greater than the solute-membrane interaction, membrane permeability will be relatively poor and vice versa. The ability of the molecule to move through the membrane increases as the number of carbons and hydrogens within the structure increases. With an increased carbon chain length, there is an increased ability of the compound to be “pushed out” of the aqueous phase and into the cellular membrane.

The rate of diffusion of a compound across a membrane depends on the concentration gradient across the membrane, the lipid:water patrician coefficient, and diffusion coefficient. The diffusion coefficient is a function of molecular size, conformation, as well as degree of ionization. Depending on which membrane the drug molecule is trying to cross, there is a functional size and/or weight cut off that prevents a molecule from being absorbed across any membrane. Membranes also favor non-ionized forms of drug molecules. The ionized form of the drug will be completely prevented from crossing the membrane due to its low lipid solubility (Ansel; Boothe; Riviere).

If a chemical candidate has two or more of the following, it is likely to have decreased absorption capabilities: more than five hydrogen bond donors, more than 10 hydrogen bond acceptors, molecular weight greater than 500, and a Log $K_{o/w}$ greater than five. In these cases, chemical modification of the drug into a salt or ester form is frequently used to increase solubility (Ansel; Boothe; Florence).

Most drug molecules in development are either weak acids or bases and after administration will to some extent be ionized depending on the drug molecule’s $pK_a$ (negative logarithm of the acidic dissociation constant) and the $pH$ of the biological fluid where it is dissolved. The rate of penetration of a drug molecule is enhanced if the molecule is present in an environment with a similar $pH$. Compounds are able to cross anatomic membranes if they are
present in their nonionized form due to nonionic diffusion. This happens when the pH of the medium is equal to the pKa of the dissolved drug, and at this time 50% of the drug exists in the ionized state and 50% in the nonionized, lipid soluble state.

Use of the Henderson-Hasselbalch equation enables the determination of the ratio of protonated (H) to non-protonated molecules. From this, acidic drugs would be best absorbed from acidic solutions where the pH is less than the pKa. In contrast, basic drugs would be best absorbed from environments that are more basic such that the pH is greater than the pKa. When the pH unit is one unit less or more than the pKa, there is tenfold difference in the ratio of ionized to unionized drug molecules. In this phenomena, it allows for a drug to be differentially distributed across a membrane in the presence of a pH gradient. Also, it has also been hypothesized that there are different pH levels depending on the location within the lumen of the intestine such as in the middle of the visceral structure the ingest may be a more basic than the pH at the immediate surface of the intestinal membrane. This may be the reason why many drugs which should be present in the ionic form are still well absorbed from the gastrointestinal tract. The primary limitation that cannot be over looked is that ionized drug is also absorbed albeit at a slower rate (Ansel; Boothe; Florence; Riviere).

*Formulation Effects on Oral Drug Absorption*

Not only do oral dosage forms provide a safe and convenient delivery mechanism for administration of an active ingredient. Dosage forms are necessary because they: protect the drug substance from environmental influences (humidity and oxygen), prevent degradation by gastric acid, conceal the bitter, salty or offensive taste or odor, or provide a rate controlled release from the products (Ansel). Many factors effect an active ingredient’s ability to be
absorbed in a patient’s body. How an active ingredient is formulated, meaning how the drug is prepared for commercialization, takes three important factors into account: disintegration, dissolution, and diffusion. Each of these factors directly influence how the matrix is broken down and the active ingredient becomes liberated in order to be available to absorb into the patient’s body.

Dissolution of a drug from its formulation is often the slowest process of drug absorption and the rate is greatly affected by the pH of the environment within the lumen of the gastrointestinal tract. The pH of the ingesta is important to consider as most drug formulations are weak acids or bases and the aqueous solubility of these compounds are influenced by the rate of dissolution from the dosage form. Drugs that are acidic in nature are more readily dissolved in the basic environment of the small intestine in comparison to the acid environment of the stomach. In contrast, drugs that have a basic pH will dissolve more readily in gastric fluid. A variety of preparations using binding agents, disintegrants, various salts, or esters influence where the formulation is degraded and dissolved in the gastrointestinal tract. Use of polymers may also be used to coat granules or tablets that are designed to dissolve at a specific desired pH which ultimately protects the drug from degradation in unwanted pH’s that will maximize absorption profile for the drug (Ansel; Boothe; Florence; Riviere).

**Physiological Factors Governing Oral Drug Absorption**

Fundamentals of oral drug absorption include achieving drug concentrations in a rapid, efficient manner such that the relationship between drug concentration in the body and the magnitude of therapeutic response can be appreciated. Physiological factors include the time it takes for the dosage form to pass through the tract (residence time) and blood flow to the
membrane. Items that affect the drug molecule moving across the membrane are: size of the drug molecule, pH of the ingesta, characterization of the drug molecule, and presence of molecules that can interact or bind the drug molecule (Boothe; Florence; Riviere).

Small, polar molecules (less than 500 Da) with an oil:water coefficient less than one are able to move between cells lining the gastrointestinal cells through tight junctions. This is known as the paracellular absorption.

The characteristics of aqueous gastrointestinal fluids will affect the drug dosage form as well as the pattern of drug absorption. The first of these to consider is pH, which varies considerably along the length of the gastrointestinal tract. Once released by the pylorus into the duodenum, the pH of the ingesta rapidly increases due to the release of bicarbonate from the pancreas that helps to neutralize gastric acid to avoid damage to the epithelial lining of gastrointestinal tract. The bicarbonate also helps to prevent inactivation of the digestive enzymes released by the pancreas as well as prevent precipitation of bile acids which are poorly soluble in acidic pH. The pH gradually increases as the ingesta moves aborally. There are marked differences in starting and ending point of pH depending on the species (Boothe; Florence; Riviere).

Passive absorption requires no energy for transport of a drug molecule across a membrane. This means that the drug components pass from the apical surface through the cell and to the basolateral membrane. This is known as the transcellular route. The driving force of diffusion across the membrane is the concentration gradient of the compound across the membrane itself. This simply means that the rate of absorption should increase directly with an increase in drug concentration in the gastrointestinal fluids. This idea is best described by Fick’s first law of diffusion where the rate of drug absorption is dependent on the membrane surface
area available for diffusion, thus more rapid absorption is achieved through the small intestine in comparison to the stomach (Boothe; Florence; Riviere).

Drug movement by facilitated diffusion requires no energy, and does not move against the concentration gradient. The drug’s structure resembles natural ligand in a manner that allows it to bind to the carrier macromolecule and traverse the membrane. Pinocytosis is a process that incorporates the drug into a lipid vesicle for carrier mediated transport into the cell cytoplasm (Currie).

There are also active transport systems in the microvilli of the small intestine that are responsible for nutrient absorption. In an active transport system, the drug’s chemical configuration resembles a natural ligand allowing it to bind to carrier macromolecules and be transported against the concentration at the expense of energy. A few therapeutic drugs (beta-lactams) may be absorbed by this active transport system (Currie; Riviere).

Opposing drug absorption is a process that works to remove a drug compound from the cell back into the lumen of the gastrointestinal tract. This process is known as “efflux transport” and cells capable of this function are present in the epithelial cells of the gastrointestinal tract, liver, lung, kidney, and brain. On these unique cells, there is a cell surface glycoprotein (p-glycoprotein) or multi-drug resistance (MDR) protein that attaches to the drug molecule and escorts it out of the cell and back into the lumen of the gastrointestinal tract. The efflux transport process may be inhibited, induced, or saturated (Boothe; Florence; Riviere).

Epithelial cells that line the gastrointestinal tract are also very rich in metabolizing cytochrome P450 (CYP450) enzymes responsible for phase I oxidative metabolism. CYP3A4 is the most prominent isozyme of the CYP450 family present within the gastrointestinal epithelium. Due to its minimal selectivity in substrates to process, it accounts for about 50% of
all drug-drug and nutrient-drug interactions. In many cases, CYP3A4 and p glycoprotein may have similar substrates and their activity intermingled in such a manner that it is difficult to attribute changes of an absorption profile to one mechanism or the other (Boothe; Florence; Riviere).

Reduced availability of a drug product to systemic circulation can be due to the processes of efflux transport and intracellular metabolism. Another significant factor affecting decreased plasma drug concentrations is first pass metabolism. Drugs that are absorbed between the stomach and proximal to the rectum enter the circulating blood stream and go directly to the liver where biotransformation and metabolism of the drug molecule may occur. For drugs where there is extensive metabolism of the molecule in this manner, absorption is significantly reduced to the point of compromising efficacy of the drug (Riviere). In order to avoid the effects of first pass metabolism, a product may be administered transmucosally – where the product is applied to the mucosal membranes of either the mouth or vagina. Mucous membranes are highly vascular, allowing rapid absorption across epithelium and entry into the systemic circulation and avoiding the gastrointestinal environment as well as exposure to first pass metabolism (Currie). In this situation, it becomes critical that the active ingredient is capable of passing through the mucosal layer which may also be facilitated by the help of vehicles present in the formulations used for application (Boothe; Riviere).

Drug-drug and drug-food interactions may alter drug absorption. Administration of food with a drug may reduce the rate of drug absorption due to prolongation of the gastric emptying as well as altering the viscosity of the ingesta which reduce the rate of dissolution and diffusion. Also, food may bind to drugs or react with the gastric fluids secreted in response to the presence
of food. An example of this is would the reduction of drug absorption secondary to binding of calcium cations when dairy is administered (Boothe; Florence; Riviere).

Depending on the formulation of the drug, the delay of gastric emptying and exposure of the drug to the environment of the stomach may inhibit the performance of the drug formulation. Content that is present within the gastrointestinal lumen may also affect absorption of the drug. Intrinsic factors that influence the absorption of the drug include: enzymes secreted by the pancreas, pancreatin and trypsin, can ligate various ester bonds within a drug molecule. Mucin, a mucopolysaccharide that lines the intestinal epithelium, binds the drug compound and prevents the absorption. Any delay in gastric emptying will delay dissolution, absorption, and time to effect of the drug (Florence; Riviere).

Since the gastrointestinal tract is also an excretory organ for elimination of metabolic byproducts and nonabsorbed solid wastes, some drugs may experience an increased absorption due to enterohepatic recycling. In enterohepatic recycling, a drug from the systemic circulation is excreted back into the intestinal tract through the bile and is then reabsorbed from the ingesta back into the blood stream.

Rectal Absorption in the Equine Patient

As with oral absorption, pH, surface area, and luminal fluid content all play a role in absorption of a formulation from the rectal cavity. In general, the rate as well as extent of drug absorption are lower when comparing rectal administration to oral. When comparing anatomy between the rectum and the small intestine, there is a relatively small surface area for the formulation to be absorbed in the rectal vault when compared to the small intestine.
The ability of a rectally delivered drug formulation to disperse over the rectal mucosa is affected by the surface area available for drug uptake or action, formulation being a solid vs. a liquid, or the components of the suppository (d. B. van Hoogdalem E.J.).

There are four possible methods for improving rectal absorption: addition of surfactants, use of solvents or cosolvents, use of solubilizing prodrugs. Addition of surfactants has been shown to increase rectal absorption in humans; however, it also appears to damage the rectal membrane which is not desirable in the patient. In equine practice, most of the formulations used are a suspension or paste which is created by dissolving the oral product (veterinary or human) in a variable amount of water (A.G. De Bower).

Absorption of a rectal drug formulation is dependent on many factors. First, the molecular size of the drug as well as partitioning of the drug between the delivered formulation and the rectal fluid is of key importance. Several dosage forms are available for rectal delivery of drugs: suppositories (emulsion or suspension), gelatin capsules (solutions and suspensions) and enemas which are quantified by macro (100 mL) and micro (1 to 20 ml). Formulations that are aqueous or alcoholic solutions have a greater chance of being absorbed more quickly than tablet or paste formulations (A.G. De Bower; H. D.-E. Corveleyn S.).

One of the benefits of administering drug products rectally is the potential for avoidance of hepatic first pass elimination. In humans, three veins drain the rectum. One vein, the superior rectal, drains the upper part of the rectum and feeds into the portal vein and finally the liver. However, the middle and inferior rectal veins drain into the inferior vena cava. Therefore, as a drug is absorbed from the rectum and into the middle and inferior veins, drug then is carried into systemic circulation by passing the liver and avoiding first pass metabolism. Gut wall metabolism following rectal administration of drugs has not been fully elucidated; however; the
presence of enzymes within the gut wall does decrease in an oral to aboral fashion. Metabolism of a drug formulation by luminal microorganisms may be an important factor to consider when evaluating rectal presystemic elimination. Microorganism populations increase in numbers moving in an aboral direction from the jejunum (A.G. De Bower; d. B. van Hoogdalem E.J.).

Inactivation of drug formulations by binding to fecal material has been suggested as a potential cause for reduced bioavailability. In a study evaluating rectal administration of an omeprazole paste, all horses defecated within the first two hours of treatment and there was macroscopic binding of the paste evident on the fecal piles. These effects as well as a small amount of drug dispensed into the rectum (5 mL) could have had a greater effect on drug absorption (Rand C. Stanley).
Modeling Oral Drug Absorption in the Horse

Currently, there is not a “standard of care” for evaluating drug movement in the equine patient. Pharmacokinetic studies evaluating oral administration in horses most commonly involve administration of either a paste or liquid formulation. However, when these are unavailable, a solid dosing form of the drug (tablet or capsule) is crushed or opened and administered as a powder and administered: spread over grain, dissolved in a small volume of water and then administered in a syringe, or as a large volume solution via nasogastric tube. Pharmacologically, multiple factors can affect a drug’s ability to be absorbed. In humans, studies have shown the volume in which a drug is administered markedly impacts the rate (time to maximum drug concentration) and extent that it reaches systemic circulation (maximum plasma drug concentration, area under the curve, and bioavailability). Depending on the characteristic of the drug, absorption may also be affected by the presence or absence of food in the stomach and small intestine (Neirinckx E.).

The Food and Drug Administration has implemented a Strategic Plan for Regulatory Science which includes a major focus on predicting the behavior of orally administered drugs through modeling. Among the models that should facilitate an understanding of the complex interactions and processes that impact drug behavior are those based on quantitative structure-activity or -property relationships. These models can guide experimental designs of hypothesis driven research while reducing animal numbers and total study cost while improving the ability to predict response to a drug among the varied populations (Doherty T.J.)

In support of these efforts, several studies have demonstrated that compounds can be characterized by solubility and permeability properties. These models can be used to study the influence of factors or predict how outside variables will alter oral absorption. The
Biopharmaceutics Classification System (BCS) is a predictive tool used to identify compounds whose oral absorption may be sensitive to intrinsic (patient’s physiology – gastrointestinal tract, blood flow, etc.) and extrinsic (food and formation) factors.

The classification system is as follows:

1. High solubility, high membrane permeability
2. Low solubility, high membrane permeability
3. High solubility, low membrane permeability
4. Low solubility, low membrane permeability

Class 1 Drugs: These drugs are both highly soluble and readily cross a membrane. In this particular drug class, there is not an expected effect of food on the absorption rate of a product. The onset or rate of the absorption may be delayed by the presence of food due to a prolonged gastric emptying rate but food will not compromise the completeness of absorption. Drugs that fall into this group are acetaminophen, nonsteroidal anti-inflammatory agents, and valproic acid.

Class 2 Drugs: Drugs present in this drug class are not soluble in an aqueous solution but are still able to readily pass through membranes. In this particular group, anything that would alter the dissolution rate would have an impact on the absorption of the drug. Changes in fluid pH, volume and viscosity, as well as bile secretion would affect absorption. Consumption of fatty meals would be expected to exert a significant beneficial effect on the absorption of the drugs in this class. With the presence of a fatty meal, the gastric emptying would be delayed, prolonging the time to maximum drug concentration. The drug would be more readily absorbed due to the secretion of bile acids in response to the fat content. Also, due to the presence of poorly water-soluble compounds, the secretion of surfactant and solubilizing properties would
enable absorption of the drug into the patient. Many drugs in this class; however, are substrates for metabolism by CYP3A4 as well as efflux transporters.

Class 3 Drugs: Class 3 drugs are highly soluble in aqueous solutions but have poor membrane permeability. The effect of food on the absorbance of these drugs are limited to whether or not the food and food components would alter membrane permeability.

The updated Biopharmaceutical Drug Disposition Classification System (BDDCS) has combined information about the elimination mechanism, the presence of gut transporter proteins and the predicted effects of food on drug absorption.

Class 4 Drugs: Drugs in the final category have both low aqueous solubility and poor membrane permeability and are considered as poor candidates for oral administration (Florence).

Application of this system has yet to be fully described in horses. As a first effort to modeling oral absorption in the horse, the impact of the method and volume of delivery on drug absorption must be established.¹

Much of equine therapeutics reflects off-label (extra-label) use, with alternative routes or drugs. Ideally, extra-label dosing regimens are supported by clinical research. Determining effects of oral drug administration has been key in developing appropriate models that predict drug concentrations in animals and people. The effects of food, drug coating, and how the drug is administered are the cornerstones in evaluating and modeling drug movement. In the horse, oral administration either in a clinical setting or as part of research studies often varies depending on the drug, the investigator, or the circumstances under which the drug is administered (Hatanaka S.; Mizuta H.).

Like humans, the rate at which the equine stomach empties when exposed to the orally administered fluid is highly dependent on the phase of the MMC, which is the electrical cycle
that controls gastrointestinal propulsion (Lammers T.). In people, small volumes of fluid (50 mL) do not exert an effect on the rate of gastric emptying. However, by increasing the amount of fluid volume administered with a drug (200 mL), the rate of gastric emptying increases regardless of the MMC (Clements J.A.; Oberle R.L). This relationship can ultimately affect the bioavailability of a drug and may be critical for drug classes (Class 1 and Class 2) when rapid dissolution and availability of the drug within the intestinal tract is limited by the rate of gastric emptying (Hatanaka S.).

Acetaminophen, a centrally-acting analgesic and antipyretic, is a small (151.2 g/mol), moderately lipid-soluble weak organic acid. It is classified by the BCS as a Class 1 model drug, which indicates high solubility, high permeability, and an overall ease of absorption into systemic circulation (Doherty T.J.; Hatanaka S.; Mizuta H.). Although poorly absorbed in the stomach, acetaminophen is readily absorbed from the small intestine of dogs, rats, and ponies. As such, a direct relationship has been found between rate of gastric emptying and serum concentrations of orally administered acetaminophen in horses (Neirinckx E.). Absorption of acetaminophen powder (dissolved in 350 mL of water) has proven an effective and safe marker for gastric emptying in ponies after administration by nasogastric intubation (Clements J.A.).

Bioavailability, labeled as F in pharmacokinetic parameters, is the determination of the extent of absorption in the body. Drugs that are administered intravenously are said to have absolute systemic absorption since the drug is placed directly into the circulating blood volume (Currie). Bioavailability only provides an estimate of the extent of absorption, it does not however, characterize the rate of absorption of the drug into the circulating blood volume (Riviere).
Modeling Rectal Drug Absorption in the Horse

Modeling of rectal administration of drugs has not been performed in the equine patient; however, multiple drugs have been administered in a rectal formulation in an effort to treat a variety of different disease states.

Diazepam – The adequate treatment of status epilepticus is intravenous (IV) delivery of an anticonvulsant. However, the technical problems associated with intravenous administration of drugs during a seizure has led to evaluation rectal administration as a practical alternative (van Hoogdalem 1991a).

Acetylsalicyclic acid (ASA) – Acetylsalicyclic acid (ASA) is nonsteroidal anti-inflammatory drug (NSAID) that has antipyretic, analgesic, and potent antiplatelet properties. ASA is used in people for the prevention and treatment of arterial thrombotic disease. In equine practice, use of ASA was proposed for the treatment of equine disease that have arterial thrombosis as a part of their pathogenesis such as endotoxemia, disseminated intravascular coagulation, and thromboembolic coli. However, ASA is rapidly converted to salicylic acid (SA) thru deacetylation via hepatic mechanisms and endogenous esterases. In horses, the half-life of ASA after IV administration has been documented at 0.11 hours. In Broome’s study, after a single rectal dose of 20 mg/kg to horses, a higher peak plasma concentration of ASA and greater bioavailability was seen (Broome T.A.)

Ketoprofen – Ketoprofen [(+-) 2-(3-benzoylphenly) propionic acid] is a NSAID that has been approved for use in people and horses for the alleviation of inflammation and pain associated with musculoskeletal disorders (Corveleyn 1996). In people, rectal administration of ketoprofen was considered to reduce the risk of gastrointestinal ulceration. The molecule itself ketoprofen appeared to be absorbed well from the rectal vault with bioavailability approaching
oral values in normal adults receiving 75 mg in a fatty or gelatin encapsulated suppository. Interestingly, both formulations showed a decreased absorption rate in patients undergoing hemorrhoidectomy (d. B. van Hoogdalem E.J.)

In horses, one gram of ketoprofen was prepared in three different formulations: a suppository (fatty and hydrophilic) base and a liquid suspension. The absolute bioavailability of ketoprofen in horses after rectal administration of all three products was relatively low with a high variability. This study was one of the first to describe the first evidence of clinical effectiveness of rectal formulations (D. P. Corveleyn S.)

Metronidazole – Metronidazole (1-2 hydroxyethyl-2-methyl-5-nitroimidazole) is a bactericidal antimicrobial agent used for treatment of anaerobic bacteria and protozoa. In people, the oral bioavailability of metronidazole approaches 100% whereas rectal administration approaches 70-80% with alterations in the formulation greatly affecting both the $C_{max}$ and $T_{max}$ (d. B. van Hoogdalem E.J.). Metronidazole is also used for prophylaxis and treatment of anaerobic infections in horses; however, in some cases, due to the concurrent issues affecting gastrointestinal motility (ileus) or decreased patient compliance due to taste, metronidazole has been administered rectally (Stein F.). Steinman evaluated the pharmacokinetics of metronidazole after IV, oral and rectal administration (G. M. Steinman A.). Despite having a significantly higher maximum plasma drug concentration after oral administration, there were no statistically significant differences in mean absorption time or the time to reach maximum plasma drug concentration. In this study, authors concluded that increasing the dose for rectal administration was needed to achieve serum drug concentrations above MIC90 of the most commonly treated microbes. When comparing the effects of rectal evacuation on metronidazole absorption, there was not a difference of drug absorption between non evacuated and evacuated
horses. Thus, for metronidazole, it does not appear that the presence of fecal matter or inactivation by binding affects drug absorption (Stein F.).

Omeprazole - In a study performed by Rand, a commercially available paste was used for rectal administration of omeprazole to evaluate both the pharmacokinetic profile as well as pharmacodynamic response (increase in gastric pH). In people, use of rectal omeprazole suppositories resulted in a bioavailability comparable to that seen with oral formulations. In this equine study, however, the paste had a tenfold decrease in AUC compared to oral administration and only 33% of treated horses showed an increase in gastric fluid indicating a pharmacodynamic response (Rand C.).

Cisapride – Cisapride, a substituted benzamide, is related to metoclopramide but lacks the antidopaminergic effects that act on the central nervous system. Cisapride promotes gastrointestinal motility by enhancing the release of acetylcholine from post-ganglionic nerve endings. In horses, cisapride has shown to not only restore but enhance motility of the entire gastrointestinal tract, increase motility at the ileoceccolic junction, and coordinate gastric and intestinal cycles in a post-operative ileus model (Steel, 1990). In human patients experiencing post-operative ileus, cisapride has been shown to have prokinetic effects after rectal administration. In people, orally administered cisapride tablets has a bioavailability of 40-50%. In comparison, the rectal relative bioavailability has been shown to be 43% of oral administration (Steel C.M.).

In seizing or obtunded horses, rectal administration of a drug may be necessary due to altered mentation and safety concerns (Feary D.J.). In seizing horses, it is often difficult to administer oral medications due to altered mentation and safety concerns. Medications such as diazepam and metronidazole have been shown to be absorbed readily through the rectal mucosa.
after administration *per rectum* in dogs and horses (Feary D.J.; Papich M.G.; G. M. Steinman A.)

In these patients, therapeutic drug levels necessary for seizure control have been achieved through administering drugs *per rectum* at two to three times the oral dose recommended in patients.

In this dissertation, zonisamide, a synthetic sulfonamide, approved for treatment of epilepsy in people, was used in a pilot study to compare oral and rectal absorption of this novel molecule in the equine patient. Zonisamide’s mechanism of action is diverse and includes: blockage of voltage-dependent sodium and type T calcium channels, modulation of the dopaminergic system, increasing GABA release from the hippocampus, and protecting neuronal membranes from oxygen free radicals (Dewey C.W.; Boothe D.M.; Yaksh; Atli A.; Backonja). Its therapeutic success in people has led to its use in companion small animals and birds (Papich M.G.). With a half-life of 30-48 hours in canine patients, the drug can be administered at 12 to 24 hour intervals (Boothe D.M.; Dewey C.W.). If this long half-life were to occur in horses, there would be sustained seizure control at convenient dosing intervals in comparison to levetiracetam (recommended three times a day). In comparison, zonisamide has minimal side effects that are limited to thyroid hormone suppression when levels are above the therapeutic range.

In both routes of administration, the serum concentrations were lower than what was expected in horses where the capsule was administered in an intact fashion, as has been studied in humans and small animals. One of the limitations in this study as well as in equine practice is the need to alter dosage forms in order to treat the patient. Further evaluation may need to be done to look at methods to administer the whole capsules to horses in order to achieve a more accurate indication of serum drug concentrations.
**Distribution**

In pharmacology, distribution determines whether a drug will reach the site of action at high enough concentrations to create a biological response. The concentration of drug at the site of target tissue reflects the total exposure of the patient to the drug. How far a drug is capable of travelling within a body is dependent on four things:

a.) Physiochemical properties of a compound. This properties include the drug’s pKa, lipid solubility, and molecular weight.

b.) Concentration gradient established between the circulating blood volume and the target tissue. Tissues that are high in blood flow per unit tissue include: heart, liver, kidney, brain, and the endocrine glands. Tissues that are medium blood flow are muscle and skin whereas adipose tissue and bone have a low rate.

c.) Ratio of how much blood is delivered to the target tissue – In disease states where patients are vascularly compromised due to blood loss, dehydration, or hemodynamic imbalances, profusion to tissue sites may decreased.

d.) Affinity of the chemical to bind to the target tissue – If a chemical has a high affinity and bonding capability for a tissue group, the drug will accumulate regardless of the blood flow to the area. In these circumstances, it will take longer for drugs to reach steady state as well as be removed from the body.

A drug may be distributed to three different compartments in the body. Each of these compartments contributes to a certain percentage of the animal’s body weight – intravascular (8%), interstitial fluid (20%), and intracellular (40%). Distribution to these areas is also due to a variety of factors. For drugs that are limited to the intravascular space, this may be due to binding of the drug to plasma proteins such as albumin (which bind weak acids) and alpha-
glycoprotein (which bind weak bases). Once a molecule has bound to plasma proteins, it moves throughout the circulation until it dissociates and binds to either another biomolecule or a tissue component. Of the chemical forces most important in plasma protein binding, noncovalent bonding is of primary importance because it offers the ability of the drug molecule to dissociate from the carrier protein. Displacement of one drug molecule from carrier proteins mean that there is a higher concentration of free drug available for tissue absorption. When a second molecule (drug or protein) is administered and provides competition for binding sites at the level of the carrier protein, care must be taken by pharmacologists to acknowledge which of the molecules is most likely to take over residence attached to the carrier protein and which will have a larger portion of free drug available. The methods for quantifying protein binding are evaluated both in vivo (ultrafiltration microdialysis, tissue cage) or in vitro (electrophoresis, equilibrium dialysis, fluorescence, nuclear magnetic resonance) (Riviere; Auer J.A.).

Within the body, there are certain “protected sanctuaries” that are protected by the blood brain barrier – which is a glial cell layer interposed between capillary endothelium and nervous tissue. In the body, these sanctuaries are confined to brain, ocular, prostatic, testicular, synovial, mammary gland, and placenta tissue. The only molecules that can penetrate the blood brain barrier are those that are nonionized (Riviere).

Other factors that determine distribution despite protein binding are the route of administration, molecular weight, rate of metabolism, polarity and stereochemistry of the apparent compound or metabolic products, and rate of excretion.

Pharmacokinetic values that are of clinical importance are that of half-life and volume of distribution. Volume of distribution (Vd) is defined as the extent of distribution of a compound within a body. The equation for determining this is:
\[ Vd = \frac{\text{Dose (mg)}}{\text{concentration (mg/l)}} \]

In this equation, the calculated volume of distribution is proportionally constant relating the determined plasma drug concentration to the administered dose. Usually, the volume of distribution does not actually relate to the real volume of the compartments. It’s used as a model to help understand the drug’s behavior in the body (Currie).

The second pharmacologic variable to be taken into account here is half–life. A drug’s half-life is the amount of time it takes for half of the drug’s concentration to leave the body. Drugs with a short half usually have a very low volume of distribution meaning that they are confined to the circulating blood volume such that they have continual exposure to the organs of elimination. In contrast, drugs with long half-lives, often have large volumes of distribution, travel to tissues farther away from the circulating blood volume and stay in the target tissue for a longer period of time. This means that it will take a longer period of time for equilibration to be reached, and a longer time for the drug to return from the tissue to the circulating blood volume for elimination (Riviere).
Metabolism

In the equine patient, metabolism is necessary for the animal to rid itself of the drug products administered to avoid adverse effects and tissue toxicity. The liver is responsible for the majority of biotransformation of drugs from acting on target tissue to preparation for clearance and excretion from the body. In concert with metabolism, the liver is also responsible for the production of bile which in pharmacology is also a route of excretion.

Factors affecting the liver’s ability to perform the processes of biotransformation include hepatic volume/perfusion rate, drug accessibility to and extraction by hepatic metabolizing enzymes and the activity of the major drug metabolizing enzymes (Riviere).

The ability of the liver to remove a drug from blood is defined as hepatic clearance. Hepatic clearance is based on two very important things: the amount of blood being supplied to the liver, and the intrinsic amount of hepatic clearance of the drug. When evaluating the drug extraction ratio (comparison of the internal clearance of the drug product to hepatic blood flow), a ratio of 1 or greater, reflects clearance is dependent on the amount of blood that is entering the liver. This means that the more blood that is passing through the liver, the more drug molecules will be extracted by the liver for elimination. In the cases of high extraction ratios, these drugs will also show significant first-pass metabolism after oral administration. In contrast, low extraction ratios or metabolism limited drugs, are dependent on the internal clearance capabilities of the hepatic tissues (Riviere).

Biotransformation of drug molecules occur most commonly through two phased reactions that decreases the molecule’s lipophilicity and increases its water solubility as well as polarity to facilitate excretion from the body.
Phase 1 reactions are responsible for introducing functional groups to drug molecules through the process of conjugation. Phase 1 metabolism occurs through four major pathways: oxidation, reduction, hydrolysis and hydration. The ultimate goal of Phase 1 chemical reactions are to deactivate drugs or prepare the drug molecule for Phase II by introducing a chemically reactive group. Traditionally, oxidative reactions have been considered most important because they play a central role in how drugs are metabolized in the body. Oxidation reactions occur in the hepatic endoplasmic reticulum and are mediated by the microsomal mixed function oxidase system (cytochrome P450). An extensive amount of research has been performed on these drug metabolizing enzymes due to their key roles in metabolizing such a high number of different substances. Across species, the same enzymes are not involved in metabolizing the same drugs, and often, substrate specifications overlap making the extrapolation difficult (Riviere).

Recently, equine CYP isoforms have been identified and named: CYP2D50, CYP2C92, CYP3A89, CYP3A96, and CYP3A97 as well as their activity compared to human CYP2D, CYP2C, and CYP3A isoforms. When comparing people to horses, lower activity of CYP1A, CYP2A and CYP3A has been detected in horses. However, CYP2C, CYP2D, and CYP2E activity appears to be increased in comparison to humans. Since the identification and comparison of isoforms in different species and comparing activity across species is a relatively new field of development, alterations in these conclusions may change over time (Scarth J.P.)

In people, 50% of known drugs are metabolized by CYP3A4 and CYP3A5. Comparative analysis between the human and equine chromosome region showed that the equine genome contains six highly similar genes and two potential pseudogene where as humans have only four known functional CYP3A genes and two pseudogenes. The three CYP3As: CYP3A89, CYP3A96, and CYP3A97 have been heterologously expressed in cells. In horses, the CYP3A89
was among the most highly expressed CYPs but variations between individual horses have been appreciated to be high. From this, it was concluded that CYP genes of the same family show high homology within and between species but can be polymorphic (D. S. Schmitz A.; Z. J. Schmitz A.)

Phase II reactions, primarily involve conjugation reactions responsible for deactivation of Phase I metabolites and non-modified parent compounds. The primary reactions present within Phase II include glucuronidation/glucosidation, sulfation, methylation, and acetylation. Once Phase II is complete, the molecule is destined for excretion (Riviere).

Several factors may contribute to a difference in drug metabolism between people and horses. First of this is the diet consumed – people tend to be omnivores while horses are strict herbivores. Anatomically, horses also have a substantially developed cecum that is responsible for hind gut fermentation where microbial production and subsequent absorption of monoamines could affect drug metabolism and physiological values. In horses, the storage capacity of the spleen in times of inactivity as well as its ability to contract and release red blood cells into the circulation during exercise and stress having the potential for massive changes in blood volume resulting in implications for variations in the pharmacokinetics of drugs.
Elimination

Drug molecules can be eliminated in urine, bile, sweat, saliva, tears, milk, and air expired from the lungs. However, the ultimate route of drug elimination from the patient’s body is through the kidney. In general, the only drugs that are available for excretion from the body are those dissolved in plasma or those that are not bound to circulating blood proteins. Drug products that are dissolved in the plasma that are available for secretion first have been bio transformed by the liver in order to create a more water soluble in order to participate in the membrane transport system employed by drug movement in the kidney (Boothe).

In an effort to simplify renal anatomy and drug excretion from the body, we must look at it as a twostep process. First, the circulating blood volume passes through the glomerulus which acts a filtration unit to retain formed cellular elements (erythrocytes, white blood cells) and proteins while allowing passage of plasma fluid into the remaining portion of the kidney. The second step of excretion utilizes a system of segmented tubules to modify the contents of the filtered plasma depending on the physiological needs of the individual. This includes balancing fluid, electrolyte, acid-base, and regulation of systemic blood pressure. Drugs are excreted from the kidney in three processes: glomerular filtration, active tubular secretion and/or reabsorption, and passive flow dependent nonionic back diffusion. The additive effects of these steps determines the ultimate elimination of the drug from the body (Boothe; Riviere).

Glomerular filtration is a bulk flow dependent unidirectional movement of drug removal from the body. Only non-protein bound drugs are eliminated in this process. The rate of elimination of the drug is dependent on the extent of drug protein binding as well as the glomerular filtration rate. As the circulating blood volume passes through the glomerulus, it must work through a system of barriers including Bowman’s capsule, the glomerular basement
membrane and the slit pores formed from epithelial foot processes that are arranged in an overlapping manner. When there is glomerular pathology that compromises these barriers, plasma proteins are not maintained within the circulating blood volume and are able to pass into the tubules of the kidney and be excreted as well (Boothe; Riviere).

Active tubular secretion/absorption is an energy dependent, saturable, carrier mediated process that is driven to either secrete drug products from the plasma into the tubule lumen or from the lumen back into the circulating plasma volume. There are two separate pairs of transport proteins which work together to create an overall polarity of tubular cell function and moderate the flow of molecules. The first is located – on the cell’s brush border, along the luminal aspect, while the second is located along the basolateral membrane adjacent to the interstitial space where plasma fluid is located. The primary ion that regulates renal function and drives ion movement and transport within the renal tubules is sodium. Proximal tubule cells have a high density of mitochondria to generate adenosine triphosphate (ATP) to help fuel the sodium-potassium ATPase-coupled transport system near the basal aspect of the cell. Depending on which transport proteins are active, these pumps will affect if drug molecules are being actively absorbed or secreted. Due to the high level of oxidative metabolism required to drive these pumps, if there is a decrease in perfusion to the kidney that leads to hypoxic or anoxic conditions significant damage to the function of the organ may be seen. In secretion, energy coupled transport at the basal aspect of the cell generates a buildup of intracellular drug concentration which is then transported into the tubular fluid by concentration-driven facilitated transport carriers. In reabsorption, the basolateral active pumps create a low intracellular concentration gradient which promotes facilitated carrier-mediated transport back through the brush border tubular membrane. The limited capacity of these carrier-mediated processes means
that above certain drug concentrations, transport will proceed at a maximal rate independent of
the concentration in blood. Also, drugs and other endogenous substrates may also compete for
these transport sites causing a competitive inhibition effect (Boothe; Riviere).

Nonionic passive reabsorption, also known as back diffusion, is a process dependent on
the urine flow rate, the lipid solubility of the nonionized drug moiety, and urine pH. At low
urine flow rates and high concentrations of the drug in the urine tubular fluid, the diffusion
follows a concentration gradient back into the interstitial fluid. Drugs that are polar or have low
lipid solubility are not affected as they cannot pass the lipid membrane.

Clearance, the maximal rate at which a body can clear any drug is controlled by blood
flow to the respective clearing organ where complete extraction occurs. For whole body
clearance, it is the summation of the clearance of each organ – renal, hepatic, and other (Boothe;
Riviere).
Chapter 2. Fundamentals of Pain Perception and Transmission in the Equine Patient

“It's a beautiful day to save lives. Let’s have some fun.”

– Grey’s Anatomy

Effects of Pain

As a veterinarian, our oath declares “first, do no harm” however; practicing medicine means balancing a patient’s state of pain, disease, or systemic compromise with the appropriate treatment needed to save a life. The first twenty four hours after any surgery is the most critical. In order to ensure the best outcome for the patient, an extensive knowledge of the patient’s physiology, pain level, as well as pharmacology of the prescribed drugs is a necessary requirement. Once the last suture is placed to close the incision, the surgeon by default becomes a pharmacologist, selecting drugs that will support, manage, and repair the trauma that has been done to the patient. In the equine patient, pharmacologic interventions for managing both somatic and visceral pain are limited due to formulations available, cost of administration, and potential long term adverse events. Equine athletes who compete in regulated events pose a unique situation where selection of medications to treat pain and inflammation are narrowed due to concerns of performance enhancement or increased risk of harm to either horse or rider. Due to these limitations, focus within the field has been driven to evaluate novel analgesics that moderate the pain pathway while limiting risk of adverse events.

Potential causes of acute pain, felt within 0.1 second, are highly variable and can extend from environmental stimuli, trauma, surgery, acute medical conditions, as well as normal
physiologic processes. Pain of short duration alerts an animal to potential injury and shifts focus to adapt to survival and signal to stop using injured tissues and promote healing. Responses to acute pain are usually a quick change in behavioral action and resolves without significant disruption in homeostasis. Clinical signs associated with acute pain are typically seen in the following body systems: neurologic (excitement, confusion, tremors, rigidity, and weakness to immobility), cardiorespiratory (hypertension, tachycardia, tachypnea, vasospasm, and venous stasis), and gastrointestinal (hypo or hypermotility, urinary retention, sweating, and hyperthermia). In most cases, acute pain resolves and hemostasis is restored (Guyton A.C.; Smith).

Unlike acute pain that resolves quickly, extensive tissue injury or disease results in pain signaling that persists for a day to weeks. Slow pain is characterized by slow burning, aching, and throbbing. Chronic pain is associated with clinical signs of both allodynia and hyperalgesia. Allodynia is the production of pain by a stimulus that previously was not painful. On the other hand, hyperalgesia occurs when previously painful stimuli produce pain of greater magnitude, duration, or area. Peripheral hyperalgesia occurs at the site of injury and is mediated by inflammatory mediators such as prostaglandins (mainly PGE2) and leukotrienes (LTB4). Persistent inflammation may recruit previously inactive neurons or silent nociceptors that are quiescent in normal tissue. These mediators, together with bradykinin and histamine, cause nociceptors to be hyper responsive to noxious stimuli. Substance P and norepinephrine release from adjacent nerves amplify pain signaling and recruit other nerves to become active as well.

In chronic pain, central signaling mirror the peripheral effects seen since they use many of the same neurotransmitters. Release of substance P and glutamate/aspartate from the intraspinal terminals of the nociceptors activate the neurokinin 1 (NK-1) and n-methyl-D-aspartate (NMDA)
and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the dorsal horn and lower the response threshold of second order dorsal horn neurons (Smith).

Peripheral fibers triggered in peripheral slow-chronic type c pain fibers terminate in Laminae II and III of the dorsal horns. Signaling then passes through one or more short fiber neurons within the dorsal horn before entering Lamina V, joins the fast pain pathway, and passes through the anterior commissure to the opposite side of the cord upward to the brain in the paleospinothalamic pathway. Ten to 25% of this pathway terminates in the thalamus while the remainder terminates in the reticular nucleus of the medulla and pons, the tectal area of the mesencephalon deep to the superior and inferior colliculi, and the periaqueductal grey region. From the brain stem, the pain signals are transferred upward into the intralaminar and ventrolateral nuclei of the thalamus into the hypothalamus. Due to this diverse pathway of signaling, localization of pain is poor (Guyton A.C.; Smith).

Chronic pain also initiates systemic changes such as modifications of behavior, reproductive capabilities, activity, and food consumption. Clinically, practitioners may see depression, inappetence, weight loss, as well as reduced growth or milk production. Chronic pain also stimulates the release of cortisol, catecholamines, and renin which impair normal cardiovascular function and contribute to hypertension (Smith).

Endogenous inhibition of pain signaling consists of a group of descending neurons from the hypothalamus, midbrain periaquedctal gray, rostral ventromedial medulla and the dorsolateral pontine tegmentum. Together these structures influence activity in the pain sensitive spinothalamic tract as well as the dorsal horn. Of this grouping of mediators, the periaqueductal grey acts as the command center for modulating pain. This occurs through encephalin activation of the pre and post synaptic inhibition of opiate receptors. Enkephalins are small, short acting
peptides that bind to opiate receptors and mimic the actions of morphine. By activating the receptor, the calcium channel in the nerve terminal’s membranes is blocked preventing the release of the transmitter at the synapse in presynaptic nerves and decreased ability to transmit the nerve signaling in post synaptic situations. Enkephalin blockade may occur for minutes to hours. Once the periaqueductal grey is activated there is subsequent stimulation of the rostral ventromedial medulla. The rostral ventromedial medulla releases serotonin from its terminals in the dorsal horn of the spinal cord. Serotonin then stimulates specific dorsal horn interneurons that contain encephalin. Once released, enkephalins act on opioid receptors located on pain responsive neurons in the spinal cord. Prompting of these specific neurons inhibits the pain responsive cells causing them to be less excitable by nociceptive signals from the peripheral signaling. In coordination with this, norepinephrine is released form the pontine tegmentum where it acts on the alpha-2 pain receptors on pain sensitive neurons of the dorsal horn causing inhibition of the pain signaling (Guyton A.C.; Smith).

Management of pain signaling is not only a centrally activating event. At the time of injury, A-delta and C-polymodal fibers transmit the nociceptive signals of noxious stimulus. However, when an animal licks or rubs at a fresh wound, large diameter A-beta mechano afferent fibers at or near the site of injury are activated. Signals from all fibers converge on the common spinothalamic tract cells. The large A-beta fiber is thought to activate an inhibitory interneuron and dampen/close down the gate of pain signaling being delivered by the neighboring receptors (Smith).
Somatic Pain

Pathway and Transmission

Somatic pain can be subdivided into three main types: superficial, deep somatic, and visceral. Superficial pain is cutaneous, well-localized, constant, and may follow the distribution of somatic nerves. Deep somatic pain is defined as diffuse, dull, poorly localized, and periodic eliciting a more pronounced autonomic change. Lastly, visceral pain also called deep or pain is derived from rapid distention, ischemia, high luminal pressure in any viscus, or pulling on the root of the mesentery (Smith).

Sensory reception of noxious or injurious stimuli is detected through neurons that have nociceptors, with free, unmyelinated nerve endings. Nociceptors exist in muscles, skin, periosteum, internal organs, tooth pulp, cornea, and meninges and serve to warn animals of imminent or ongoing tissue injury that should evoke protective reflexes and behavioral pain responses. The rate of tissue damage also serves as a stimulus for pain such that the intensity of pain is closely related to the rate of tissue damage from causes ranging from ischemia, infection, or contusion. This correlation is due to the local increase in potassium ions or proteolytic enzymes that attack nerve endings by making the membranes more permeable to ions. In cases where tissue ischemia is occurring, tissue becomes painful within minutes due to a drastic increase of lactic acid around the nervous tissue (Guyton A.C.; Smith).

Nociceptors are divided into two classifications: A-delta and C-polymodal. A-delta fibers respond to deforming mechanical stimuli (such as tissue compression and nitric oxide (NO) release from tissue damage. These fast-sharp pain signals are transmitted in bursts of 6-30 m/second. They do not respond to excessive temperatures or chemicals unless they have already
been sensitized for some reason. Structurally, A-delta fibers are small in diameter, myelinated, unimodal and have a high threshold (Guyton A.C.; Smith).

C-polymodal nociceptors respond to thermal damage (temperatures greater than 45°C), noxious chemicals (caustics, acids, bases, hypertonic solutions) as well as inflammatory mediators (bradykinins, histamine, prostaglandins, serotonin, acetylcholine, proteolytic enzymes). C-polymodal fibers are also small diameter, however, they are unmyelinated, and have slowly conducting fibers. Interestingly, prostaglandins as well as substance P enhance a neurons sensitivity to pain but do not directly excite them (Guyton A.C.; Smith).

Axonal conduction along either an A-delta or a C-polymodal nerve fiber occur in the same manner. Without stimulation from the nociceptor, the nerve is at rest. When the nerve experiences a suprathreshold stimulation, a localized change occurs in the permeability of the axonal membrane. This change, an action potential, is an increased permeability of the nerve fiber to sodium in relation to potassium. Sodium moves into the nerve along its current and the membrane potential becomes positive. This action potential is self-propagating, short-lived, and propagated along the axonal nerve fiber. Once the action potential reaches the nerve terminal, calcium moves from the superficial membrane or interstitial space and binds to the axonal terminal which triggers discharge of the neurotransmitter from vesicles into the junctional cleft. Once the neurotransmitter is released; the mediator then binds to its corresponding receptor on the post synaptic membrane. After the neurotransmitter has completed its signaling, it can be taken back up into the nerve terminal, it may diffuse away from the receptor site, or undergo metabolism by the appropriate metabolizing enzyme (Riviere).

Depending on what neurotransmitter is released, there may be two effects it has on the post-synaptic nerve. If the neurotransmitter is excitatory, it will trigger a general increase in
permeability of the post-synaptic membrane to all ions. This stimulates an action potential to be conducted along the remainder of the nerve fiber. However, if the neurotransmitter was inhibitory in nature, the membrane will become only selectively permeable to smaller ions such as potassium and chloride. The outward movement of potassium from the nerve fiber in replacement for chloride will increase the net charge within the nerve fiber. In this state, the nerve fiber is hyperpolarized, meaning that the threshold to stimuli will be increased and inhibits the response of the corresponding cell (Riviere).

Once a noxious stimuli is transduced by A-delta and/or C-polymodal nociceptors, the signals synapse with the dorsal horn of the spinal cord using glutamate as a neurotransmitter in several laminae depending on the detected information. Lamina I (marginal zone) is the most superficial layer and receives both A-delta and C-polymodal fibers that carry both pain and temperature information. Here, they excite second order neurons of the neospinothalamic tract. Lamina II (substantia gelatinosa) consists mostly of interneurons that integrate information from A-delta and C fibers from Lissaur’s tract to coordinate signal. Lamina III and IV integrate the pain signaling from both warm and cold stimuli. Lamina V and VI are both critical for pain processing and modulation. These lamina receive information from both thermal and mechanical sensitive nociceptors and project information directly to the thalamus and brain. Within this lamina, there is also receipt of input from the descending brainstem pathways to help modulate pain signals. Once the transmission is received in one of these lamina, long fibers cross to the opposite side of the cord through the anterior commissure and pass upward in the anterolateral columns (Guyton A.C.; Smith).

Pain signals from the spinal cord to the brainstem or brain are transmitted by the dorsal column pathway and the spinothalamic tract. The dorsal column-medial lemniscus pathway
carries information about touch, pressure, and pain. Within this pathway, some nociceptors travel directly to the brainstem via this tract to have a rapid feedback between the periphery and brain. Cells from the spinothalamic tract originate from the Lamina V and carry information about temperature, touch, and pain. Also, cells from the spinothalamic tract do not synapse with the brainstem, and instead innervate the ventral posterior and other nuclei of the thalamus (Guyton A.C.; Smith).

At the level of the thalamus, the lateral thalamus is involved in the discriminative sensory component of pain while the medial aspect mediates the emotional and motivational aspects of pain. Most of the spinothalamic pathways terminate in the ventrobasal complex along with the dorsal column (Guyton A.C.; Smith).

Painful stimuli also activate the subcortical regions of the periaqueductal gray, hypothalamus, amygdala, and cerebellum. In some cases, activation of insular and cingulate cortices may also occur; however, these areas also receive stimulus from the thalamus (Smith).

Autonomic, emotional, and motor responses of pain are species-specific. Cerebral cortex activation plays a central role in interpreting the quality of pain – even though pain perfection/location might be a function of lower centers. In horses, the most common appreciated motor responses to pain include moaning, grunting, squealing, changes in facial expression as well as aggression. Responses to pain are not only limited to outward effects of pain. Nociceptive activation of the ventral medulla results in increased heart rate, respiratory rate, and blood pressure. Activation of the hypothalamus causes a release of vasopressin and adrenocorticotropic hormone (ACTH) which directly affect hemodynamics as well as blood glucose concentration. Activation of the reticular formation enhances a sense of vigilance and attention to surroundings. Finally, once the periaqueductal gray is active, there is a recruitment
of an endogenous descending pain suppression system. Through this mechanism, attempts are made to modulate the intensity of painful stimuli at the level of the spinal cord (Guyton A.C.; Smith).
Models of Equine Somatic Pain

Due to the high incidence of lameness in the equine patient as well as the need to control pain immediately after surgery, there is a constant demand to develop effective treatments for pain in the equine patient. When developing a research model, a few important factors must be kept in mind. First, the model must mimic the actual disease that is being developed, it needs to be repeatable between studies with minimal variation, it must create persistent pain that allows therapeutic interventions to be evaluated, and it must be reversible in nature such as to preserve animal welfare (McClure S.R.). Equine pain models have involved application of noxious stimuli which may be reversible or non-reversible depending on the pathology being evaluated. These models fall into categories surrounding what type of noxious stimulus was applied. Currently, the most commonly used models of permanent and transient models of lameness include use of either chemical injection of a noxious substance, induced mechanical pathology, or transient application of mechanical discomfort.

Intra articular administration of various chemicals have been found to cause a transient lameness associate with acute synovitis that allows for gait evaluation as well as therapeutic intervention. Chemicals evaluated have included botulinum toxin type A and B, endotoxin (LPS), and recombinant interleukin-1β, (DePuy T.; Gutierrez-Nibeyro S.D.; Khumsap S.; Nelson B.B.). Depending on the type of substance injected, the duration of activity and subsequent evaluation is variable.

For osteoarthritis, the use of creating an irreversible osteochondral fragment model within the selected joint (carpus most frequently used) has become popular for evaluating the effects of therapeutic interventions (Donnell J.R.; Nixon A.J.). Since this is an irreversible model, this allows for evaluation of both acute as well as chronic therapeutic interventions.
Models of transient lameness induction have involved a variety of techniques including use of a modified horse shoe that allows for application of sole pressure with a 10 mm diameter, blunt ended, headless set screw. Depending on the study’s objective, the location of the set screw is varied and tightness of the set screw allows for pressure application. This model has been used over shorter periods of time (2-9 hours) to follow responses to therapy. (Hoerdemann M.; Merkens H.W.; S. J. Schumacher J.).

Wilgenbusch demonstrated that using a circumferential stainless steel pipe clamp measuring 450, 500, 550 mm in diameter fit over both freshly trimmed fore feet would create a transient lameness. After baseline measurements were taken on a force platform, the clamps were applied and adjusted until achieving a subjective AAEP lameness score of 2.5/5. Clamps were left in place for a total of 120 hours and then released. Serial force platform data was taken until gait returned to normal. Force platform analysis was performed using a 0.9 m x 0.6 m biomechanical stationary platform (BP6009000; Advanced Medical Technology, Inc., Watertown, MA) placed in the center of a walkway. Five photoelectric cells spaced 0.5 m apart at the level of the shoulder were used evaluate the velocity as well as acceleration. The whole study was then repeated on the contralateral forelimb. McClure went on to validate this method titrating the pressure applied to the clamp until an objective asymmetry index between 25-30% was appreciated. After 120 hours, clamps were released and serial force platform data was recorded until the horse returned to soundness. McClure used application of a diclofenac ointment as treatment effect when challenging his model. This model created a consistent lameness that provided successful evaluation of a therapeutic intervention (McClure S.R.). By keeping the clamp in place for five days, the model created a prolonged, quantifiable lameness that allowed for evaluating interventions for chronic pain (Wilgenbusch C.).
Visceral Pain

*Peritoneal Embryology, Anatomy, and Physiology*

The lateral mesoderm is the embryonic origination of the peritoneal cavity. In development, the intermediate mesoderm splits and gives rise to the somatic (parietal) and splanchnic (visceral) mesoderm. The somatic mesoderm is a contributing part of the body wall, pelvis, and diaphragm while the splanchnic mesoderm remains closely associated to the endoderm and becomes integrated in the wall of the internal organs. The coelom becomes the space enclosed by the somatic and splanchnic mesoderm. This space becomes a closed sac in male horses; however, it communicates with the external environment in females via the fallopian tubes. The diaphragm serves as the separation between the pleural and peritoneal cavity (Slatter; Smith).

Both the somatic and splanchnic mesoderm becomes the mesothelial lining of the peritoneal cavity. This lining is composed of a single layer of mesothelial squamous cells resting on a basal lamina attached to connective tissue layer. The connective tissue of the peritoneal cavity contains collagen and elastic fibers that allows for motion of the peritoneal cavity. To minimize friction, the mesothelial cells are coated with a thin serous film. The somatic peritoneal lining receives arterial supply from the lower intercostal, lumbar, and iliac vessels while the venous drainage is managed by the caudal vena cava. Spinal nerves supplying the abdominal wall innervate corresponding locations on the somatic peritoneum while the phrenic nerve supplies areas overlying the diaphragm. Irritation of the parietal peritoneum is perceived as somatic pain which is conducted centrally by the visceral autonomic nervous system. In contrast to the parietal peritoneum, the splanchnic (visceral) peritoneum does not contain pain receptors (Smith).
The peritoneal cavity is defined as the potential space between the parietal and visceral peritoneum. The mesothelial cells that make up the lining of the peritoneal cavity produce the peritoneal fluid as well as surfactant. Surfactant acts as a lubricant to enable the abdominal viscera to move freely around each other as well as with the movement of the abdominal wall. Mesothelial cells lining the abdominal cavity are an abundant source of plasminogen activator which is responsible for normal fibrinolytic activity on the peritoneal surfaces (Slatter) (Smith).

Peritoneal fluid, a dialysate of plasma, is clear to pale yellow and is under constant production and absorption to maintain a colloid osmotic pressure of 28 mmHg with a nonlinear relationship between pressure and peritoneal protein concentration (3 g/dL). Under normal conditions, the peritoneal fluid is relatively acellular, with macrophages being the predominant cell type present (Latimer K.S.; Sammour T.; Slatter; Smith).

Defenses to the inciting cause of injury rely on the innate immune system as well as other mechanisms to absorb and localize trauma. The initial reaction to any inflammatory stimulus to the peritoneal cavity is the release of histamine, serotonin, and prostaglandins from the resident peritoneal macrophages and mast cells. In response to the histamine and serotonin, there is vasodilation and increased vascular permeability of the peritoneal vasculature leading to transudation of fibrinogen rich plasma into the peritoneal cavity.

Peritoneal macrophages also stimulate neutrophil chemotaxis via direct and indirect pathways. Macrophages release TNF-α and IL-1 to stimulate peripheral neutrophil margination and degranulation, and alter vascular endothelium to promote further leukocyte adherence and recruitment into the peritoneal cavity. Disruption of the cellular membrane results in phospholipid products being produced and activation of the inflammatory (arachidonic acid) cascade leading to increased prostaglandin production.
Activation of the extrinsic coagulation pathway, humoral opsonins, antibodies, and complement (C3a and C5a) further serve to enhance the inflammatory response and stimulate neutrophil chemotaxis and degranulation of basophils and mast cells. Humoral opsonins coat the bacteria and promote phagocytosis. Peritoneal associated lymphoid tissue produce immunoglobulins. Activated T lymphocytes and local antibody production are key in the local immune response as well (Latimer K.S.; Sammour T.; Slatter; Smith).

During times of effusion, mesothelial cells readily exfoliate, undergo hypertrophy and hyperplasia, and display characteristics of anisocytosis and anisokaryosis. In their activated state, activated mesothelial cells may also be difficult to distinguish from macrophages (Latimer). Disruption and/or loss of the mesothelial cells lining the peritoneal cavity cause a release of tissue thromboplastin which reduces the fibrinolytic capabilities of the peritoneal surface shifts the fibrinolysis-coagulation equilibrium. This shift toward fibrin formation aids to the seal the defect, provide framework for the fibroblasts to lay down collagen, as well as produce fibrous adhesions to localize bacteria. Disruption in fibrin clearance from the peritoneal fluid leads to development of fibrin clumps within the peritoneal cavity which occlude the peritoneal stomatas and impede movement and clearance of fluid and particles. Clumping of the fibrin also sequesters microbes from defense exposure, seals off any defects in the bowel wall, and acts as the first step in the process of fibrous adhesions (Davis; Latimer K.S.; Olivier van Till J.W.; Smith).

If the inflammatory defense response resolves, the mesothelial lining is restored in short order. Within four hours of injury, round cells of uncertain origin cover the traumatized area. The origination of mesothelial cells has not been fully determined; however, thoughts are that they differentiate from fibroblasts in subperitoneal connective tissue or implant from adjacent
normal structures or free-floating peritoneal macrophages. Once the peritoneal lining has been returned to homeostasis, normal fibrinolytic activity of the mesothelial cell returns and initiates removal of the accumulated fibrin clots (Smith).

Bacterial contamination is capable of spreading throughout the entire peritoneal cavity within three to six hours due to contractions of the abdominal wall, diaphragm, and intestine (Davis). During respiration, peritoneal fluid is cleared from the abdominal cavity through stomata between mesothelial cells covering the diaphragm into unidirectional lymphatic lacunae. The diaphragmatic lymphatics drain into the mediastinal lymph nodes, thoracic duct, and finally to the systemic circulation. Particles less than 10 µm in diameter are rapidly cleared from the peritoneal cavity (bacteria are 0.5-2.0 µm and red blood cells are 7-8 µm in diameter) and appear quickly in systemic circulation and in the lungs. In dogs, finely particulate graphite administered into the peritoneal cavity could be observed in the diaphragmatic lymphatics 10-90 minutes after injection. Factors that affect particle movement from peritoneal fluid into systemic circulation include: gravity, respiratory and diaphragmatic movements, intestinal activity as well as intraperitoneal pressure (Auer J.A.; Slatter; Smith).

Commonly, septic peritonitis is characterized by peritoneal fluid >5,000 nucleated cell count (NCC)/µL of which an increased number of degenerate neutrophils, > 2.5 g/dL total protein, and microscopically visible bacteria (Hunt E.; Malark J.A.; Reed; Southwood L.). Diffuse septic peritonitis in horses has been associated with abdominal abscesses, gastrointestinal ruptures, rectal tears, full thickness gastroduodenal ulcers, accidental intestinal puncture during abdominocentesis, and anastomotic leakages (Arnold C.E.; Chase J.P.; Elce). Peritonitis is one of the most common fatal post-operative complications following colic surgery with a 46% survival rate (Auer J.A.; Gray S.N.). In association with these pathologies, bacteria gain access
to the peritoneum and initiate an inflammatory response. The most common organisms cultured from septic peritoneal fluid in the horse are: *Escherichia coli*, *Klebsiella aerogenes*, and *Streptococcus faecalis* (Dyson; Shearman D.J.).

Visceral pain relies on neuronal signaling from the autonomic nervous system. Which is composed of both the sympathetic and parasympathetic nervous systems. Most organs are innervated by both systems which help to mediate the control (Riviere).

In brief, the sympathetic nervous system originates from cell bodies localized within the intermediolateral columns of the thoracic and lumbar regions of the spinal cord. The sympathetic nervous system, or the sympathoadrenomedullary axis, monitors the moment to moment of the body and maintains hemostasis. However, it is also the key originator of the “fight or flight” stimulation when mass, coordinated action is needed during times of danger or stress. The adrenal medulla is a key component of this system. It is homologous to a sympathetic ganglion in the periphery, however, it houses secretory chromaffin cells that release epinephrine and norepinephrine. The adrenal medulla is innervated by pre-ganglionic fibers from the mid-thoracic spinal cord. For the rest of the sympathetic nervous system, cell bodies exit the cord within the bilateral, ventral nerve routes and enter the paravertebral chain of sympathetic ganglia. These prevertebral ganglia are located in the peripheral tissues and are grouped according to their location. The cranial, middle, and caudal cervical prevertebral ganglia provide fibers to the head and neck whereas the thoracic cavity is supplied by the cervical and anterior thoracic ganglia. Abdominal sympathetic ganglia supply fibers to the abdominal cavity and pelvic viscera (celiac, cranial mesenteric, caudal mesenteric). Neurotransmitters within this system include use of acetylcholine at the level of the ganglion and
norepinephrine at the post ganglionic effector cell. Due to the release of norepinephrine post synoptically, the sympathetic nervous system is known as “adrenergic” (Riviere).

In contrast, the parasympathetic nervous system, also known as the cholinergic or craniosacral outflow, originates in the midbrain, medulla oblongata, and sacral spinal cord. Different from the overall homeostasis provided by the sympathetic nervous system, the parasympathetic pathway is not organized for mass action. Instead, it regulates localized organ changes and reacts to generate and maintain biologic energy. The vagus nerve is the most important participant in the parasympathetic trunk. It originates from the medulla oblongata and with efferent fibers running to all thoracic and abdominal viscera. Within the sacrum, nerve fibers originate from the sacral spinal cord and terminate in the ganglion cells located in the colon, bladder and sex organs. Contrasting to the sympathetic nervous system, the parasympathetic nerves have a discreet discharge and affect specific effector organs. Unlike the adrenergic system, the parasympathetic also uses acetylcholine as a neurotransmitter both at the ganglion as well as the postganglionic effector cell (Riviere).

Integration of the autonomic nervous system is crucial. Afferent fibers as well as brain nuclei influence peripheral motor function. Afferent fibers transmit information concerning visceral pain, cardiovascular activity and respiration from the peripheral receptive areas to the central nervous system. These fibers are non-myelinated and pass into the central nervous system using autonomic nerve trunks such as the vagus cranial nerve and the pelvic nerves. Afferent fibers provide signaling predominantly to the hypothalamus which then modulates both sympathetic and parasympathetic outflow. The hypothalamus is primarily involved in the function of blood pressure, body temperature, carbohydrate metabolism, electrolyte balance,
sexual responses, emotions and sleep. The medulla oblongata integrates the signaling from hypothalamus to help regulate blood pressure and respiration (Riviere).

As has been stated, viscera have many different types of sensory receptors. The parenchyma of the liver and lungs are insensitive to pain; however, the liver capsule as well as the bronchi and parietal pleura of the lungs are extremely sensitive to pain. What is interesting though is that highly localized damage to the viscera seldom cause severe pain. However, any stimulus that causes diffuse stimulation of pain nerve endings throughout a viscous structure (occluding the blood supply to a large area of intestine) causes pain that can be severe. All true visceral pain that originates from either the thoracic or abdominal cavities is transmitted through the autonomic nervous system. In cases where there is an ischemic event, the formation of acidic metabolic products or degradative products (bradykinin or proteolytic enzymes) serve to signal activation of broad areas along autonomic nerve fibers. Mechanical stimulation of a viscous structure and subsequent activation of pain signaling may occur due to over distention/filling of the hollow viscous structure, and smooth muscle spasms. (Guyton A.C.)

The brain is unable to determine which internal organs are the source of visceral pain. Sensations of pain from the abdomen and the thorax are transmitted through two pathways into the central nervous system – the true visceral pathway using the sensory fibers of the autonomic nerves (both sympathetic and parasympathetic) and the referred pain sensations on surface areas of the body. These referred pain sensations result when a visceral structure appreciates pain followed by signaling that usually spreads to the parietal pleura or peritoneum. Parietal surfaces are supplied with extensive pain innervation from peripheral nerves. Once the peripheral nerves of the parietal pleura/peritoneum/pericardium perceive pain, it is conducted directly into the local
spinal nerves directly over the painful area. Due to this dual transmission, pain from the viscera is localized to a surface area of the body at the same time (Guyton A.C.).

Treatment of acute, visceral pain is a key component of equine practice. Even more critical is the treatment and management of post-operative pain after an exploratory laparotomy. Due to the animal size, vascular compromise secondary to underlying pathology as well as risk associated with general anesthesia, recovery and immediate post-operative management of the equine patient is a challenge. The vast majority of work describing the pharmacology behind drug disposition, movement and effect has been performed in healthy animals with limited levels of pain and inflammation. Assumptions are then made and applied to practice using these “healthy” animal studies where, in truth and practice, when these agents are being used for therapeutic intervention characteristics of drug movement are very different.
Chapter 3. Pilot Study: Non-septic, transient, peritonitis model for use in evaluating drug movement in the equine patient

“I’ll bet you a beer this will work”

– Dr. John Schumacher

Abstract

Thirteen adult healthy horses (geldings and mares) weighing approximately 900-1,300 lbs. (409-590 kg) were selected for use in this study. Horses were screened for inclusion into this study based on complete blood count, serum biochemistry profile, screening abdominal ultrasound as well as abdominal examination per rectum. Horses were assigned to one of the treatment groups: abdominocentesis only (n=1), 500 mL of balanced crystalloid solution (n=1), 500 mL balanced crystalloid solution containing 50 mL heparin sodium citrate infusion (n=2), autologous plasma infusion with 50 mL of heparin sodium citrate (n=1), autologous whole blood with 50 mL heparin sodium citrate (n=2), or 500 mL autologous whole blood without anti-coagulant (n=6). Horses were monitored with physical examinations, urine/fecal output and water/food consumption monitored three times daily during the study. Peritoneal fluid and whole blood was also collected for a complete blood count and serum biochemistry in order to assess evidence of systemic response to peritoneal inflammation. Horses did not display any signs of systemic disease and all physical examinations were within clinical normal limits. In the group where whole blood was infused, horses showed evidence of mild abdominal discomfort, as well as a transient increase in peritoneal fluid nucleated cell count and total protein.
Introduction

In horses, peritoneal inflammation has been evaluated after repeated abdominocentesis (teat cannula or 18 gauge needle) with or without a planned enterocentesis. Post castration, there is an accumulation of a small amount of blood secondary to castration that causes a self-limiting peritonitis characterized by a transient increase in nucleated cells of peritoneal fluid without causing systemic disease (S. J. Schumacher J.; S. J. Schumacher J.) To date, there is no validated aseptic peritonitis model developed in the horse that produces predictable abdominal inflammation for a period of time sufficient to allow for evaluation of the effects of treatment. The objective of this study was to produce a minimally invasive and painful model for non-septic peritonitis that is self-limiting and does not develop into systemic disease or require treatment with analgesic drugs.
Materials and Methods

Animals

This project was approved by our Institutional Care and Use Committee. Thirteen adult healthy horses (geldings and mares) weighing approximately 900-1,300 lbs. (409-590 kg) were selected for use in this study. A physical examination, complete blood count, serum biochemistry profile, transabdominal ultrasonography, and abdominal examination per rectum was performed to ensure that each horse was healthy with no evidence of concurrent systemic or abdominal disease prior to being admitted into the study. Transabdominal ultrasound evaluated the amount and character of the peritoneal fluid present, motility of the small intestine, and intestinal wall thickness (<3 mm). Horses were excluded prior to study initiation if there was any evidence of systemic disease; increased abdominal fluid volume, echogenicity, or intestinal wall thickness on ultrasound examination; or any abnormalities detected during the abdominal examination per rectum.

Peritonitis Induction Model

Peritoneal fluid was collected from each horse prior to the initiation of the study with either manual (lip twitch) restraint or detomidine sedation (5 mg intravenously). Peritoneal fluid was collected at the most dependent part of the abdominal wall, distal to the xiphoid process of the sternum and approximately three cm to the right of midline. This area was clipped and aseptically prepared using alternating chlorhexidine scrub and alcohol rinse. The site of centesis was locally anesthetized using three mL of lidocaine (2%) deposited in the subcutaneously. A 1.5 inch 18-gauge hypodermic needle (Monoject, Cardinal Health, and Dublin, OH, USA) was
inserted at the surgically prepared area through the abdominal wall. In cases where fluid could not be collected using the hypodermic needle, a stab skin incision using a #15 scalpel blade was made in the anesthetized skin and muscle tunic. A 5-cm blunt-tipped, bovine teat infusion cannula was inserted through the stab incision and gently advanced through muscle and the peritoneum. Horses were excluded from the study if the baseline peritoneal NCC was >5,000 cells/µL and/or total protein greater than >2.5 g/dL. If a horse was withdrawn from the study as a result of preliminary screening, a replacement horse was used for pre-study evaluation.

Horses within the infusion treatment groups had a two inch x two inch area in the left paralumbar fossa half way between the last rib and tuber coxae aseptically prepared with alternating chlorhexidine scrub and alcohol rinse. The skin at the center of the scrubbed area was locally anesthetized using three mL of lidocaine (2%). After a stab skin incision using a #15 scalpel blade was made in anesthetized skin, a 3.5-inch bovine teat cannula was inserted through the stab incision and gently advanced through muscle and the peritoneum by the investigators. A three-way stop cock was used to keep the abdominal cavity unexposed to room air between infusions. The abdominocentesis group did not receive the infusion procedure.

On the day of pilot study initiation, horses were assigned to one of the following treatment group: abdominocentesis only (n=1), 500 mL of balanced crystalloid solution (Plasmalyte, Baxter HealthCare Corporation, Deerfield, IL) (n=1), 500 mL balanced crystalloid solution (Plasmalyte, Baxter HealthCare Corporation, Deerfield, IL) containing 50 mL heparin sodium citrate infusion (n=2), autologous plasma infusion with 50 mL of heparin sodium citrate (n=1), autologous whole blood with 50 mL heparin sodium citrate (n=2), and 500 mL autologous whole blood without anti-coagulant (n=6).
Crystalloid Fluid Infusion - One horse was infused with 500 mL of a balanced crystalloid electrolyte solution (Plasmalyte, Baxter HealthCare Corporation, Deerfield, IL) as a baseline control for both the infusion process as well as fluid volume. Two horses were infused with 500 mL of a commercial, balanced crystalloid electrolyte solution (Plasmalyte, Baxter HealthCare Corporation, Deerfield, IL) containing 50 mL of the anticoagulant heparin sodium citrate. This treatment group would help assess the contribution of the anticoagulant for initiating the inflammatory response.

Autologous Plasma - One horse was infused with autologous plasma (500 mL) combined with 50 mL of heparin sodium citrate. In order to accomplish this, aseptic collection of three L whole blood (minimum amount necessary to ensure collection of 500 mL of plasma after processing) into a blood collection bag containing 120 mL heparin sodium citrate. Once the whole blood was collected, it was immediately centrifuged and 500 mL of plasma was aseptically harvested and infused back into the respective horses under aseptic conditions.

Whole Blood - To assess the contribution of the anticoagulant present with whole blood in its ability to initiate an inflammatory response, 500 mL whole blood was collected into a sterile bag containing 50 mL heparin sodium citrate. In the final treatment group, six horses were infused with autologous whole blood without anticoagulant present. Autologous whole blood (500 mL) aseptically collected from the horse’s jugular vein immediately before injection into the peritoneal cavity. A 14-gauge, 1.5 inch needle (Monoject, Cardinal Health, Dublin, OH, USA) was used to sterilely collect 500 mL of whole blood into sterile 60 mL syringes by the investigators. As the whole blood was collected from the jugular vein, it was immediately infused into the peritoneal cavity to avoid clot formation.
E*valuation of Peritonitis Induction Model

After intraperitoneal infusions (where applicable) had been performed, horses were returned to their stalls for further evaluation. At days 1 through 5 post infusion, abdominal ultrasounds were performed to evaluate peritoneal fluid accumulation, gastrointestinal motility and intestinal wall thickness. Abdominal examinations *per rectum* were performed daily to detect changes within the abdominal cavity. Peritoneal fluid was collected daily as previously described. If peritoneal fluid parameters were normal or had returned to normal (<5,000 NCC/µL and <2.5 g/dL total protein) on any of these days, or failed to increase to > 10,000 NCC/µL, the horse was returned to pasture and no further evaluation was performed. All peritoneal fluid samples were collected in two EDTA tubes, and immediately refrigerated (4°C) and stored for evaluations of peritoneal nucleated cell counts and total protein. Twenty milliliters of whole blood was also collected for a complete blood count and serum biochemistry profile in order to assess evidence of systemic response to peritoneal inflammation.

Horses were monitored with physical examinations, urine and fecal output, and water and food consumptions three times daily during the study. Physical examination parameters including increased heart and respiratory rate, prolonged capillary refill time, mucosal character, and skin tent were used to assess pain, perfusion, and hydration. Assessment of abdominal discomfort was monitored based on the criteria and grading scale set forth previously by (Southwood L.L.).
**Statistical Analysis**

Parameters (nucleated cell count and total protein) were evaluated using a one-way ANOVA (SAS/IML 9.1, User’s Guide: statistics, Cary, NC) and Tukey’s test for multiple comparison for repeated measures. Significance was considered at $P \leq 0.05$. 
**Results**

At no point during the pilot study did horses develop signs of systemic illness with temperature, heart and respiration rates, capillary refill time, and mucous membrane color being within clinical normal limits. Complete blood cell counts and serum chemistries also stayed within reference ranges between baseline and completion of the study.

Decreased gastrointestinal sounds were appreciated in three treatment groups: balanced crystalloid solution with anticoagulant (48 hours post treatment; n = 1), plasma (60 hours post treatment; n = 2), and whole blood (60 hours post treatment; n = 3). Splinting of the abdominal muscles were noted in three abdominal infusion treatment groups: balanced crystalloid solution with anticoagulant (12, 36, and 48 hours post treatment; n=1), plasma (36 and 48 hours post treatment; n = 1), and whole blood infusion (12, 36, and 48 hours post treatment; n = 3). All gastrointestinal sounds as well as splinting of the abdomen returned to clinical normal levels prior to completion of the study.

Transabdominal ultrasound findings considered consistent with peritonitis included: increased volume of peritoneal fluid, thickened small intestinal wall (> 3 mm in diameter), and decreased evidence of motility. Eight horses showed evidence of decreased gastrointestinal motility in this study. The description of this population is found within Table 3.1. Thickened small intestinal walls (4 mm, n = 2; 5 mm, n=1) were appreciated in three horses, and occurred 24 hours post whole blood intra-abdominal infusion.
Table 3.1. Subjective abnormal abdominal ultrasound findings of horses after being treated with intra-abdominal infusion of autologous plasma, crystalloid solution and heparin, and whole blood (n=7).

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Number Horses Affected</th>
<th>Hours Post Infusion (horse number)</th>
<th>Characterization of Motility</th>
</tr>
</thead>
<tbody>
<tr>
<td>Autologous Plasma</td>
<td>1</td>
<td>48 (1)</td>
<td>Decreased motility</td>
</tr>
<tr>
<td>Crystalloid Heparin</td>
<td>2</td>
<td>24 (1), 48 (1)</td>
<td>Decreased motility</td>
</tr>
<tr>
<td>Whole Blood</td>
<td>4</td>
<td>24 (4), 48 (3)</td>
<td>Decreased motility</td>
</tr>
</tbody>
</table>
All palpations of the abdomen *per rectum* were performed by a single clinician (HAD). In four horses treated with intra-abdominal infusion of whole blood only, the large colon subjectively felt firmer and more pronounced at 24 hours (n = 1), 48 hours (n = 3), and 72 hours (n = 3).

Peritonitis in the equine patient has been defined as NCC >5-10,000 /µL and a total protein >2.5 g/dL depending on the literature. Only one sample from the whole blood group at 72 hours reached peritoneal white blood cell and total protein concentration consistent with the clinicopathologic diagnosis of peritonitis. Data for peritoneal NCC count and total protein are summarized in Tables 3.2 and 3.3 as well as Figures 3.1, 3.2, 3.3, and 3.4.
Table 3.2. Peritoneal nucleated cell counts for each treatment group for each time point post treatment (n=13). Values are reported as the mean and range.

<table>
<thead>
<tr>
<th>Hours Post Infusion</th>
<th>Abdomino-centesis (n=1)</th>
<th>Autologous Plasma (n=1)</th>
<th>Crystalloid (n=1)</th>
<th>Crystalloid Heparin (n=2)</th>
<th>Whole Blood (n=6)</th>
<th>Whole Blood Heparin (n=2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0 (Prior)</td>
<td>1750</td>
<td>1900</td>
<td>600</td>
<td>745 ± 35</td>
<td>1238.33 ± 570</td>
<td>570 ± 874.61</td>
</tr>
<tr>
<td>24</td>
<td>1550</td>
<td>2450</td>
<td>2220</td>
<td>12650 ± 10830</td>
<td>5086.67 ± 8745</td>
<td>12015 ± 8057.06</td>
</tr>
<tr>
<td>48</td>
<td>2460</td>
<td>23540</td>
<td>1140</td>
<td>6640 ± 4640</td>
<td>822 ± 20730</td>
<td>38410 ± 8802.50</td>
</tr>
<tr>
<td>72</td>
<td>2350</td>
<td></td>
<td></td>
<td></td>
<td>8911 ± 825</td>
<td>10685 ± 6181</td>
</tr>
<tr>
<td>96</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>10705</td>
<td>11510 ± 3305</td>
</tr>
<tr>
<td>108</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>7400</td>
<td>4690</td>
</tr>
</tbody>
</table>
Figure 3.1. Peritoneal nucleated cell counts comparing treatment groups abdominocentesis (n=1), whole blood with heparin (n = 2), and whole blood only (n= 6). Values represent mean values for horses where applicable. Error bars are standard deviation.
Figure 3.2. Peritoneal nucleated cell counts comparing treatment groups crystalloid fluid infusion (n=1), crystalloid fluid with heparin (n = 2), and autologous plasma (n= 1). Values represent mean values for horses where applicable. Error bars are standard deviation.
Table 3.3. Peritoneal total protein values for each treatment group for each time point post treatment (n=13). Values are reported as the mean and range.

<table>
<thead>
<tr>
<th>Hour</th>
<th>Abdomino-centesis (n=1)</th>
<th>Autologous Plasma (n=1)</th>
<th>Crystalloid (n=1)</th>
<th>Crystalloid Heparin (n=2)</th>
<th>Whole Blood (n=6)</th>
<th>Whole Blood Heparin (n=2)</th>
</tr>
</thead>
<tbody>
<tr>
<td>0</td>
<td>0.9</td>
<td>0.8</td>
<td>0.2</td>
<td>1.65 ± 0.35</td>
<td>1.42 ± 0.41</td>
<td>0.65 ± 0.45</td>
</tr>
<tr>
<td>24</td>
<td>0.9</td>
<td>1.3</td>
<td>0.7</td>
<td>0.75 ± 0.35</td>
<td>1.03 ± 0.58</td>
<td>1.9 ± 0.1</td>
</tr>
<tr>
<td>48</td>
<td>0.5</td>
<td>1.6</td>
<td>0.5</td>
<td>1.7 ± 0.3</td>
<td>1.03 ± 0.73</td>
<td>1.05 ± 0.25</td>
</tr>
<tr>
<td>72</td>
<td>0.7</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.45 ± 0.15</td>
</tr>
</tbody>
</table>
Figure 3.3. Peritoneal total protein comparing treatment groups abdominocentesis (n=1), whole blood with heparin (n = 2), and whole blood only (n= 6). Values represent mean values for horses where applicable.
Figure 3.4. Peritoneal total protein comparing treatment groups crystalloid fluid infusion (n=1), crystalloid fluid with heparin (n = 2), and autologous plasma (n= 1). Values represent mean values for horses where applicable.
Adverse events during the course of the study were limited to two horse with inadvertent enterocentesis at 24 and 48 hours which no further samples were taken. Development of a ventral edema plaque around the sites of sample collection occurred in five horses and might have been due to an allergic reaction secondarily to the use of chlorhexidine scrub solution when performing sterile preparations to the area.

Based on these 13 horses, there were no significant differences in the peritoneal nucleated cell counts and total protein between the treatment groups.
Discussion

The goal of using models for evaluation of disease states is to develop a model that mimics the severity of the natural disease. After an initial insult to the abdominal cavity, the resident peritoneal macrophages and mast cells release histamine and serotonin. These mediators act on the peritoneal vasculature to cause increased permeability and transudation of proteins and fluids into the abdominal cavity. The inflammatory response is continually propagated by release of various chemokines (TNFα, IL-1), prostaglandins, and leukotrienes (Barton M.H.; Davis). Animal models for peritonitis have been used to mimic all facets of sepsis in people including speed of onset, range of clinical signs, hemodynamic changes, immunologic changes associated with treatment, and histologic changes in abdominal organs secondary to sepsis (Doi K.). These studies are often performed using the rodent model. Creation of peritonitis in the rat is typically created using one of three methods: injection of an exogenous toxin, alteration of the animal’s endogenous protective peritoneal barrier, or infusion of exogenous bacteria into the peritoneal cavity. Under sterile conditions, injection of lipopolysaccharide (LPS) causes an early and transient increase in inflammatory mediators more intense than seen in human peritoneal sepsis. By ligating the cecum and subsequently puncturing the visceral surface, the abdominal cavity is exposed to multiple types of bacteria flora creating a model of peritonitis similar to that often encountered in rodent research to model human sepsis. Finally, peritonitis created by infusion of exogenous bacteria can be somewhat regulated by controlling type and amount of bacteria instilled into the peritoneal cavity; however, clinical response to this model of peritonitis has been variable in horses (Brocco M.C.; Doi K.; M. L. Mendes L.C.N.).
Peritonitis modeling may also occur under aseptic conditions including chemical serosal irritation and vascular compromise to the viscera. Exposure of the abdominal cavity to gastric contents, bile, pancreatic enzymes, or whole blood results in irritation to the serosal surface of the abdominal cavity. Depending on the type and amount of chemical used, extent and time of exposure, the serosal irritation may result in erosion and subsequent visceral rupture leading secondary bacterial infection of the abdomen (Chase J.P.; Shearman D.J.).

No matter which model is used to initiate pathology, once the animal (most likely rodent) begins to show signs of systemic disease, therapeutic agents or treatment interventions are administered for evaluation (Chase J.P.). From rodent models, researchers have been able to evaluate medical management of peritonitis using systemic drugs as well as peritoneal infusions of drug and lavage techniques. For instance, Mendes et al, used direct infusion of *E.coli* or *Bacteroides fragillis* to create peritoneal inflammation in rats. In that study, the researchers were able to appreciate both systemic and local response indicative of inflammation (M. L. Mendes L.C.N.; M. L. Mendes L.C.N.). Recently, intraperitoneal infusion of LPS has been shown to initiate a response sufficient to study the inflammatory mediators both in the peripheral blood as well as in the peritoneal fluid (Peiro J.R.).

Horses in this study did develop evidence of a mild, transitory inflammatory response after infusion of whole blood into the abdomen; however, levels of both NCC and total protein did not meet acceptable levels to be classified as clinicopathological peritonitis. Despite this, patients treated with whole blood showed evidence of peritoneal inflammation on ultrasonographic evaluation with decreased motility, thickened loops of small intestine, and increased/alterations of the peritoneal fluid character. Also, horses showed mild evidence of abdominal pain (abdominal splinting) which would correspond to what was being appreciated
clinically. Subjectively, examinations also confirmed decreased motility as increased turgidity of the wall of the large colon was appreciated during abdominal palpations per rectum. Further studies should also monitor peritoneal pH as well as peripheral and peritoneal D-Dimer, glucose, and lactose levels as these have become valuable diagnostic aids in assessing systemic disease in the equine patient. (Auer J.A.; M. L. Delgado M.A.; M. L. Delgado M.A.).

In this pilot study, investigators did not detect a significant difference between the treatment groups. This may be due to the volume (500 mL) of infusion that was used. The volume may not be sufficient enough to elicit an inflammatory response due to decreased ability to contact the serosal surfaces of the abdominal cavity. Despite there not being a statistical difference between groups, the whole blood infusions (with and without the anticoagulant present) did appear to be more likely to initiate a response than the other treatments. Based on the horse’s tolerability to the various treatment modalities, further studies should be considered using larger volumes of blood to further evaluate this aseptic model of peritonitis. This may also include the evaluation of a variety of endogenous intraperitoneal cytokine (TGF-β) release as well as the effects of pharmacotherapy on their levels (Arguelles D.).

Studies evaluating the concentration of antimicrobial drugs within the peritoneal cavity are limited to healthy horses with intact, non-inflamed peritoneal mesothelial linings. In the majority of research studies, the pharmacologic effects of antimicrobial and anti-inflammatory drugs are evaluated in healthy, normal animals; however, the effects of therapeutic interventions often behave differently under inflammatory conditions. By creating a mild chemical inflammatory peritonitis in horses, the risks of causing systemic disease is minimized and allows for evaluation of performance of therapeutic options within the inflamed abdomen.
Chapter 4. Impact of Route, Volume, and Fed/Fasted State on Acetaminophen Disposition after Oral Administration in the Horse

“Live by the words of Aaron Tippin –
You’ve got to stand for something, or you’ll fall for anything...”

-Dr. Haden Bunn

Abstract

To investigate the impact of: route, volume, and fasting versus fed state on orally administered acetaminophen using six healthy adult horses in a randomized, cross-over study design. All six horses received a 20 mg/kg dose of acetaminophen using two different oral routes of administration (nasogastric versus syringe), two different volumes (100 vs 1500 mL), and in the fed versus fasted state. Whole blood was intermittently collected from an indwelling intravenous catheter at designated time points over a 24-hour period. Acetaminophen was quantitated in serum using an ACTM Flex® reagent on a Siemens Dimension Xpand Plus® general chemistry analyzer. Data was subjected to non-compartmental analysis and key parameters were compared between methods of administration. Maximum plasma drug concentration (C_{max}: 11 \mu g/mL ± 4) as well as area under the curve (AUC: 1916.9 \mu g/mL/hr ± 1117) were higher when given with 1.5 L of water via nasogastric tube vs dissolved in 100 mL through a syringe and in the fasted versus fed state. Systemic exposure of acetaminophen was increased when the drug was given dissolved in a large volume via a nasogastric tube in a fasted state.
Introduction

Currently, there is not a “standard of care” for evaluating drug movement in the equine patient. Pharmacokinetic studies evaluating oral administration in horses most commonly involve administration of either a paste or liquid formulation. However, when these are unavailable, a solid dosing form of the drug (tablet or capsule) is crushed or opened and administered as a powder one of several ways: spread over grain, dissolved in a small volume of water and then administered in a syringe, or as a large volume solution via nasogastric tube. Pharmacologically, multiple factors can affect a drug’s ability to be absorbed. In people, studies have shown the volume in which a drug is administered markedly impacts the rate (time to maximum drug concentration) and extent that it reaches systemic circulation (maximum plasma drug concentration, area under the curve, and bioavailability) (Neirinck E.). Depending on the characteristics of the drug, absorption may also be affected by the presence or absence of food in the stomach and small intestine.

Acetaminophen, a centrally-acting analgesic and antipyretic, is a small (151.2 g/mol), moderately lipid-soluble weak organic acid. It is classified by the Biopharmaceutics Classification System as a Class 1 model drug indicating high solubility, high permeability, and with an overall ease of absorption into systemic circulation (Hatanaka S.). Although poorly absorbed in the stomach, acetaminophen is readily absorbed from the small intestine of dogs, rats, and ponies (Clements J.A.; Doherty T.J.; Mizuta H.). As such, a direct relationship has been found between rate of gastric emptying and serum concentrations of orally administered acetaminophen in horses (Lammers T.) Absorption of acetaminophen powder (dissolved in 350 mL of water) has proven an effective and safe marker for gastric emptying in ponies after administration by nasogastric intubation (Clements J.A.).
The purpose of this study was to demonstrate that the method of oral drug delivery in horses impacts drug disposition. Investigators hypothesized the oral bioavailability of acetaminophen, specifically maximum plasma drug concentrations and area under the curve, would be less when administered to horses via a syringe compared to nasogastric tube, in a small versus large volume via nasogastric tube, and in a fasted versus non-fasted state. Results from this study will allow researchers to be able to establish a foundation for drug evaluation in the horse.
Materials and Methods

Animals

This study was approved by the university’s Institutional Animal Care and Use Committee. The study was implemented using a randomization table in a four-way cross-over design. Six adult healthy horses (five geldings and one mare), weighing 454-590 kg were selected from the equine teaching herd. The entirety of the study was comprised of four treatment groups (Table 4.1).

Table 4.1. Treatment group descriptions and paired comparisons (n=6) horses per grouping.

<table>
<thead>
<tr>
<th>Treatment Group</th>
<th>Treatment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group 1</td>
<td>SYR 100 mL</td>
</tr>
<tr>
<td>Group 2</td>
<td>NGT 100 mL</td>
</tr>
<tr>
<td>Group 3</td>
<td>NGT 1.5 L</td>
</tr>
<tr>
<td>Group 4</td>
<td>NF NGT 1.5 L</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Comparison</th>
<th>Treatment Groups</th>
<th>Method</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effects of route of administration</td>
<td>1, 2</td>
<td>SYR 100 mL, NGT 100 mL</td>
</tr>
<tr>
<td>Effects of volume of administration</td>
<td>1, 3</td>
<td>NGT 100 mL, NGT 1.5 L</td>
</tr>
<tr>
<td>Effects of fed vs. fasted</td>
<td>3, 4</td>
<td>NGT 1.5 L, NF NGT 1.5 L</td>
</tr>
</tbody>
</table>

NGT = nasogastric tube, NF = non-fasted, SYR = syringe.
Apparent health of the horses was determined by physical examination, complete blood count and serum biochemistry profile. All horses received acetaminophen (powder at a dose of 20 mg/kg [Alfa Aesar]) dissolved in water with methods varying among the four treatment groups. The horses in treatment Groups 1-3 were fasted for 8 hours prior to treatment and for 4 hours after drug administration. The horses in Group 4 were not fasted prior to or during the study. Immediately prior to drug administration, a 4-inch diameter area in the jugular groove was clipped and prepared in an aseptic manner for five minutes using a chlorhexidine scrub and isopropyl alcohol for catheter placement. A 14-gauge 5.5 inch intravenous catheter (Abbocath, Hospira, Lake Forest, IL) was placed in jugular vein using sterile technique.

**Drug Administration**

The volume and method of delivery were randomly assigned to one of four groups as follows: Group 1 (SYR 100mL) – the dose was dissolved with 100 mL of water and administered orally through a syringe to fasted horses; Group 2 (NGT 100 mL) – the dose was dissolved in 100 mL of water and administered to fasted horses via funnel through a preplaced nasogastric tube followed by 800 mL of air to empty all liquid from the nasogastric tube (3/8 inches internal diameter, 9 feet long). Group 3 (NGT 1.5L) – the dose was dissolved in 1.5 L of water and administered to fasted horses via funnel through a preplaced nasogastric tube. The dose was followed by 800 mL of air to empty all liquid from the nasogastric tube (3/8 inches internal diameter, 9 feet long). Group 4 (NF NGT 1.5L) - the dose was dissolved in 1.5 L of water and administered to non-fasted horses via funnel through a preplaced nasogastric tube. The dose was followed by 800 mL of air to empty all liquid from the nasogastric tube (3/8 inches...
internal diameter, 9 feet long). In groups 2, 3, and 4, the nasogastric tube was placed with the use of manual restraint and removed immediately after drug administration.

**Sample Collection**

Blood samples were collected through the indwelling jugular catheter of each horse at pre-determined, timed intervals. Whole blood was collected at times 0, 10, 20, 30, 45, 60, 75, 120, 150, 180, 270, 360 minutes (1, 1.25, 2, 2.5, 3, 4.5 hours), 6, 9, 12, and 24 hours after treatment and placed in red topped tubes (BD Vacutainer, Sodium Heparin, BD, Franklin Lakes, NJ, USA). Once a sample was collected, the catheter was flushed thoroughly with heparinized saline (Monoject PreFill IV Flush, Cardinal Health, and Dublin, OH). Blood samples were separated into their components (packed red blood cells and serum) by centrifugation at 1900 g (3000 rpm) for 15 minutes and serum was stored at 0°F until samples processed. Catheters were removed, and horses were returned to their paddocks after the 24-hour sample. After at least a 72-hour washout period, the study was repeated using a different dosing technique and the opposite jugular vein.

**Sample Analysis**

Acetaminophen equine serum concentrations were quantitated using an ACTM Flex® reagent (Siemens) which enzymatically hydrolyzes acetaminophen into acetate and p-aminophenol. The concentration of p-aminophenol is then detected colorimetrically and quantitated using a bi-chromatic endpoint technique (Siemens Dimension Xpand Plus® general chemistry analyzer; New York, NY). Unknown concentrations of acetaminophen in each sample were predicted by comparing the signal to a calibration curve (2, 10, 25, 50, 100, 150, and 300
µg/mL) generated by fortifying equine serum with known amounts of acetaminophen that ranged from 2-300 µg/mL. A calibration curve was accepted if the coefficient of determination (r^2) was at least 0.998 and the predicted concentrations were within 10% of the actual concentrations. Assay guidelines were followed to determine the lower and upper limits of quantification (LOQ) for acetaminophen as 2 µg/mL and 300 µg/mL respectively, based on the lowest and highest control that was studied and was accurately and precisely predicted within 15%. Intra and inter assay variability was less than 10% for all controls.

**Pharmacokinetic Analysis**

Serum acetaminophen concentration versus time data samples were subjected to non-compartmental analysis (Phoenix Winnonlin, Cetera®, Version 8, Sunnyvale, CA, USA) using the log-linear trapezoidal method. Parameters included AUC from time zero extrapolated to infinity (µg*hr/mL), C_{max} (oral, µg/mL) at time (T_{max};h); terminal half-life (t_{1/2}; h), mean residence time (MRT; h), and elimination rate constant (k_{el}) . Relative bioavailability for each group was based on the ratio of AUC of that group relative to the group with the greatest AUC. Descriptive statistics (mean, 95% confidence interval) were generated for each parameter. PK parameters were compared by route of administration (Table 1) using repeated measures analysis of variance (RM-ANOVA; α=0.05) with post-hoc testing via Tukey’s method in SAS v9.1 (SAS Institute, Cary, NC).
Results

Pharmacokinetic parameters for each group are listed in Table 2.2. The AUC (µg/mL/hr) for each route of administration are as follows: Group 1 (SYR 100 mL) (652.89 ± 336.83), Group 2 (NGT 100 mL) (1393.67± 630.91), Group 3 (NGT 1.5L) (3445.87±1116.72), and Group 4 (NF NGT 1.5L) (1916.86 ± 847.20). The $C_{\text{max}}$ (µg/mL) for the formulations were as follows: Group 1 (SYR 100 mL) (8.12± 6.31), Group 2 (NGT 100 mL) (11.10 ±6.57), Group 3 (NGT 1.5L) (21.92 ± 3.91), Group 4 (NF NGT 1.5) (11.37±3.29). Relative bioavailability (%) was based on the ratio of AUC of Groups 1, 2 and 4 to AUC of Group 3 (the highest mean AUC): for Group 1, 18.9%, Group 2, 40% and Group 4, 57%.
Table 4.2. Mean pharmacokinetic parameters for acetaminophen when administered in apparently healthy horses (n=6). Data is reflected as the geometric mean and the 95% Confidence Interval.

<table>
<thead>
<tr>
<th></th>
<th>Group 1 (SYR 100 mL)</th>
<th>Group 2 (NGT 100 mL)</th>
<th>Group 3 (NGT 1.5 L)</th>
<th>Group 4 (NF NGT 1.5 L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>( \text{AUC} (\mu \text{g/mL/min}) )</td>
<td>652.9 (299-1006)</td>
<td>1393.7 (610-2177)</td>
<td>3445.9 (2274-4618)*</td>
<td>1916.9 (1028-2806)*</td>
</tr>
<tr>
<td>( \text{Cmax (ng/mL)} )</td>
<td>8.1 (2-15)</td>
<td>11.1 (4-18)</td>
<td>21.9 (18-26)*</td>
<td>11.4 (8-15)</td>
</tr>
<tr>
<td>( t_{1/2} ) (min)</td>
<td>41.9 (26-58)</td>
<td>115.2 (-2-232)</td>
<td>81.7 (32-132)</td>
<td>81.2 (3-160)</td>
</tr>
<tr>
<td>( \text{MRT (min)} )</td>
<td>100.2 (80-120)</td>
<td>210 (-45-465)</td>
<td>134.6 (97-172)</td>
<td>150.3 (62-239)</td>
</tr>
<tr>
<td>( \text{CL/F (mL/min/kg)} )</td>
<td>45.2 (4-87)</td>
<td>20.4 (0-41)</td>
<td>6.4 (4-9)*</td>
<td>13.1 (5-22)</td>
</tr>
<tr>
<td>( \text{Vd/F (mL/kg)} )</td>
<td>2710.6 (-2-5423)</td>
<td>2582.2 (562-4602)</td>
<td>651.8 (441-863)</td>
<td>1105.9 (238-1974)</td>
</tr>
<tr>
<td>( \text{Kel (1/min)} )</td>
<td>0.02 (0.01-0.03)</td>
<td>0.01 (0-0.02)</td>
<td>0.01 (0.01-0.02)</td>
<td>0.02 (0-0.04)</td>
</tr>
<tr>
<td>( F ) (relative)</td>
<td>-</td>
<td>2.4 (1.4-4.2)</td>
<td>6.1 (3.5-10.6)</td>
<td>3.2 (1.9-5.6)</td>
</tr>
</tbody>
</table>

*Indicates a statistically significant difference \((p < 0.05)\) between the specified group and Group 1 (SYR 100 mL).

*F (relative) comparison between the specified group and Group 1 (SYR 100 mL). Values indicate a fold difference

AUC = area under the curve; \( C_{\text{max}} \) = maximum plasma drug concentration; \( t_{1/2} \) = elimination half-life; MRT = mean resonance time; CL/F = apparent oral clearance; Vd/F = apparent oral volume of distribution; kel = disappearance kel; NGT = nasogastric tube; NF = non-fasted; SD = standard deviation; CI = confidence interval; * indicates significant differences. Apparent oral clearance and apparent oral volume of distribution do not take into account the bioavailability of the drug.
The effects of method of oral delivery on acetaminophen absorption were based on comparison of Group 1 (SYR 100 mL) to Group 2 (NGT 100 mL) (p<0.05) (Figure 1). The AUC and $C_{\text{max}}$ tended to be significantly greater for Group 2 (NGT 100 mL) when compared to Group 1 (SYR 100 mL). Relative bioavailability of the SYR method compared to NGT was 18.9%.
Figure 4.1. Serum acetaminophen concentrations comparing route of administration between Group 1 (SYR 100 mL) to Group 2 (NGT 100 mL) (n= 6). Data is reflected as the geometric mean and the 95% Confidence Interval. Accompanying pharmacokinetic data is found in Table 4.2. C\textsubscript{max} and AUC were significantly different between groups (p<0.05).

AUC = area under the curve; C\textsubscript{max} = maximum plasma drug concentration; NGT = nasogastric tube
The effects of volume on acetaminophen absorption were based on comparison of Group 2 (NGT 100 mL) to Group 3 (NGT 1.5L) (Figure 4.2). The AUC and $C_{\text{max}}$ were statistically significantly greater for Group 3 (NGT 1.5L) when compared to Group 2 (NGT 100 mL) ($p<0.05$). Relative bioavailability of the lower compared to higher volume was 40%.
Figure 4.2. Serum acetaminophen concentrations comparing volume of administration Group 2 (NGT 100 mL) to Group 3 (NGT 1.5 L) (n = 6). Data is reflected as the geometric mean and the 95% Confidence Interval. Accompanying pharmacokinetic data is found in Table 4.2. \(C_{\text{max}}\) and AUC were significantly different between groups (p<0.05).

AUC = area under the curve; \(C_{\text{max}}\) = maximum plasma drug concentration; NGT = nasogastric tube
The effects of fasting on drug absorption were based on comparing Group 3 and 4. A non-fasted state had an improved effect of drug bioavailability as Group 3 (NGT1.5 L) had a significantly increased AUC and $C_{\text{max}}$ in comparison to Group 4 (NF NGT 1.5 L) ($p<0.05$) (Figure 2.3). Relative bioavailability of fasted versus fed state was 57%. 
Figure 4.3. Serum acetaminophen concentrations comparing treatment Group 3 (NGT 1.5L) to Group 4 (NF NGT 1.5L) (n=6). Data is reflected as the geometric mean and the 95% Confidence Interval. Accompanying pharmacokinetic data is found in Table 4.2. \( C_{\text{max}} \) and AUC were significantly different between groups (p<0.05).

AUC = area under the curve; \( C_{\text{max}} \) = maximum plasma drug concentration; NGT = nasogastric tube; NF = non fasted

No statistically significant differences could be detected when comparing other pharmacokinetic variables.
Discussion

The Food and Drug Administration has implemented a Strategic Plan for Regulatory Science which includes a major focus on predicting the behavior of orally administered drugs through modeling. Among the models that should facilitate an understanding of the complex interactions and processes that impact drug behavior are those based on quantitative structure-activity or -property relationships. These models can guide experimental designs of hypothesis driven research while reducing animal numbers and total study cost and improving the ability to predict response to a drug among the varied populations (Doherty).

Much of equine therapeutics reflects off-label (extra-label) use with alternative routes or drugs. Ideally, extra-label dosing regimens are supported by clinical research (Hatanaka S.). Determining effects of oral drug administration has been key in developing appropriate models that predict drug concentrations in animals and people. The effects of food, drug coating, and how the drug is administered are the cornerstones in evaluating and modeling drug movement (Mizuta H.). In the horse, oral administration either in a clinical setting or as part of research studies often varies depending on the drug, the investigator, or the circumstances under which the drug is administered.

Like people, the rate at which the equine stomach empties when exposed to the orally administered fluid is highly dependent on the phase of the migrating motor complex, the electrical cycle which controls gastrointestinal propulsion (Lammers T.). In people, small volumes of fluid (50 mL) do not exert an effect on the rate of gastric emptying. However, by increasing the amount of fluid volume administered with a drug (200 mL), the rate of gastric emptying increases regardless of the motor complex phase (Clements J.A.; Oberle R.L). This relationship can ultimately affect the bioavailability of a drug and may be critical for drug classes
(Class 1 and Class 2) where there is rapid dissolution and the availability of the drug within the intestinal tract is limited by the rate of gastric emptying (Hatanaka S.).

Acetaminophen is a Class 1 model drug indicating high solubility, high permeability, and overall ease of absorption. Historically, it has been used for assessing and tracking gastric emptying as it is readily absorbed in the small intestine of ponies (Hatanaka S.). Clinically, oral dosing in horses is most commonly done by making a “slurry” of a small volume of liquid (100 mL) and syringing the dose into the horse’s mouth (SYR 100 mL). There are many variables that can have an effect results when administering a drug orally via a syringe. If the horse does not like the taste of the drug, they often will not swallow it. This can reflect in serum samples collected during a pharmacokinetic study. In this study, a secondary peak was appreciated in the absorption portion of the curve. Authors concluded that this may have been due to horses holding the dose in the oral cavity and only partially swallowing the dose initially. This would result in a delayed $C_{\text{max}}$ and slight fluctuation in absorption rates in this treatment group.

A statistical difference could not be found when comparing acetaminophen administration with the syringe versus NGT. However, this may reflect the small volume that was used for this comparison: as with people, when the volume of the solution was increased from 100 mL to 1.5 L and administered using a NGT, both $C_{\text{max}}$ and AUC significantly increased indicating an increased bioavailability secondary to increased volume of water used in administration. For this study, the smaller volume was chosen for comparison of delivery method since administration of 1.5 mL through a dosing syringe could not be accomplished in a timely fashion and thus was not feasible. The sample size also likely contributed to our inability to find a statistical difference since the AUC numerically was more than fourfold higher and the $C_{\text{max}}$ was almost 50% higher in the NGT group compared to the syringe (Figure 2.1, Table 2.2).
Administering the acetaminophen directly through a NGT with 100 mL water showed a significant increase in drug absorption over syringe administration with 100 mL. This increase in absorption, this is most likely due to bypassing the issues associated with oral product administration such as product loss delayed swallowing. Though clinically this would not be possible, in the academic arena where drug movement is often studied this would be the most direct method of assessing drug movement without the compounding issues of administration.

Similar to people, the effect of volume of administration also affects the extent to which a drug may be absorbed as was illustrated with the comparison of NGT 100 mL vs. 1.5L. In future endeavors where drug movement is being evaluated, it would be prudent to take this into account when planning the amount of volume to be used during administration.

Animals that were non-fasted had a statistically significant increased AUC and C<sub>max</sub>, both indicating that the effects of food being present in the stomach or small intestine greatly affects the absorption of drug into the blood stream. Depending on the drug structure, this may be due to binding of the drug in food material, alteration of intraluminal pH, or decreased gastrointestinal motility and exposure of the drug to the blood stream.

In conclusion, investigators were able to establish the most accurate determination of oral drug absorption in the horse: animals should be fasted for eight hours prior to study initiation, and drug should be administered via a nasogastric tube with the formulation (tablet or capsule) dissolved in 1.5L of water.
Chapter 5. Clinical Application of Firocoxib Canine Chews in Equine Practice

“Just because you can – doesn’t mean you should.”

– Dr. Reid Hanson

Abstract

The purpose of this study was to compare the bioavailability of equine firocoxib to canine chews in horses as well as evaluate therapeutic levels with clinical response. Horses (n=8) received a single loading dose of firocoxib (0.3 mg/kg) as an oral paste, chew, or intravenously in a randomized triple cross over study. Firocoxib was quantitated by high performance liquid chromatography (25-2,500 ng/mL). Data was subjected to non-compartmental analysis. An in vitro analysis was performed to determine appropriate handling of firocoxib during collection and storage. Samples from client horses (n=44) treated with firocoxib chews were evaluated for drug levels and clinical response. This study failed to find statistically significant differences in Cmax and absolute oral bioavailability at a power of greater than or equal to 90%. Firocoxib should be transported and stored in glass vials. Clinical patients appear to respond favorably to treatment with chews without adverse effects.
Introduction

Firocoxib is a member of the coxib class of NSAIDs. Firocoxib, described as COX-2 selective, has recently been approved for use in both horses as a paste and for dogs as a chew by the United States Department of Agriculture and European Union (P. M. Kvaternick V.). However, the preparations differ, with the paste (56.8 mg of firocoxib/tube, able to be administered in 11.4 mg increments (250 lb. doses) and chew as a tablet (57 to 227 mg tablets that can be scored in half). Firocoxib made its debut in veterinary medicine in dogs, demonstrating efficacy for treatment of experimental induced synovitis and naturally occurring osteoarthritis (McCann ME; Pollmeier M. Toulemonde C.).

According to the Policy of Extra-Label Drug Use, which describes the criteria for extra-label drug use in food animals, the substitution of the canine chew for the equine paste is illegal in the United States (Canada; P. M. Kvaternick V.) However, substitution of the chew for paste is none-the-less becoming increasingly popular in equine practice. Despite improved safety, the therapeutic index of COX-2 selective drugs remains sufficiently narrow, suggesting use should be based on disposition studies in the target species. The purpose of this study was three-fold: to determine, in horses, the disposition of firocoxib when administered at the recommended (labeled) loading dose (0.3 mg/kg) in equine formulations, either as the intravenous solution or as the oral paste, and with the canine chew tablets; compare the absolute bioavailability of the two oral products; collect clinical samples from equine patients who were being treated with the canine chew and compare response of therapy to firocoxib plasma levels.
Initially, the authors anticipated the firocoxib product prepared as a chewable tablet might not be a readily absorbed in horses, and thus hypothesized that the chews would be 30% less bioavailable compared to the paste at an equivalent dose.
Materials & Methods

Animals

Eight healthy, adult horses (7 geldings, 1 mare) were studied using a randomized, triple cross-over design. The sample size (8 horses) was based on the number necessary to demonstrate a 50% difference in $C_{\text{max}}$ based on a reported variability of 31% around the mean. Animals included both client owned animals and horses from the equine teaching herd. All procedures were approved for use by the Institutional Animal Care and Use Committee, which included approval of a client-informed consent form which was signed by participating clients.

Drug Administration

Horses were randomly assigned to one of three initial treatment groups, with each group receiving (0.3 mg/kg oral [PO] and 0.2 mg/kg intravenous (IV)) firocoxib (Equioxx®; equine IV or paste formulations), Merial, Duluth, GA): Group 1 - a single intravenous dose, Group 2 – single dose of oral paste, and Group 3 – single dose of chewable tablets. The chewable tablets (Previcox®, canine formulation, Merial, Duluth, GA) were offered by hand (n=6) or, if the horse was reluctant to eat the tablets, were administered by syringe application after mixing the tablets with 30 mL water (n=2).
Sample Collection

Prior to drug administration (day 0), 20 mL of blood was withdrawn from the jugular vein for a complete blood count and serum chemistry profile to ensure the animal had no underlying systemic disease. A 14 gauge 13.75 cm intravenous catheter (Abbocath, Hospira, Lake Forest, IL, USA) was then placed in the jugular vein using sterile technique. Once the catheter was placed, the horse received its pre-assigned treatment and blood samples (10 mL) were collected through the indwelling catheter. If the horse assigned to the intravenous treatment group, the loading dose of the intravenous solution was administered through a percutaneous injection into the opposite external jugular vein from where the catheter was placed. After each sample collection, the catheter was flushed thoroughly with heparinized saline.

Samples were collected at 30 minutes, 1, 2, 4, 8, 16, 24, 48, 72, and 96 hours after dosing. Blood was placed in heparinized glass collection tubes (BD Vacutainer®, Sodium Heparin, BD, Franklin Lakes, NJ). After the 24-hour sample time point, the indwelling catheter was removed and the remaining samples were collected through a 20 gauge needle and 12 mL syringe (Monoject, Cardinal Health, Dublin, OH). A from alternate right or left jugular veins. Blood samples were separated into their components (packed red blood cells and plasma) by centrifugation, and plasma was stored frozen at -80 °F in glass vials (Borosilicate Glass Disposable Culture Tube, VWR®, Radnor, PA, USA) until analyzed. Following a washout period (approximately 5 drug half-lives), animals were crossed over to their next study group and the process repeated until each animal had received all three treatments. After the last sample was collected for the last study in each horse, a complete blood cell count and serum chemistry profile was
repeated.

In addition to pre- and post-complete blood cell count and serum biochemistry monitoring, a physical examination was performed twice daily during the study period. Horses were also observed for evidence of NSAID toxicity, including, abdominal discomfort, weight loss, fever, or diarrhea. Any horses that elicited any of the above clinical signs would result in the immediate discontinuation of the study for that horse, confirmed diagnosis of gastric ulceration or NSAID toxicity, and initiation of necessary treatment.

Sample Analysis

Horse plasma was analyzed for firocoxib concentrations by high pressure liquid chromatography (HPLC) with ultraviolet (UV) detection. The HPLC system consisted of a Waters 2695 separation module and a 2489 UV-Visible detector (Waters Oasis® HLB, Waters Corporation™, Milford, MA, USA). Separation was achieved with a Sunfire C18, 5 µm, 150 x 4.6 mm column (Waters Oasis® HLB, Waters Corporation™, Milford, MA, USA) maintained at 40 °C (M. T. Kvaternick V.; P. M. Kvaternick V.). The mobile phase consisted of 45:55:0.025 acetonitrile/ water/trifluoroacetic acid (VWR®, Radnor, PA, USA) with the flow rate set to 1 mL/ min (Cox S.; M. T. Kvaternick V.; P. M. Kvaternick V.). The standard curve was generated ranging from 25 to 2,500 ng/mL by fortifying equine plasma with known amounts of firocoxib (Toronto Research Chemicals Inc. (TRC), Toronto, Ontario, Canada) reference standard and accepted if the coefficient of determination (r2) was at least 0.999 and the predicted concentrations were within 10% of the actual concentrations.
Firocoxib was extracted from horse plasma with solid phase extraction (SPE) cartridges (3 mL, 60 mg) (Waters Oasis® HLB, Waters Corporation™, Milford, MA, USA). Briefly, previously frozen plasma samples were thawed and vortexed. The SPE cartridges were conditioned with 2 mL acetonitrile and then 2 mL water. Aqueous plasma samples (1 mL of plasma plus 2.0 mL water) were loaded and allowed to elute by gravity. The cartridges were rinsed with 2.0 mL of 5% acetonitrile in water (gravity elution) and a vacuum of ~10 in of Hg was used to remove the residual solvent. Firocoxib was eluted with 2.0 mL acetonitrile which was then evaporated to dryness under a stream of nitrogen during 25 min at 40°C. The residue was reconstituted with 250 µL of 40% acetonitrile/water, with vortex/mixing for 20 sec and then the solution was centrifuged at 1900 x g (M. T. Kvaternick V.; P. M. Kvaternick V.). The injection volume was 100 µL. The retention time for firocoxib was 8.6 minutes and UV absorbance was monitored at 290 nm (Cox S.; M. T. Kvaternick V.; P. M. Kvaternick V.).

Unknown concentrations of firocoxib in each sample were determined by comparing the signal to a calibration curve. The standard curve was generated by fortifying equine plasma with known amounts of firocoxib that ranged from 25-2,500 ng/mL (Cox S.). A calibration curve was accepted if the coefficient of determination (r²) was at least 0.999 and the predicted concentrations were within 10% of the actual concentrations. The linear correlation coefficient for firocoxib was 0.9999. The lower limit of detection was 10 ng/mL and the lower and upper limits of quantification (LOQ) for firocoxib were 25 ng/mL and 2,500 ng/mL respectively. The relative measurement of uncertainty (RSD %) for firocoxib 25, 100, 1,000, 2,500 and 5,000 ng/mL were 9.1%, 4.9%, 2.1%, 1.1% and 1.1% respectively. Intra and inter assay variability was less than
10% for all controls.

In order to determine appropriate handling, processing and storing of the firocoxib, a bench top in vitro analysis was performed to determine whether or not firocoxib was capable of binding to plastic tubes (especially important for sample collection and storage). To do this, whole blood (6 mL) was collected from a horse and transferred into a heparin glass containers (BD Vacutainer, Sodium Heparin, BD, Franklin Lakes, NJ, USA). Plasma was separated by centrifugation at 1,900 g (3,000 rpm) for 30 min at room temperature, and then transferred to either a glass or plastic disposable culture tubes and spiked with firocoxib standard at 50, 1,000 and 10,000 ng/mL to test the binding of the drug to the storage vial.

Plasma samples were allowed to sit 60 hours inside of refrigerator (4 °C) and then tested under the same sample preparation procedure and HPLC chromatographic conditions previously described. From this analysis, the area under the curve (AUC) from time 0 (time of firocoxib injection into plasma) to 60 hours (time of completion of in vitro study) of firocoxib was determined for both glass and plastic tubes.

In the second phase of this study, plasma samples were collected from private practice veterinarians who were currently prescribing firocoxib as the canine preparation. Samples were admitted into the study as long as the horse had been on a maintenance dose of firocoxib (0.1 mg/kg once daily by mouth) for a period of 3 to 5 days, and were not concurrently on any other medications at the time of the sample collection. Along with the sample for submission, veterinarians were asked to record the horse’s age, breed, collection time, time of last dose, reason for treatment, and perceived response. Whole blood samples (10 mL) were collected from the external jugular vein at either a peak (2 hours
post dose) or trough (prior to the next dose). Once returning to the clinic, the whole blood was separated into its components and the plasma achieved was frozen for transport to the Auburn University Clinical Pharmacology laboratory for the samples to be evaluated with HPLC as described above. A total of 42 samples were evaluated from the submitting practices. Combining the therapeutic levels achieved from these samples with the veterinarians submitting information (indicating reason for treatment, clinical response, or adverse events), authors were able to quantify firocoxib levels plasma levels and compare them to therapeutic response.

**Pharmacokinetic Analysis**

Plasma firocoxib concentration versus time data (both in vitro and in vivo) samples were subjected to non-compartmental analysis (Phoenix Winnonlin,® Pharsight,® Sunnyvale, CA, USA) using the log-linear trapezoidal method. Parameters of interest included AUC (ng\*hr/mL), C\text{\textsubscript{max}} (oral, mcg/mL) at time (T\text{\textsubscript{max}};h); t\textsubscript{1/2} (h); mean residence time (MRT; h), mean absorption time (MAT [h] where MAT = MRT\textsubscript{oral} – MRT\textsubscript{IV}), and absolute (AUC\textsubscript{oral}/AUC\textsubscript{IV}) and relative (AUC\textsubscript{oral paste}/AUC\textsubscript{oral chews}) bioavailability. For in vitro samples, only AUC were determined. Descriptive statistics (mean + standard error of the mean and 95th upper and lower confidence intervals) were generated for each parameter. Parameters were compared between oral paste and chew using Proc GLM (SAS/IML 9.1, User’s Guide: statistics, Cary, NC) using Tukey’s test for multiple comparison for repeated measures. A one way ANOVA was used to compare differences in the firocoxib plasma levels between sample collection groups.
Results

During the time course of the pharmacokinetic study, no animals appeared to experience any adverse events. Further, physical examinations and clinical laboratory blood work did not statistically differ and were within clinical reference ranges.

Pharmacokinetic parameters for each preparation are listed in (Table 5.1, Figure 5.1). Relevant parameters with corresponding standard errors were: $C_0$ (ng/mL): 268 ± 58; $C_{\text{max}}$ (ng/mL): 143 ± 21 (paste); 135± 17 (chew); $t_{\text{1/2}}$ (hr): 58 ± 19 (paste), 49± 11 (chew); 61 ± 42 (IV); AUC (ng/mL/hr): 8898 ± 2254 (paste); 8686 ± 2498 (chew); 8028 ± 3856 (IV). The absolute bioavailability (F) of firocoxib was 90% ± 24% (paste) vs 91% ± 27% (chew). Relative bioavailability for paste vs. chews was 108% ± 35%, indicating unity of absorption between the two products. This study failed to find statistically significant differences in $C_{\text{max}}$ and absolute oral bioavailability at a power of greater than or equal to 90%.
Figure 5.1. Firocoxib mean plasma drug concentrations (with SE) versus time in 8 apparently healthy horses when administered at 0.3 mg/ kg as three different formulations.

Red = IV Equioxx®, Green = Equioxx® paste, Blue = Previcox®; SE = standard error of the mean
Table 5.1. Mean pharmacokinetic parameters for firocoxib when administered as either canine chews or equine paste in apparently healthy horses (n=8).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Route</th>
<th>Mean</th>
<th>SE</th>
<th>Lower CI</th>
<th>Upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC(ng/mL/hr)</td>
<td>IV</td>
<td>8028</td>
<td>3856</td>
<td>4172</td>
<td>11884</td>
</tr>
<tr>
<td></td>
<td>Chew</td>
<td>8686</td>
<td>2498</td>
<td>6187</td>
<td>11184</td>
</tr>
<tr>
<td></td>
<td>Paste</td>
<td>8898</td>
<td>2254</td>
<td>6645</td>
<td>11152</td>
</tr>
<tr>
<td>C₀ (ng/mL)</td>
<td>IV</td>
<td>268</td>
<td>58</td>
<td>210</td>
<td>326</td>
</tr>
<tr>
<td>Cₘₐₓ (ng/mL)</td>
<td>Chew</td>
<td>135</td>
<td>17</td>
<td>117</td>
<td>152</td>
</tr>
<tr>
<td></td>
<td>Paste</td>
<td>143</td>
<td>21</td>
<td>122</td>
<td>165</td>
</tr>
<tr>
<td>t₁/₂ (hours)</td>
<td>IV</td>
<td>61</td>
<td>42</td>
<td>19</td>
<td>102</td>
</tr>
<tr>
<td></td>
<td>Chew</td>
<td>49</td>
<td>11</td>
<td>38</td>
<td>59</td>
</tr>
<tr>
<td></td>
<td>Paste</td>
<td>58</td>
<td>19</td>
<td>40</td>
<td>77</td>
</tr>
<tr>
<td>MRT</td>
<td>IV</td>
<td>87</td>
<td>56</td>
<td>31</td>
<td>143</td>
</tr>
<tr>
<td></td>
<td>Chew</td>
<td>70</td>
<td>12</td>
<td>58</td>
<td>83</td>
</tr>
<tr>
<td></td>
<td>Paste</td>
<td>85</td>
<td>26</td>
<td>59</td>
<td>111</td>
</tr>
<tr>
<td>MAT</td>
<td>Chew</td>
<td>13</td>
<td>13</td>
<td>-11</td>
<td>37</td>
</tr>
<tr>
<td></td>
<td>Paste</td>
<td>24</td>
<td>14</td>
<td>-2</td>
<td>50</td>
</tr>
<tr>
<td>Tₘₐₓ (hours)</td>
<td>Chew</td>
<td>4</td>
<td>1</td>
<td>-2</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>Paste</td>
<td>2</td>
<td>1</td>
<td>-4</td>
<td>8</td>
</tr>
<tr>
<td>CL (hours)</td>
<td>IV</td>
<td>47</td>
<td>6</td>
<td>40</td>
<td>53</td>
</tr>
<tr>
<td>F</td>
<td>Chew</td>
<td>91%</td>
<td>27%</td>
<td>64%</td>
<td>118%</td>
</tr>
<tr>
<td></td>
<td>Paste</td>
<td>90%</td>
<td>24%</td>
<td>66%</td>
<td>114%</td>
</tr>
<tr>
<td>Relative F</td>
<td></td>
<td>108%</td>
<td>35%</td>
<td>73%</td>
<td>143%</td>
</tr>
</tbody>
</table>

AUC = area under the curve; C₀ = maximum plasma drug concentration after intravenous infusion; Cₘₐₓ = maximum plasma drug concentration; t₁/₂ = elimination half-life; MRT = mean resonance time; MAT = mean absorbance time; Tₘₐₓ = time to maximum plasma drug concentration; CL = clearance; F = bioavailability.

Significant differences could not be detected for any parameters between paste and chews. C₀ = maximum plasma drug concentration after IV administration; Cₘₐₓ = maximum plasma drug concentration.
concentration; AUC = area under the curve; t1/2 = elimination half life; CL = clearance; MRT = mean resonance time, MAT = mean absorption time; F = bioavailability, Relative F (paste vs. chews)
For the in vitro study, the AUC in plastic tubes was less than the AUC in glass tubes. The percent difference for firocoxib AUC for 50, 1,000, and 10,000 ng/mL were 21.26%, 41.18%, and 50.45% respectively (Table 5.2). From this methodology, we were able to determine the necessity that the samples be collected and stored within glass tubes.

Table 5.2. Percent difference between firocoxib concentrations after being stored in either glass or plastic tubes for 60 hours.

<table>
<thead>
<tr>
<th>Firocoxib Concentration (ng/mL)</th>
<th>Glass Tubes</th>
<th>Plastic Tubes</th>
<th>AUC (ng/mL/hr)</th>
<th>Glass vs. Plastic</th>
<th>Percent Difference</th>
</tr>
</thead>
<tbody>
<tr>
<td>50</td>
<td>21151</td>
<td>16654</td>
<td>-4497</td>
<td></td>
<td>21.26%</td>
</tr>
<tr>
<td>1000</td>
<td>515677</td>
<td>303324</td>
<td>-212353</td>
<td></td>
<td>41.18%</td>
</tr>
<tr>
<td>1000</td>
<td>5218493</td>
<td>2585592</td>
<td>-2632901</td>
<td></td>
<td>50.45%</td>
</tr>
</tbody>
</table>

AUC = area under the curve
A total of 42 samples were evaluated from submitting private practices. Of the samples being submitted, all samples were evaluated from patients receiving the canine formulation of firocoxib. Of the submitting horses, ages ranged from 5-26 years of age (mean = 14.2 years, +/- 5.5 years). Breeds represented in the sample pool included: Domestic warm blood (n= 19), Thoroughbred (n= 12), Quarter Horse (n= 4), Irish Sport Horse (n= 2), Standard Bred (n=1), Irish Draft (n=1), Arabian (n=1), Morgan (n=1), Welsh cross (n=1), Quarter Horse/Thoroughbred (n=1), and Thoroughbred/Warm Blood (n=1).

Sample collection times were broken down into three different groups: peak (0-2 hours post- dose administration) n=7, mid dosing period (3-21 hours) n=28, and trough concentration (22-26 hours) n = 9. Firocoxib concentrations for the peak dosing group were 65.16 ± 32.35 ng/mL; mid dosing 80.26 ± 54.65, and 60.38 ± 27.39 ng/mL. A statistical difference of firocoxib drug concentrations between the treatment groups could not be detected. The reason for treatment were broken down into soft tissue (n=12), musculoskeletal (n=15), and generalized lameness (n=17). A favor- able response to treatment was recorded in (n=35) and unknown in (n= 9).
Discussion

Although this study may have established equivalent bioavailability between the two products, this study is not intended to support such extra label drug use. Indeed, other considerations should be taken when using canine chews in horses. Accordingly, the veterinarian prescribing or administering canine chews to horses in lieu of an equine formulation is placing him or herself in a position to be held both criminally and civilly liable for such use. Although this study may have established bioequivalence when an equal mg/kg dose is administered, the canine preparation may not allow for the same level of dosing accuracy that the equine paste presents. Thus, for a small horse (miniature, foal, pony), an accurate dose can be metered out from the paste tube, but the smallest tablet size of the canine chew is 57 mg. The tablets are only half scored, and the risk of unequal distribution of drug within a tablet may prevent an equivalent dose from being administered should a fraction of a tablet be administered. Thus, extra precaution is recommended when smaller horses are being dosed.

The heme containing COX enzyme plays an important role in the production of prostaglandins and thromboxane molecules that are responsible for the maintenance of normal physiology of multiple organ systems, including inflammation, hemostasis, joint health, renal function, and the gastro-intestinal system. As such, nonselective inhibition of the COX isoenzymes results in a narrow therapeutic window for these traditional drugs. Not surprisingly, their use is associated with serious adverse events, including gastrointestinal ulceration (both gastric and right dorsal colitis), renal and hepatic toxicity (dogs), and prolonged bleeding times (Chapman; Cook V.L.; M. T. Kvaternick V.; Pollmeier M. Toulemonde C.;
Although long-term use of firocoxib in horses at the recommended dose has not yet been effectively assessed, the Adverse Event Reporting site at the Food and Drug Administration’s Center for Veterinary Medicine indicates that oral ulcerations is the 3rd most common adverse event thus far reported (Medicine). However, animal safety studies performed in horses during the equine formulations approval process demonstrated that a 3- to 5-fold dose increase was associated with ulceration of the oral gingiva and stomach, pathology associated with the kidneys (tubulointerstitial nephropathy and papillary necrosis), and elevations in liver enzymes.

The chemical structure of firocoxib (a weak acid) facilitates efficient absorption from the gastrointestinal tract at the level of the stomach. In the horse, firocoxib administered as the paste has an absolute bioavailability of 79%, due to low first pass metabolism (via dealkylation and glucuronidation) (Merial). In contrast, bioavailability of the drug in the dog based on the package insert is cited at 38% (Merial). It is not clear if the differences between bioavailability between the species are due to the active ingredient’s activity in the different gastrointestinal systems or differences in the preparation itself (ie, chew tablet versus paste).

Once in circulation, firocoxib is highly protein bound (98%) to albumin. Despite this high protein binding in horses, the unbound drug is characterized by a large volume of distribution, which contributes to a long t\textsubscript{1/2} (30 to 40 hours) in horses (Merial). The half-life in horses is 3 to -10x longer than the t\textsubscript{1/2} reported for other non-selective NSAIDs currently used to control pain in horses (eg, phenylbutazone, flunixin meglumine, naproxen) (Letendre L.T.; P. M. Kvenernick V.).

In contrast to horses, the elimination half-life of firocoxib in dogs is only 8 hours. The longer half- life in horses impacts therapeutic use of firocoxib in several ways. First, it allows
once a day dosing in horses, facilitating owner compliance, as well as providing longer pain relief. Second, the longer half-live firocoxib results in a 50-fold oral dose differential between the two species: horses are dosed at 0.1 mg/kg/day compared to 5 mg/kg/day in dogs. It is this 50-fold difference in dose that has led equine practitioners to administer the canine preparation rather than the approved horse product to equine patients. Despite the size difference, the canine preparation is cheaper (approximately 50% more expensive) when dosed in horses.

Third, the longer $t_{1/2}$ in horses also results in different times to steady-state between the species. In dogs, firocoxib does not reach a true steady-state when using the labeled dosing interval. However, in horses, with a 40-hour half-life, drug concentrations in horses will minimally fluctuate during a 24-hour dosing interval. Further, because little drug is eliminated during each interval, drug will accumulate with each subsequent dose until steady-state is reached. Thus, the full effect of the drug in horses will not be realized until 3 to 5 drug half-lives – or approximately 5 to 7 days – have lapsed once a dosing regimen is implemented. This delay to steady-state necessitates a loading dose (0.3 mg/kg) in horses if a rapid onset in effect is desired. By administering an initial loading dose, the patient reaches therapeutic drug levels after the first dose and a clinical response is appreciated within the first 24 hours of treatment. The Federation Equestre Internationale (FEI) has listed firocoxib as a controlled medication for equine competitors. Firocoxib is commonly administered prior to sanctioned athletic competitions and as such, studies at that loading dose are prudent.

Among the more important reasons to study firocoxib after IV administration of a loading dose is the United States Equestrian Federation has established that maximum permitted plasma concentration of firocoxib be less than 0.240 µg/mL at competition time (Internationale). Compared to this standard, when firocoxib is administered at the manufacturer’s recommended
loading dose, drug levels were below the standard of limitations 30 minutes to an hour after IV administration. After an oral loading dose, neither preparation (paste or chew) achieved levels higher than USEF standards at any time point after the administration of medication.

In horses, NSAIDs are generally well absorbed from the gastrointestinal tract through oral dosing. However, we were concerned that firocoxib would be less bioavailable when administered as the chew compared to the paste for two reasons. First, in herbivores, and specifically horses, oral medication may bind to hay or other ingesta, thus affecting oral absorption and the ability of the drug to reach effective levels. Second, studies have demonstrated variable oral absorption of NSAIDs in horses, depending on the formulation used. For example, after administration of ketoprofen in an oil-based formulation, bioavailability in horses was <5%. When the formulation was changed to a gelatin capsule, bioavailability increased to 50% (Agency). A major difference between the paste and the chew are the inactive ingredients; these could negatively impact oral absorption thus increasing potential for therapeutic failure, or increased absorption, which would increase potential for an adverse event.

This study confirmed that despite the different formulations available for firocoxib, once administered at the same mg/ kg dose, they are similarly bioavailable, and based on the clinical samples collected, are capable of controlling both soft tissue and orthopedic pain.
Chapter 6. Pilot Study: Pharmacokinetics of the Antiepileptic Drug Zonisamide after Oral and Rectal Administration in the Horse

“Every time you conduct a study, you run in front of the pharmacokinetic canon. Sometimes you miss, other days you take a direct hit”

– Dr. Ralph Claxton

Abstract

The purpose of this study was to describe the disposition and time course of drug concentrations of zonisamide when administered either orally or per rectum in the healthy horse. Eight healthy adult horses were used in a randomized, crossover study. Under fasted conditions, horses received zonisamide orally via nasogastric tube (20 mg/kg, PO), and per rectum (PR, 40 mg/kg) via a Foley catheter. Whole blood was collected intermittently for 72 hours post administration. Zonisamide was quantitated in equine plasma using a homogeneous particle enhanced turbidimetric immunoassay and time versus concentration data was subjected to non-compartmental pharmacokinetic analysis. Descriptive statistics were reported for measurable parameters. All animals appeared to tolerate zonisamide well at the doses administered. After oral administration $C_{\text{max}}$ was $7.4 \pm 9.6 \mu\text{g/mL}$ at $T_{\text{max}}$: 4 ± 1.7 hours. MRT and disappearance half-life were 21 ± 512.4 μg/mL and 14 ± 5.7 hours, respectively. AUC was 162 ± 278 μg/mL/hour. Zonisamide was not consistently detected after rectal administration. Zonisamide (20 mg/kg PO) maintains serum concentrations in the human therapeutic range for 13 hours in healthy horses and might be effective for treatment of seizures. In contrast, zonisamide was not
consistently detected after 40 mg/kg after rectal administration which does not support use of this
current dosing form in this route.
Introduction

Epilepsy in horses is relatively uncommon and occurs most frequently in foals or due to a secondary condition in adults. Foals are more subject to seizures as they can be caused by genetics, neonatal septicemia, hypoxic ischemic encephalopathy, metabolic disturbances such as hypoglycemia and electrolyte abnormalities, bacterial meningitis or abscess, viral encephalitis, medications, liver failure, trauma, and congenital anomalies (Aleman M.; Beaufrere H.; Lacombe V.A.) In adult equine patients, brain injury secondary to a traumatic event is the most common cause for seizure development. Common clinical signs associated with traumatic brain injury include but are not limited to ataxia, aniscoria, flaccid paralysis, and abnormal mentation such as hyperexcitability or lethargy (Smith).

Treatment and management of severe brain injuries in horses is expensive, labor intensive and frequently results in a guarded to grave prognosis. For immediate intervention, diazepam and midazolam have been employed in both foals and adult equine patients. Single seizure episode control with diazepam is effective, relatively inexpensive, and simple; however, recurrent seizures become more difficult to manage (Boothe D.M.).

For long-term seizure control, phenobarbital and potassium bromide have been the drugs of choice to manage seizures in horses or foals. However, the high doses of phenobarbital needed to control seizures results in hypothermia and decrease in respiratory drive which ultimately leads to hypercapnia (elevation in CO₂). Respiratory depression, which is more severe in neonates because of their reduced hepatic clearance, makes longer term seizure control with phenobarbital problematic in both practice and referral institution settings (Boothe D.M.). Recently, levetiracetam has been used for seizure control in the equine patient. Serum levetiracetam concentrations achieved are generally within the published therapeutic ranges for
dogs and cats; however, as in other species, the drug has a short half-life of six hours in horses (Cesar). This short half-life would require frequent administration which is labor intensive as well as cost prohibitive for long-term management.

Zonisamide, a synthetic sulfonamide, has been approved for treatment of epilepsy in people. Zonisamide’s mechanism of action is diverse and includes: blockage of voltage-dependent sodium and type T calcium channels, modulation of the dopaminergic system, increasing GABA release from the hippocampus, and protecting neuronal membranes from oxygen free radicals. Its therapeutic success in people has led to its use in companion small animals and birds (Beaufreere H.; Boothe D.M.; Dewey C.W.). With a half-life of 30-48 hours in canine patients, the drug can be administered at 12 to 24 hour intervals (Boothe D.M.). If this long half-life were to occur in horses, there would be sustained seizure control at convenient dosing intervals in comparison to levetiracetam.

In seizing or obtunded horses, rectal administration of a drug may be necessary due to altered mentation and safety concerns (Feary D.J.). Drawbacks of rectal administration include interruption of absorption due to defecation, patient acceptability, or binding of the drug formulation to feces present within the rectum (A.G. De Bower). Ensuring that a product is capable of oral absorption after rectal administration is key to determining its use in the clinical setting. The objectives of this study were to describe the disposition and time course of drug concentrations of a new antiepileptic, zonisamide, when administered either orally or per rectum in the healthy horse.
Materials & Methods

Animals

This study was approved by the Institutional Animal Care and Use Committee for the university. Using a randomized, crossover study design, healthy adult horses (n=8), weighing between 409-591 kg were selected from the teaching herd at Auburn University. Complete blood counts and serum biochemistry profiles were performed prior to study initiation and at study completion. Using a randomization table, horses were assigned to one of two designated dosing routes (oral or rectal administration) for the first treatment day, and then the route of administration was switched for the second treatment day.

The day before drug administration (day 0), a physical examination was performed and 20 mL of blood withdrawn from the jugular vein for complete blood count and serum biochemistry profile to ensure the animal had no underlying systemic disease. Horses were fasted for eight hours prior to and two hours after study initiation.

Drug Administration

Once the dose of zonisamide was determined, the corresponding number of capsules (Glenmark Pharmaceuticals, Mahwah, NJ) were opened and the powder inside the capsule was completely dissolved with either 100 mL (rectal administration) or 1.5 L of water depending on the route of administration.

For both routes of administration, manual restraint was employed using a twitch on the horse’s nose. After nasogastric administration, the 1.5 L zonisamide suspension was administered via a funnel followed by 800 mL of air to empty all liquid. The nasogastric tube was removed immediately after drug administration. A Foley catheter gently guided by hand
and advanced six inches into the rectum, and 100 mL zonisamide suspension was infused. Once the drug was infused into the rectum, the Foley catheter and twitch were removed.

On the first day of dosing, a pilot dose determination study was performed. Horses were administered either 10 mg/kg zonisamide via a nasogastric tube (n=4) or 20 mg/kg rectally (n=2). Serum concentrations (determined as described below) were considered subtherapeutic via both routes. The zonisamide dose was subsequently doubled for each route (20 mg/kg PO and 40 mg/kg PR).

Sample Collection

Immediately prior to drug administration, an 8 cm diameter area in the jugular groove was clipped and prepared in an aseptic manner for five minutes using a chlorhexidine solution and isopropyl alcohol for sample collection purposes. A small local area of the skin was anesthetized for catheter placement using 2.0 mL of 2% lidocaine solution. A 14 gauge 5.5 inch intravenous catheter (MILA 14 G, MILA International, Florence, KY, USA) was placed in the left jugular vein using sterile technique. Blood samples (5 mL of whole blood that was discarded and 5 mL for the sample) were collected through the indwelling catheter through the catheter’s injection cap at times 0 (prior to administration), 5, 15, 30 minutes, 1, 2, 4, 6, 8, 10, 12, 24, 36, 48, 60, and 72 hours after dosing. Blood was placed in red top tubes. Following collection of each sample, the catheter was flushed with 5 mL of heparinized saline (Monoject PreFill IV Flush, Cardinal Health, Dublin, OH). After the 24 hour sample had been collected, the intravenous catheter was removed and all consecutive blood draws were done via venipuncture with a 20G 1.5 inch needle and syringe (Monoject, Cardinal Health, Dublin, OH). Horses were
closely monitored for adverse events and a physical examination was performed every six hours until completion of the study. Horses were returned to pasture after the 48 hour sample was collected. Blood samples were separated into their components (packed red blood cells and serum) by centrifugation at 1900 g (3000 rpm) for 15 minutes, and plasma was stored frozen at -80°C until sample analysis.

**Sample Analysis**

Zonisamide concentrations were detected in equine plasma using a homogeneous particle enhanced turbidimetric immunoassay (QMS® Zonisamide reagent, Siemens) with a Siemens Dimension Xpand Plus® general chemistry analyzer (New York, NY). Unknown concentrations of zonisamide in each sample were determined by comparing the signal to a five point calibration curve. The standard curve was generated by fortifying equine plasma with known amounts of zonisamide that ranged from 2-300 µg/mL. A calibration curve was accepted if the coefficient of determination \( r^2 \) was at least 0.998 and the predicted control concentrations (5, 10, 25, 50 and 75 µg/mL) were within 10% of the actual concentrations. The lower and upper limits of quantification (LOQ) for zonisamide were 2 µg/mL and 50 µg/mL, respectively, based on the lowest and highest control that was studied and was accurately and precisely predicted within 15%. Intra and inter assay variability was less than 10% for all controls.

**Pharmacokinetic Analysis**

For each horse, serum zonisamide concentration versus time was subjected to standard non-compartmental pharmacokinetic analysis using computer assisted linear regression software (WinNonLin®, v.7.0 Pharsight Corporation, Mountain View, CA). A programmatic correction
was used to record and adjust values depending on the dose each animal was administered.

Pharmacokinetic parameters reported in the study were: maximum serum drug concentration (C_{max}), time to maximum concentration (T_{max}), mean residence time (MRT), disappearance rate constant (k_d), disappearance half-life (t_{1/2}, determined from the relationship t_{1/2} = 0.693/k_d), area under the curve (AUC_x), and percent of the AUC that was extrapolated from the terminal component of the curve (AUC_{extrapolated}), the ratio of apparent volume of distribution (V_z/F) as well as a ratio of apparent clearance (CL_{ss}/F) to bioavailability. Data included median ± standard deviation and a 95% confidence interval.
Results

The clinically-relevant pharmacokinetic values for all oral administration are as follows: maximum serum drug concentration (C$_{max}$) was 7.4 ± 9.6 µg/mL, time to maximum drug concentration (T$_{max}$) was 4.0 ± 1.7 hours, and elimination half-life (t$_{1/2}$) was 13.4 ± 5.7 hours. Figure 4.2 depicts the zonisamide serum drug concentrations plotted against time course of study after oral administration (representing both 10 mg/kg and 20 mg/kg dosing). All animals apparently tolerated all drug administration with no evidence of adversity.

In the dose determination study, four horses were administered 10 mg/kg orally, and all horses had detectable serum drug concentrations ranging from 5-9 µ/mL. These concentrations were subtherapeutic to the concentration range (10-40 µ/mL) used for therapeutic drug monitoring in human medicine. Four horses were administered zonisamide suspension at 20 mg/kg and achieved serum within the human therapeutic drug monitoring range (Figure 6.1, Table 6.1).

For *per rectum* administration, all serum samples for each of the time points were below the limit of quantification of the assay levels. Thus, no pharmacologic inferences could be calculated from these values. All recommendations and conclusions are based on oral administration.
Table 6.1. Combined pharmacokinetic parameters after oral administration of 10 and 20 mg/kg of zonisamide in apparently healthy horses (n=8).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Median</th>
<th>STD</th>
<th>Lower CI</th>
<th>Upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC (µg/mL/hour)</td>
<td>162.4</td>
<td>278</td>
<td>-356</td>
<td>958</td>
</tr>
<tr>
<td>AUC extrapolated (µg/mL/hour)</td>
<td>0.2</td>
<td>0.1</td>
<td>-0.1</td>
<td>25.1</td>
</tr>
<tr>
<td>MRT</td>
<td>21</td>
<td>8.5</td>
<td>-1.3</td>
<td>39.1</td>
</tr>
<tr>
<td>CL/F</td>
<td>1.5</td>
<td>1</td>
<td>-0.9</td>
<td>3.9</td>
</tr>
<tr>
<td>C&lt;sub&gt;max&lt;/sub&gt; (µg/mL)</td>
<td>7.4</td>
<td>9.6</td>
<td>-9.6</td>
<td>35.6</td>
</tr>
<tr>
<td>T&lt;sub&gt;max&lt;/sub&gt; (hour)</td>
<td>4</td>
<td>1.72</td>
<td>-0.2</td>
<td>50.6</td>
</tr>
<tr>
<td>Vd/F</td>
<td>965</td>
<td>785</td>
<td>-676</td>
<td>3036</td>
</tr>
<tr>
<td>t&lt;sub&gt;1/2&lt;/sub&gt; (hour)</td>
<td>13.4</td>
<td>5.7</td>
<td>-2.2</td>
<td>25</td>
</tr>
</tbody>
</table>

AUC = area under the curve; MRT = mean resonance time; CL/F = apparent oral clearance; C<sub>max</sub> = maximum serum drug concentration; T<sub>max</sub> = time to maximum serum drug concentration; Vd/F = apparent oral volume of distribution; t<sub>1/2</sub> = elimination half-life; STD= standard deviation; CI = Confidence Interval (95%)
Figure 6.1. Combined oral dosing (10 and 20 mg/kg) of serum zonisamide concentrations plotted against time course of study (n=8). Data is reflected as the geometric mean and the 95% Confidence Interval. Accompanying pharmacokinetic data is found in Table 6.1.
Figure 6.2. Serum zonisamide concentrations plotted against time in apparently normal horses receiving zonisamide at either 10 mg/kg (n= 4) or 20 mg/kg (n= 4). Data is reflected as the geometric mean and the 95% Confidence Interval. Accompanying pharmacokinetic data is found in Table 6.2.
Discussion

Treatment and management of severe brain injuries in horses is expensive, labor intensive and frequently results in a grave to guarded prognosis. For immediate intervention, diazepam and midazolam have been employed in both foals and adult equine patients. Single seizure episode control with diazepam is effective, relatively inexpensive, and simple; however, recurrent seizures become more difficult to manage (Papich). For long-term seizure control, phenobarbital and potassium bromide have been the drugs of choice to manage long term seizures in horses or foals. However, the high doses of phenobarbital needed to control seizures results in hypothermia and decrease in respiratory drive which ultimately leads to hypercapnia (elevation in CO₂). Equine patients treated with potassium or sodium bromide can present with a multitude of dose-dependent adverse effects that are considered unacceptable including: central nervous system effects (such as depression, drowsiness, sedation, stupor, recumbency, ataxia, and paresis), gastrointestinal tract problems (such as inappetence, weight loss, and pancreatitis), muscle pain and skin disorders (Raidal). In comparison, zonisamide has minimal side effects that are limited to thyroid hormone suppression when levels are above the therapeutic range.

More recently, the use of levetiracetam has been evaluated in the equine patient (Cesar). However, with such a short half-life, the drug must still be dosed every four to six hours to maintain levels within therapeutic ranges. In comparison, zonisamide’s long half-life allows for twice daily dosing which is more convenient for administration and owner compliance. Also, with sustained drug levels throughout a day, the patient is less likely to experience the significant peaks and troughs seen with levetiracetam that contribute to break through seizures.

In seizing horses, it is often difficult to administer oral medications due to altered mentation and safety concerns. Medications such as diazepam and metronidazole have been
shown to be absorbed readily through the mucosa after administration *per rectum* in dogs and horses (Papich; G. M. Steinman A.) In these patients, therapeutic drug levels necessary for seizure control or therapeutic levels have been achieved through administering drugs *per rectum* at two to three times the oral dose recommended in patients. One of the limiting factors with this study is how the product was prepared for administration to the horses. Administration of zonisamide in this study was designed to simulate clinical application. Based on the patient dose, the corresponding number of capsules (100 mg) were opened and the powder was dissolved with water depending on the route of administration. Similar to what has recently been reported in canine patients zonisamide does not appear to be absorbed *per rectum* (Brewer).

In both routes of administration, the serum concentrations were lower than what was expected in patients where the capsule was administered in an intact fashion as has been studied in humans and small animals (Boothe D.M.). One of the limitations in this study as well as in equine practice is the need to alter dosage forms in order to treat the patient. Further evaluation may need to be done to look at methods to administer the whole capsules to horses in order to achieve a more accurate indication of serum drug concentrations.

Despite having a low sample size (n=4), dosing at 20 mg/kg of zonisamide appears to reach published human therapeutic levels and as such, might be considered as a possible alternative for treating epilepsy in the equine patient. None of the horses experienced any adverse events during the course of the pharmacokinetics studies as well as all maintained complete blood counts and serum biochemistry profiles within clinically normal limits. Since zonisamide was well received in healthy adult horses, it should be a consideration for use in equine patients with seizure activity as well as serve for pilot data for use in foals.
Chapter 7. Cannabinoid Pharmacology

“Just take a look with me right here…”

-Dr. Robert Judd

Cannabinoid Receptor

The endocannabinoid system has been shown to be both complex and multimodal as it plays an important role in the regulation and function of many physiological processes. Areas that have been described include both the central and peripheral nervous systems, physiologic functions (cognition, behavior, and memory), motor control, pain sensation, cardiovascular function, immunoregulation, and gastrointestinal motility (Boisselier R.L.).

The mechanism by which cannabinoids behave within the human body was developed in parallel with the discovery of the opioid receptors, and led to the discovery and identification of endocannabinoid receptors and their endogenous cannabinoid ligands. The activities of the two systems include similar inhibitory actions on nociception, gastrointestinal and cardiac function, and stress (Di Marzo V.; J. N. Hill A.J.; Hosking R.D.; Rice).

Although endocannabinoids, phytocannabinoids, and synthetic molecules all have different chemical arrangements, structure activity models have shown that these 3D protein configurations have the ability to interact with the cannabinoid receptors in a similar way. Cannabinoids can bind to at least two rhodopsin like-G-protein coupled receptors (GPCR) family A receptors: the cannabinoid receptors (CB₁R and CB₂R) as well as the orphan G-protein
coupled receptor (GPR55). When a GPCR ligand (such as a cannabinoid) activates the G-protein’s alpha subunit, GTP is exchanged for GDP which then dissociates and causes secondary signaling. Cyclic adenosine monophosphate (cAMP) formulation is inhibited by G\textsubscript{i/o} proteins leading to a decreased protein kinase A dependent phosphorylation and conversion of AMP to cyclic AMP. Binding to the cannabinoid receptor may also modulate ion channels in the presynaptic nerve by inhibiting the N- and P/Q-type calcium channels and activation of inward rectifying potassium and potassium A channels. (Boisselier R.L.; Di Marzo; Di Marzo V.; Hosking R.D.).

CB\textsubscript{1}R is mainly expressed in the brain, spinal cord, and dorsal root ganglia (Rice, 2002). In the brain, CB\textsubscript{1}R is present with a high density in the olfactory bulb, cerebral cortex, hypothalamus, hippocampus, striatum, and cerebellum. Within the spinal cord, CB\textsubscript{1}R is present in all areas associated with the processing of nociceptive information including within the superficial dorsal horn, dorsolateral funiculus, and lamina X. CB\textsubscript{1}R it is the primary receptor responsible for the psychoactivity of both the physiological effects of the endocannabinoids as well as the psychotropic effects of the exogenously administered cannabinoids (Boisselier R.L.; Grotenhermen; Hohmann A.G.; Hosking R.D.; Rice).

CB\textsubscript{1}R receptors mainly act presynaptically through a retrograde signaling system that suppresses neurotransmitter release. Endocannabinoids released from the neuron activate presynaptic CB\textsubscript{1}R which then inhibit the voltage gated calcium channels and reduces the release of both excitatory (glutamate) and inhibitory (GABA) ligands. Depending on the dose and affected brain regions, researchers have determined that interactions of the endocannabinoids and GABAergics cells may be crucial in the regulating motor response, anxiety, as well as abuse and dependence to drugs or alcohol by modulating the effects of the nicotinic cholinergic system.
Through activation of the CB₁R, N-methyl-D-aspartate (NMDA) receptor activity is decreased, resulting in a decrease in the excitotoxicity (Boisselier R.L.; Grotenhermen; Hohmann A.G.; Hosking R.D.; Rice).

CB₁R receptors are also found to a lesser extent in the peripheral tissues including cardiovascular, gastrointestinal, reproductive, musculoskeletal, and skin. In the enteric nervous system, CB₁R activation has been shown to inhibit gastric acid secretion, cause relaxation of the lower esophageal sphincter, decrease intestinal motility, and mediate the effects of visceral pain as well as inflammation. In the cardiovascular system, CB₁R helps to mediate the heart rate as well as blood pressure. In the kidney, activation of the CB₁R plays an important role in renal physiology by regulating vascular hemodynamics and stimulating ion movement in different areas of the nephron (Boisselier R.L.).

Anandamide (AEA) was the first endocannabinoid to be isolated and found to be widely distributed in the porcine brain. AEA binds to the CB₁R acting like as a partial agonist at low concentrations and a full agonist at higher concentrations. Degradation of AEA occurs postsynaptically and at intracellular membranes into arachidonic acid and ethanolamine by fatty amide hydrolase (FAAH) (Di Marzo; Hosking R.D.). Interestingly, 2-arachydonylglyceraol (2-AG) is present at a 170-fold higher concentration than AEA in brain, and despite a low binding affinity, acts as a full agonist on the CB₁R (Rice).

CB₂R shares between 44-66% sequence homology with CB₁R with the highest homology present in the transmembrane region (Rice 2002). CB₂R was initially identified in macrophages in the marginal zone of the spleen and was later found to be highly expressed in the tonsil. Of the circulating human immune cells, the highest concentration of CB₂R mRNA was found in the B-lymphocytes and natural killer cells, a moderate amount in monocytes, and minimal in
polymorphonuclear cells. Within the gastrointestinal tract, activation of the CB2R receptors are likely to work in conjunction with the CB1R to inhibit visceral inflammation and pain. CB2R receptors are also found in the CNS, primarily on neurons and microglia (Boisselier R.L.).

Publications have proposed that 2-AG may also be the optimal endogenous ligand for the CB2R (Rice). Degradation of 2-AG occurs post-synaptically in the cytosol and at intracellular membranes by monacylglycerol lipases (MAGLs) to form arachidonic acid and glycerol (Di Marzo; Hosking R.D.). AEA also binds to the CB2R, however, but it does not evoke an appreciable effect of receptor mediated activity (Rice).
Cannabinoid Ligands

Three major groups of ligands for the cannabinoid receptor have been characterized: endocannabinoids, phytocannabinoids, and synthetically manufactured cannabinoids. No matter the orientation of the chemical compound, all of the cannabinoids have a wide range of effects on various parts of the mammalian body depending on which receptor subtype binding affinity (Boisselier R.L.).

Endocannabinoids are produced “endogenously” by mammals but were not characterized until 1992. Several endocannabinoids have been isolated in the brain including: anandamide (AEA), 2-arachydonylglycerol (2-AG), noladin ether, virodhamine, and N-arachydonoyldopamine (NADA). Anandamide and 2-AG are the two most clearly defined endocannabinoids that have been characterized in scientific literature (Boisselier R.L.; Hohmann A.G.).

Unlike hormones that are stored in secretory vesicles, endocannabinoids are produced from calcium sensitive biosynthetic pathways that are can be stimulated. In neurons, there is an elevation of intracellular calcium caused by post-synaptic neuronal depolarization or stimulation of post-synaptic neurotransmitter release which stimulates the enzymes catalyzing the biosynthesis of AEA and 2-AG in one of two pathways. In the first pathway, pre-synaptic neurotransmitter release stimulates a post synaptic G-protein-coupled receptor (GPCR). Once the GPCR is stimulated, phospholipase C (PLC) is activated, membrane phosphatidyl inositol 4,5 bisphosphate (PIP2) is cleaved and forms inositol triphosphate (IP3) and diacylglycerol (DAG). IP3 and DAG mobilize intracellular calcium stores which activates diacylglycerol lipase to form 2-arachydonoylglycerol (2-AG). In the second pathway, post-synaptic calcium channels allow an elevation of intracellular calcium stores. Elevation in the calcium activates N-acyl transferase
(NAT) which combines with phosphatidyl-ethanolamine (PhosEA) and phosphatidyl-choline (PhosC) to create \( N\)-arachidonoyl-phosphatidyl-ethanolamine (NAPE). Phospholipase D is cleaves NAPE to make anandamide (AEA).

A total of 66 phytocannabinoid subtypes, named according to the dibenzopyran system, have been identified. Phytocannabinoids are chemicals present in the resin secreted from trichromes that are produced within the *Cannabis sativa* herb. Of the subtypes, cannabichromene (CBC), cannabidiol (CBD), tetrahydrocannabinol (\( \Delta^9 \) THC), cannabinol (CBN), cannabinodiol (CBDL), and cannabitriol (CBTL) have been evaluated in scientific literature. Within the plant, phytocannabinoids are synthesized from fatty acid precursors via a series of transferase and synthase enzymes. Once the fatty acid becomes activated, geranyl pyrophosphate acts on olivetolic acid (the phenolic precursor) to make cannabigerol (CBG). From here, \( \Delta^9 \) THC, CBD, and CBC synthase enzymes react with CBG to create their specific phytocannabinoids with pentyl side chain groups.

Interestingly, during periods of storage, \( \Delta^9 \) THC has been appreciated to be broken down to CBN (Boisselier R.L.; Grotenhermen; Hosking R.D.).

To date, the most important cannabinoids present in the plant are \( \Delta^9 \) THC, CBD, CBC, and CBG. The vast majority of scientific research has been done looking at the psychoactive tetrahydrocannabinol (\( \Delta^9 \) THC) and nonpsychoactive cannabidiol (CBD). The molecules of \( \Delta^9 \) THC as well as its metabolites are low molecular weight (~300 Da), highly lipophilic and water insoluble, with an octanol:water partition coefficient ranging from 6,000 – 9,440,000. (Boisselier R.L.; Grotenhermen; Hosking R.D.).

Cannabidiol (CBD) was the first phytocannabinoid to be isolated from the *Cannabis* plant in 1930-1940s. In 1960s, CBD was employed as an anticonvulsant due to having similar
pharmacologic effects as phenobarbital and diphenydantion (DPH) (P. L. Mechoulam R.; Reddy). Besides anti-convulsant effects, CBD has been used for its anxiolytic, anti-psychotic, and anti-nausea effects.

The psychotropic effects of marijuana are produced by the phenols of Δ9 THC. Within the Cannabis sativa plant, the Δ9 THC is present as a ratio acids and phenols. The ratio of Δ9 THC acids to phenolic Δ9 THC phenols present within the leaves and flowers varies depending on the location as well as climate where the plant was grown (Grotenhermen; P. L. Mechoulam R.; P. M.-R. Mechoulam R.).

In the 1970s, synthetic cannabinoids were developed as probes to help investigate the endogenous cannabinoid system. However, since the 2000s, they have been found to have elaborate popularity in recreational drug use with extensive abuse as an alternative to phytocannabinoid use (Boisselier R.L.).

One way to differentiate cannabinoids is to evaluate their affinity and selectivity for each of the receptors. Table 1 describes the receptor affinity for each group of cannabinoids. CBD has very low affinity for the cannabinoid receptors; however, it serves as an antagonist for CB1R and CB2R agonists.
Table 7.1. Cannabinoid and receptor relationships with corresponding response.

<table>
<thead>
<tr>
<th>Cannabinoid</th>
<th>Type of Cannabinoid</th>
<th>CB1R Affinity</th>
<th>CB2R Affinity</th>
<th>Receptor Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>2-Arachidonoyl glycerol (2-AG)</td>
<td>Endocannabinoid</td>
<td>Low – High (depending on authors)</td>
<td>High</td>
<td>Agonist</td>
</tr>
<tr>
<td>Anandamide (AEA)</td>
<td>Endocannabinoid</td>
<td>Good (Agonist)</td>
<td>Poor</td>
<td>Agonist</td>
</tr>
<tr>
<td>Δ9 THC</td>
<td>Phytocannabinoid</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Partial Agonist (CB1R)</td>
</tr>
<tr>
<td>CBD*</td>
<td>Phytocannabinoid</td>
<td>Low</td>
<td>Low</td>
<td>Agonist</td>
</tr>
<tr>
<td>Various</td>
<td>Synthetic Cannabinoids</td>
<td>Stronger Affinity than Endo and Phyto</td>
<td>Stronger Affinity than Endo and Phyto</td>
<td>Agonist</td>
</tr>
</tbody>
</table>

*may interact with other targets
Pharmacokinetics of Cannabinoids

Pharmacokinetic evaluation of the cannabinoids is challenging for many different reasons including low analyte concentrations, rapid and extensive metabolism, and differentiation of the cannabinoids from normal matrix of the animal (Huestis).

Absorption

The absorption characteristics of both Δ9 THC and CBD have been described after various routes of administration in people and dogs. Each of these are described below.

Intravenous

People - A double-blind, randomized, and placebo control study has been used to investigate the pharmacokinetic and pharmacodynamic responses of intravenous administration of Δ9 THC in humans. Patients in this study were administered 0, 2.5 and 5 mg of Δ9 THC. After 10 minutes, the peak plasma THC concentrations were 82±87.4 (2.5 mg) and 119.2 ±166.5 (5 mg) (Huestis). Radiolabeled CBD was administered at a dose of 20 mg and achieved levels of 37-61 ng/mL (n = 3, mean 48.4 ng/mL). Based on the calculated area under the curve after intravenous administration, a plasma clearance of 960-1560 mL/min was determined (Ohlsson 1986).

Dogs - After intravenous dosing of 3.75-5.63 mg/kg, CBD distribution into tissues was rapid but had a prolonged terminal elimination half-life of 9 hours (Samara E.).
**Inhalation**

*People - The* time course of plasma concentration of inhaled Δ9 THC resembles intravenous administration. After only a single puff of a cannabis cigarette, Δ9 THC was detectable in the blood stream at levels just below intravenous administration – indicating that inhalation is an efficient method of drug delivery. Bioavailability varied according to depth of inhalation, puff duration, breath hold, and frequency of resulting with a range of 2-56% (Grotenhermen; Huestis). Accumulation of Δ9 THC in the lung after exposure has been documented due to the extensive perfusion to the lung and high uptake of basic compounds into lung tissue (Huestis). In Ohlsson’s study, plasma blood concentrations were compared between intravenous and inhalation administration of deuterium labeled CBD. The average bioavailability of CBD in patients after smoking was 31±13%, with a fourfold difference between routes (Ohlsson A.).

**Oral**

*People - Absorption of* Δ9 THC is slower and the plasma drug concentrations are lower than when administered either inhaled or intravenously. Vehicles of administration of the Δ9 THC may also affect absorption with evidence glycocholate and sesame oil based medium resulting in increased absorption. Based on its high octanol:water partition coefficient (estimated to be between 6,000 and 9 x 10^6 depending on the method of detection), dose, route of administration, and physiological factors all have affect absorption of Δ9 THC. Oral administration of Δ9 THC has been shown to be highly variable with peak maximal plasma drug concentrations ranging from 60 minutes to six hours with high inter and intra subject variability. Oral bioavailability of Δ9 THC has been reported to be highly variable at 4-20%. Recently,
formulation development has been evaluated to either employ the use of nanoparticles to deliver the active ingredient or to use excipients to cross link and create barrier forming polymers to protect the active ingredient and minimize first pass metabolism (Badowski; Conte R.; Grotenhermen; Huestis; Punyamurthula N.S.) CBD concentrations have been evaluated in people after oral intake at a variety of doses. Agurell detected 1.1-11 ng/mL of CBD one hour after administration of chocolate cookies containing 40 mg of CBD (Agurell S.). After administration of 5.4 mg of CBD orally, Nadulski reported CBD concentrations ranging from 0.3-2.57 ng/mL one hour after oral administration (Nadulski T.).

**Dogs** - Multiple pharmacokinetic studies have evaluated the oral administration of a CBD product. At a dose range of 7.5-11.25 mg/kg, it was originally noted that the CBD bioavailability was low and highly variable (0-19% of the dose). From this, authors concluded that it may be due to the gelatin capsule formulation as well as first pass metabolism occurring in the liver (Samara E.).

Bartner evaluated oral administration of both microencapsulated oil beads as well as a CBD infused oil at two different dosing (75 and 150 mg administered every twelve hours. In this study, the maximum plasma CBD concentration was significantly higher (649.43 and 903.69 ng/mL for dogs receiving the oil formulation than the microencapsulated beads (364.93 and 546.06 ng/mL, respectively). When comparing the pharmacokinetic results from the two doses, the overall CBD exposure appeared to be dose-proportional. The CBD oil formulation also had the smallest amount of inter-subject variability. In this study, the half-life was noted to be shorter two and three hours, in comparison to what was appreciated after intravenous administration (Bartner L.R.; Samara E.).
In a separate study evaluating a different CBD infused oil dosed orally at 2 and 8 mg/kg, the terminal half-life was determined to be 4.2 hours. In this study, maximum plasma drug concentration was determined to be 102.3 ng/mL and 590.8 ng/mL for 2 and 8 mg/kg dosing respectively (Gamble L.J.).

Oromucosal

People - On going research and development has been performed in people to evaluate cannabinoid products that may be administered in alternative routes besides inhaled and oral administration. Products administered sublingually are being designed to avoid first pass metabolism by the liver. When administered sublingually alone or in combination with CBD, there were no statistically significant difference in the mean THC maximum concentration, half-life, or AUC for either Δ9 THC or its metabolite 11-0H-THC (Huestis). Despite administration of the same concentration (25 mg) of both Δ9 THC and CBD in a sublingual formulation, the amount of detectable CBD present within the plasma was less than Δ9 THC. Interestingly, all studies used to evaluate administration of Δ9 THC or CBD administered via sublingual, buccal, oromucosal, or oral routes, have demonstrated high intra- as well as inter subject variability (Huestis).

Ophthalmic

Δ9 THC mixed with mineral oil was administered topically to the cornea of rabbits. Plasma concentrations peaked after an hour and remained high for several hours (Grotenhermen).
Rectal

*Human* – The rectal bioavailability of the cannabinoid products have been variable depending on the suppository formulation; however, administration of the products rectally reduced the first pass effect seen after oral administration. When compared to the oral route, rectal administration was found to be two times more bioavailable due to increased absorption as well as decreased effects of first pass metabolism (Grotenhermen; Huestis).

Transcutaneous

*Human* – Transdermal delivery of cannabinoids reduces the negative side effects seen with inhalation dosing and avoids first pass metabolism. Cannabinoids are highly hydrophobic, making transport across the aqueous layer of the skin the rate limiting step of the diffusion process. In comparison, the permeabilities of CBD and CBN were 10-fold higher than that of THC, indicating that the physicochemical properties of CBD may lend itself to application in this manner (Huestis). However, in humans as with mice, it appears that CBD accumulates within the stratum corneum of the epidermal layers and is not well absorbed (Barry; Lodzki M.).

*Dog* – Bartner evaluated a CBD-infused transdermal cream administered topically to the pinna of dogs after a 75 and 150 mg dose. In their study, they demonstrated that the CBD infused transdermal cream reached a significantly lower plasma drug concentration than the other two oral formulations evaluated in the study. Authors surmised that this was due to possible CBD accumulation within the stratum corneum as well as thickness of the pinna skin (Bartner L.R.).
**Distribution**

Distribution of Δ9 THC and CBD into tissues have been evaluated in people. Plasma drug concentrations reach peak highs after both intravenous and inhalation administration of Δ9 THC after 20-30 minutes and decreased to baseline after four hours. Δ9 THC has been shown to be highly lipophilic and moves rapidly from plasma into highly vascularized tissue such as liver, heart, lung, kidney, placenta, adrenal cortex, and thyroid and pituitary gland. Δ9 THC has also been shown to bind to adipose tissue which is its long-term storage site (Grotenhermen; Huestis).

**Δ9 THC –** Δ9 THC has an alkaline pKa (10.6) and is very lipophilic, both of which facilitate distribution of the molecule to the brain, fatty tissues, and lungs. Distribution of Δ9 THC has been well characterized in humans with 90% being distributed into the plasma with an initial volume of distribution of 2.5-3L indicating high protein binding. The metabolites THC-COOH and THC-COOH glucuronide have shown to have a similar protein binding characteristics as the THC parent compound (Brunet B.; Huestis).

In regularly using patients, the initial volume of distribution was found to be quite larger with a volume of distribution to be 6.38 ± 4.1 L. The increase in volume of distribution is due to persistent drug concentrations being detected in the peripheral adipose tissue of the human patient. In a repeat, consecutive dosing study evaluated in people, the ratio of fat to brain Δ9 THC concentration was 21:1 after seven days, and increased to 64:1 after 27 days of exposure. At steady state concentrations, the volume of distribution becomes significantly larger at 10 L/kg. From these studies, researchers have suggested that fatty acid conjugates of THC and 11-OH-THC may be formed which lead to the increased stability of the compounds in the fat tissue (Grotenhermen; Huestis).
In animals and people, Δ9 THC rapidly crosses the placenta whereas the two metabolites cross the placenta less efficiently. Δ9 THC has also been shown to concentrate in breast milk of humans due to the highly lipophilic nature of the milk itself (Huestis).
**Metabolism**

Protein binding, enterohepatic circulation, extensive accumulation, and prolonged release from adipose tissue contribute to the prolongation of metabolism of the cannabinoids in any species. In fact, it has been found that the rate limiting step of Δ9 THC in becoming metabolized has to do with redistribution of the cannabinoid from the adipose tissue into blood for processing in the liver.

For Phase 1 of cannabinoid metabolism, oxidative metabolic patterns dominated by hydroxylation, hydrolysis, N- and O- dealkylation, or deamination taking place on the aliphatic chains or substituted aromatic rings. From these reactions, over 80 metabolites have been identified for Δ9 THC. The major metabolites of Δ9 THC are 11-hydroxy THC (11-OH-THC) and 11-nor-9-carboxy-THC (THC-COOH). Of these metabolites, 11-OH-THC is the only one that may contribute to the pharmacological activity equal to or greater than Δ9 THC (Brunet B.; Dinis-Oliveira; Stott C.).

Secondary pathways of metabolism involve carboxylation and glucuronidation. For instance, THC-COOH is glucuronidated to 11-nor-9-carboxy-THC glucuronide. Once metabolism has been completed, multiple derivatives are assembled that will have various affinity for either the CB₁ or CB₂ receptors leading to either a perceived clinical effect, storage of the molecule, or elimination from the body. Conjugates of 11-OH-THC with long chain fatty acids are stored within tissues while other molecules will become polarized to facilitate renal clearance (Boisselier R.L.; Dinis-Oliveira; Grotenhermen). Similar to Δ9 THC, CBD is subject to extensive first pass metabolism with primary oxidation of the ninth carbon to the alcohol and carboxylic acid. However, a larger portion of the dose is excreted unchanged in the feces (Huestis).
Many studies have investigated the metabolism of cannabinoids in human hepatocytes, liver microsomes, or the fungus *Cunninghamella elegans*. From these studies, it was determined that the cannabinoids undergo extensive first pass metabolism where cytochrome P450 enzymes (CYP2C9, 2C19, and 3A4) are the primary mediators of the metabolic reactions. Each metabolic reaction is specific for the particular cannabinoids as well as the species to which the product is administered. In Stott’s study where a Δ9 THC/CBD oromucosal spray was administered in conjunction with known drugs that either had an inhibitory or induction of CYP enzymes, it was found that both Δ9-THC and CBD inhibit CYP1A1, 1A2, and 1B1 during *in vitro* analysis. Also, during the *in vitro* analysis, CBD was appreciated to be an inhibitor of CYP3A4 as well as CYP2C19; however, this was only appreciated at high concentrations (IC50 = 6-9 μM). Despite evidence of inhibition, authors concluded that it was not very likely that Δ9-THC nor CBD would cause a relevant inhibition of CYP450 enzymes at current dosing with available formulations (Stott C.).

For endocannabinoids, fatty acid binding proteins (FABPs) are responsible for transferring AEA from the membrane proteins to fatty acid amide hydrolase (FAAH) for metabolism into ethanolamine and arachidonic acid. Metabolism of 2-AG is hydrolyzed into AEA and glycerol by FAAH or monoacyl glycerol lipase (MAGL) (Hohmann A.G.; Nagarkatti P.).
Elimination

Elimination of the cannabinoid parent compound as well as metabolites have been described in terms of elimination from the plasma as well as excretion from the body.

In people, after intravenous administration of Δ9 THC, an equilibrium is reached six hours after administration between plasma and tissues. Similarly, after smoking either a low (15 mg) or high dose (34 mg) Δ9-THC cigarette, the concentration of the THC-COOH metabolite was detectable for 3.5 days (2-7 days) for the low and 6.3 days (3-7 days) for the high dose. The major reason for the slow elimination of Δ9 THC from the plasma is due to the delayed time taken for redistribution of the Δ9 THC from the tissue back into the blood. Calculation of the true elimination half-life is difficult to determine due to this delayed time of redistribution but also the low plasma drug concentration (Grotenhimen).

In one human study, after oral and intravenous administration, elimination half-life was similar for Δ9 THC (25-36 hours). Longer half-lives of THC have been appreciated in animals after higher doses and longer periods of measurement with ranges of 12.6 days with a period of observation of four weeks. However, care should be taken when interpreting whether THC could be reliably distinguished from the metabolites which may overestimate the length of the half-life.

Human studies have shown that Δ9 THC is excreted from the body as acid metabolites with the majority being excreted in feces (65-80%), 20-35% in urine, and less than 5% excreted unchanged in feces. Due to the extremely lipid soluble nature of the cannabinoids, there is a significant amount of renal tubular reabsorption, leading to low levels of excretion and a single dose of Δ9 THC may result in a detectable metabolites from three up to 12 days. This also
applies to the Δ9 THC metabolites with the primarily metabolite of THC-COOH acid
glucuronide having a half-life of 30-60 hours depending on the monitoring period (Dinis- Oliveira; Grotenhermen).

Repeated dosing of Δ9 THC has been shown to decrease renal clearance from maximum
of 1.2L/h (20 mL/min) at 100 minutes to 0.06 L/h (1 mL/min) after four days of Δ9 THC
administration. Clearance of CBD has been shown to be similar to Δ9 THC ranging from 58 – 94
L/h (960-1500 mL/min). The excretion of metabolites in urine (16% over 72 hours) is similar to
that of Δ9 THC; however, there is a higher percentage of unchanged CBD excreted in feces
(Grotenhermen).
Pharmacodynamic Effects on People

Effects of cannabis in people has been well characterized as being a sedative, anxiolytic, and induction of thought disruption. Phytocannabinoids differ in their psychoactivity with Δ9 THC having the greatest effect, cannabinol (CBN) is 90% less psychoactive, and cannabidiol (CBD) lacks psychoactivity entirely (Boisselier R.L.; Hosking R.D.). Psychotropic effects seen clinically are seen after the peak plasma drug concentrations have been achieved. Rodent studies using radiolabeled Δ9 THC have illustrated that the maximal radioactivity was reached in the brain after two to four hours, and the concentrations achieved were 0.06% of the administered dose. When translated to the human population, researchers also found that the amount of radiolabeled drug present was less than 1% of the administered dose (Huestis).

Phytocannabinoids have also been shown to protect neurons from toxic stimuli or prevent degeneration through ligand reactions with the CB receptors or mediating innate antioxidant properties on the central nervous system. Cannabidiol (CBD) has shown to have a positive effect on attenuating psychotic, anxious, and depressive behaviors (Boisselier R.L.; W. C. Hill A.J.).

Cannabinoids play a minor role in vascular function in the normal patient; however, profound effects may be appreciated in patients with altered cardiovascular disorders. Cannabinoid use increases myocardial oxygen demand which could induce several cardiac adverse events including myocardial ischemia, coronary thrombosis, and vasospasm (Boisselier R.L.).

Tolerance to cannabinoid administration has been appreciated in people receiving 30 mg of Δ9 THC every four hours for 10-12 days. In the tolerant state, few pharmacologic changes
were noted with the exception of increased clearance (605 to 977 mL/min) and initial volume of distribution (2.6 to 6.4 L/kg).
Pharmacodynamic Effects on Dogs

Recently, Gamble conducted a randomized, placebo-controlled, veterinarian and owner blinded cross over study in osteoarthritis (OA) affected dogs that were administered CBD oil (2 mg/kg) or placebo oil every twelve hours for 4 weeks. Veterinary assessments and owner questionnaires were performed at baseline as well as at weeks two and four of treatment. In this study, there were no observable side effects and the canine brief pain inventory and Hudson activity scores showed a significant decrease in pain and increase in activity (Gamble L.J.). This was the first documented study in scientific literature documenting a desirable pharmacodynamic response to treatment with a cannabinoid.
Chapter 8. Pharmacokinetic and pharmacodynamics characterization of a CBD oil in the horse after oral and transmucosal administration

“Come to the dark side, we have cookies”

-Dr. Jennifer Taintor

Abstract

The purpose of this study was to describe the disposition and time course of drug concentrations of CBD and Δ9 THC when administered transmucosally to healthy horses. Under fasted conditions, thirteen healthy adult horses were administered a cannabinoid oil (0.1 mg/kg) transmucosally. Whole blood was collected intermittently for 72 hours post administration. Pharmacodynamic variables were evaluated for indication of sedation over the course of 24 hours after administration. Cannabinoids were quantitated in equine serum using liquid chromatography-tandem mass spectrometry triple-quadrupole (LC-MS) and time versus concentration data was subjected to non-compartmental pharmacokinetic analysis. Descriptive statistics were reported for measurable parameters. All animals appeared to tolerate the cannabinoid well at the dose administered. After transmucosal administration, C\text{max} was 27.2 (13 - 53.9) ng/mL at T\text{max}: 2.9 (1.9 - 4.3) hours. MRT and disappearance half-life were 18 hours (11-94 - 28) and 15 hours (9 - 25), respectively. AUC was 247.1 (166.1 – 367.8) ng/mL/hour.

Cannabinoid oil (0.1 mg/kg) was well tolerated for administration to horses; however, the dose appears to be too low to evaluate pharmacodynamics effects. However, initial pilot data using oral administration of a cannabinoid “cookie” was well tolerated at 14 mg/kg twice daily for seven days.
Introduction

Changes in the regulation of products containing cannabinoids has led to an increase in their medical use (Krietzer 2009; Burns 2006). Cannabidiol, a cannabinoid derived from the *Cannabis* plant is not associated with the adverse psychotropic effects typical of tetrahydrcannabinoid (Δ9 THC) yet may maintain many of the therapeutic benefits of THC. Passage of the 2014 and 2018 Farm Bills should lead to path for the legal use of cannabidiol (CBD) derived from industrial hemp, thus increasing medicinal cannabinoid use. Industrial hemp was defined by the 2014 Farm Bill to be *Cannabis sativa* plants that contain not more than 0.3% Δ9 THC or other tetra cannabinoids on a dry matter basis. The 2018 Farm Bill removes CBD derived from industrial hemp from regulation by the Drug Enforcement Agency and legalizes it from the federal standpoint throughout the United States. However, marijuana or any cannabinoid constituents that are not approved by the Food and Drug Administration as a drug and are derived from marijuana remain Schedule 1 drug with the DEA. For Industrial Hemp, the Secretary of the United States Department of Agriculture has been charged with developing procedures and protocols whereby a crop and subsequent products containing CBD have been verified to originate from an industrial hemp cultivar of *Cannabis sativa*. Once this pathway is established, veterinarians should expect clients to treat animals with industrial hemp oil products. Indeed, currently supplements comprised of non-psychotropic cannabinoids are being marketed specifically for equine patients to treat pain arising from: musculoskeletal pain (osteoarthritis, lameness associated with soft tissue injury, or laminitis and/or visceral (diarrhea, colic, enteritis, and pleuropneumonia).

The efficacy and potency of cannabinoids in producing anti-nociception comparable to that of morphine and has been the driving force for evaluation of this product for pain control in
the equine patient (Hohmann A.G.). However, multiple challenges exist regarding the scientific basis for use of cannabidiol in horses. In the absence of mandated premarket assessment, the quality of products in terms of content of cannabinoids (both strength and specific chemicals), other herbal-based pharmacologically active ingredients (e.g., terpenes, flavonoids) and potentially detrimental compounds (i.e., herbicides, pesticides, drugs) cannot be verified. Further, the disposition of the products is likely to vary both because of formulation differences as well as species differences in those factors that influence compound absorption. Among these latter concerns is the extent of first pass metabolism which is likely to vary among species. Likewise, the design of dosing regimens is dependent on the elimination half-life of the compound of interest. These and other factors can influence the amount and type of cannabinoid that causes pharmacodynamic response and as such, should be understood prior to the implementation of clinical trials that provide evidence of efficacy and safety.

The objectives of this study were to: 1.) describe in normal, healthy horses the disposition of cannabidiol (presented in a cookie or oil) after single dose oral or transmucosal administration; and 2.) Record pharmacodynamic measurements associated with specific cannabidiol serum concentrations. The data collected herein should serve as a template for future studies involving dietary supplements containing cannabidiol.
Materials & Methods

All procedures were approved by Auburn University’s Institutional Animal Care and Use Committee (IACUC).

Pilot Study

Three adult horses (528-578 kg) diagnosed with navicular syndrome by gait analysis using a Lameness Locator using diagnostic blocking (nerve and/or intraarticular anesthesia) and confirmed through radiographs were used in this study. Horses had not been treated with any intraarticular medications for six months prior to study start or any other medications for two weeks prior to study start. The day before drug administration (day 0) and at the close of the study (day 7), a physical examination, complete blood count, and serum biochemistry profile were performed. Each horse was administered cookie product containing 360 mg of CBD (14 mg/kg by mouth twice daily, 12 hours apart (morning and evening) for seven days (Canna-Biscuits for Dogs, Maple Bacon MaxCBD, Canna-Pet, Seattle, WA).

The pharmacodynamic response to therapy in this pilot study was evaluated using the Lameness Locator which is a body mounted, inertial sensor system that objective analyzes horse gait at a trot on a flat surface. Evaluations were performed at baseline and daily during the course of treatment. Whole blood samples were collected at two and 12 hours after each dose.

Harvesting of serum and serum cannabinoid analysis was performed as described below. Neither Δ9 TCH nor CBD were detected at any time point in any horse during the 7 day period. A small amount of CBC was detectable. No animal demonstrated improvement in lameness. Based on this, authors were led to believe that horses may be similar to humans and the cannabinoids undergo first pass metabolism, thus leading to decreased levels being present in the
Authors used this pilot study to develop as a foundation for selecting a formulation as well as dose that would more likely yield quantifiable levels of CBD.

*Animals*

Adult apparently healthy adult geldings (n=13) weighing at least 450 kg were studied. The sample size was determined to be sufficient to define, with 95% confidence, the true population mean of either the area under the curve or $C_{\text{max}}$ with an interval that varies by 40% around the mean. The day before drug administration (day 0), a physical examination and complete blood count and serum biochemistry profile were performed to identify potential underlying systemic disease. Horses were fasted for eight hours prior to and two hours after dosing.

*Sample Collection*

Immediately prior to drug administration, an eight cm diameter area in the jugular groove was clipped and prepared in an aseptic manner for five minutes using a chlorhexidine solution and isopropyl alcohol for sample collection purposes. A small local area of the skin was anesthetized for catheter placement using 2.0 mL of 2% lidocaine solution. A 14 gauge 5.5 inch intravenous catheter (MILA 14 G, MILA International, Florence, KY) was placed in the left jugular vein using sterile technique.

Each horse was administered a dose of 0.1 mg/kg CBD contained in hemp oil (12.6 mg CBD/mL). An aliquot of the oil was held for analysis to confirm cannabinoid content. The dose (ranging from 3 to 4 mL) was applied topically over the maxillary mucosa proximal to the incisors and in the interdental space to avoid oral ingestion.
Whole blood (20 mL after five mL waste) was collected via the catheter into heparinized tubes (BD Vacutainer, Sodium Heparin, BD, Franklin Lakes, NJ, USA) at 0 (prior to dosing), and 5, 15, 30, 45 minutes 1, 1.5, 2, 4, 6, 8, 10, 12, 16, 24, 36, 48, 60 hours after dosing. After sampling, the catheter was flushed with five mL heparinized saline (Monoject PreFill IV Flush, Cardinal Health, Dublin, OH). After the 24 hour sample was collected, the IV catheter was removed and the whole blood collected from the jugular vein through venipuncture with a 20G 1.5 inch needle and syringe (Monoject, Cardinal Health, and Dublin, OH, USA). Blood samples were separated into their components (packed red blood cells and serum) by centrifugation at 1900 g (3000 rpm) for 15 minutes and serum was stored at -80°C until samples were processed.

**Pharmacodynamic Assessment**

These pharmacodynamic evaluations took place at baseline, 1, 6, 12, and 24 hours after administration. Pharmacodynamic responses evaluated included sedation, ataxia, response to stimuli (auditory and touch), as well as avoidance reactions to mechanical stimuli. Responses were evaluated in all horses the day prior to the study (baseline) and at three different time points after administration of the CBD oil (1, 6, 12, and 24 hours after administration).

The degree of sedation was based on physical examination, and specifically heart and respiratory rates as well as the height of the lowest point of the lower lip from the ground (T. P. Love E.J.). The degree of ataxia was assessed on a four point numerical scale: no change from normal non sedated state (0); stable but swaying (1); swaying and leaning against the wall (2); swaying, leaning on the wall with carpi flexed and/or hind limbs crossed (3). Finally, the horses’ response to auditory stimulation (hand clap 60 cm from head) and touch (running hand from ears to shoulder) was assessed in a similar numerical scale: no reaction (0), slight head movement
with no limb movement (1), vigorous head movement with no limb movement (2), vigorous head movement with movement of one or more limb (3). Nociception was assessed by applying a pressure algometer with a 1 cm$^2$ rubber plunger tip perpendicularly to mid cannon bone as well as along the axial spine at approximately 10 kg/cm$^2$/s over two to three seconds until a local avoidance reaction is elicited. Avoidance reactions included would be skin twitching (1), local muscle fasciculation (2), lifting of the thoracic limb (3), or stepping away from the pressure (4) (Haussler; M. J. Love E.J.; T. P. Love E.J.).

During the course of the study, the horses were closely monitored for the most common signs of marijuana toxicity following ingestion include bradycardia, hypotension, depression, ataxia, hypersalivation, weakness, hypothermia and seizures (Donaldson).

Sample Analysis

Horse serum was analyzed for CBD as well as $\Delta_9$-THC using a liquid chromatography-tandem mass spectrometry triple-quadrupole (LC-MS) (Ammann J.; Raharjo T.J.). The UHPLC=MS system consisted of an Agilent 1290 system coupled with an Agilent 6460 Triple Quad Mass Spectrometer (Agilent Technologies, Santa Clara, CA, USA) equipped with an electrospray ionization (ESI) interface. Separation was achieved with a Zorbax Eclipse Plus C18 column (Agilent Technologies, Santa Clara, CA, USA). The mobile phase consisted of 0.1% Formic Acid and acetonitrile (VWR®, Radnor, PA, USA) with the flow rate set to 0.5 mL/min.

Cannabinoid standards for product analysis and for serum analysis were made by adding to either sesame oil or equine serum known amounts of following cannabinoids: CBG, CBD, CBN, $\Delta_9$-THC, and CBC. The standard curve was generated for both CBD and $\Delta_9$ THC ranging
from 0.98 to 1,000 ng/mL by fortifying equine serum with known amounts of CBD and Δ9 THC as reference standards and THC-D3 as internal standard (Cerilliant a Sigma-Aldrich® company, Round Rock, TX, USA), and accepted if the coefficient of determination (r²) was at least 0.999 and the predicted concentrations were within 20% of the actual concentrations. The cannabinoids were extracted from horse serum with solid phase extraction (SPE) cartridges (3 mL, 60 mg) (Waters Oasis® HLB, Waters Corporation™, Milford, MA, USA). Briefly, previously frozen serum samples were thawed and vortexed. The SPE cartridges were conditioned with 2 mL methanol and then 2 mL distilled water. Serum samples were prepared for solid phase extraction by combining 1.5 mL of serum with 1.5 mL of acetonitrile and 60 µL of internal standard. The tube was vortexed for 20 seconds and then centrifuged at 3000 rpm for 12 min at 5°C. Two mL of the supernatant were then loaded into the cartridge and allowed to elute by vacuum. The cartridges were rinsed with 1.0 mL of water and a vacuum of ~10 in of Hg was used to remove the residual solvent. Cannabinoids were eluted with 1.5 mL methanol which was then evaporated to dryness under a stream of nitrogen during 30 min at 40 °C. The residue was reconstituted with 60 µL of methanol, with vortex/mixing for 20 sec and then the solution was centrifuged at 14,000 rpm for 10 minutes at room temperature. Forty five µL of the clear supernatant was transferred to a sampling vial for the LC-MS. The injection volume was 1 µL. The retention time for CBD and Δ9 THC was 1.35 min and 2.39 min respectively. The LOD was established at 1.95 ng/mL and the LLOQ was 3.9 ng/mL. The lower limit of quantitation (LOQ) in equine serum currently was 25 ng/mL with < 15 % precision and accuracy
Pharmacokinetic Analysis

Serum compound concentrations versus time curves were analyzed by non-compartmental analysis using pharmacokinetic software (Phoenix WinNonLin®, Pharsight Corporation, Mountain View, California, USA). Non-compartmental analysis was performed using the linear-log trapezoidal option for determination of the area under the concentration (AUC) versus time (Phoenix WinNonlin®). From this, the following were determined: maximum serum drug concentration ($C_{\text{max}}$), time to maximum concentration ($T_{\text{max}}$), mean residence time (MRT), disappearance rate constant ($k_d$), disappearance half-life ($t_{1/2}$, determined from the relationship $t_{1/2} = 0.693/k_d$), area under the curve ($AUC_{\infty}$), percent of the AUC that was extrapolated from the terminal component of the curve, and the ratio of apparent volume of distribution ($V_z/F$). Data included geometric mean ± standard deviation and a 95% confidence interval.
Results

The CBD oil contained the following concentration of cannabinoids (mg/mL, followed by % composition) in descending order of concentration: CBD (12.6 mg/mL; 1.4%), CBC (0.77; 0.09%). Δ9-THC (0.5 mg/mL; 0.06%), CBG (0.2 mg/mL; 0.03%), and CBN (0.2 mg/mL; 0.03%).

Transmucosal dosing of the horses (3-4 mL) occurred without issue (head shaking, nose rubbing, or actively trying to lick product off gums). All horses were closely monitored up to five minutes after administration and no visible volume was lost from their mouths; however, the amount swallowed could not be quantitated.

The time course of measurable serum cannabinoids across time are demonstrated in Figure 8.1. Key pharmacokinetic parameters for the transmucosal oil (Table 8.1) were: maximum serum drug concentration (C_{max}): 27.2 (13.8-53.8) ng/mL, time to maximum concentration (T_{max}): 2.9 (1.9-4.3) hour, mean residence time (MRT): 18.3 (11.9–27.96), disappearance half-life (t_{1/2}): 15 (19-25.13) hour, area under the curve (AUC): 247.1 (166.1-367.84) ng/mL/minute, ratio of volume of distribution to bioavailability (Vd/F): 8851 (4730-16550) mL/kg, and ratio of clearance to bioavailability (Cl/F): 405 (270-600) mL/min/kg.
Table 8.1. Mean pharmacokinetic parameters for CBD when administered in apparently healthy horses (n=10).

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Geometric Mean</th>
<th>Lower CI</th>
<th>Upper CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>AUC∞ (ng/mL/minutes)</td>
<td>247.1</td>
<td>166.1</td>
<td>367.8</td>
</tr>
<tr>
<td>AUC%extrapols (ng/mL/min)</td>
<td>6</td>
<td>2.4</td>
<td>14.9</td>
</tr>
<tr>
<td>Cmax (ng/mL)</td>
<td>27.2</td>
<td>13.8</td>
<td>53.8</td>
</tr>
<tr>
<td>Tmax (hours)</td>
<td>2.9</td>
<td>1.9</td>
<td>4.3</td>
</tr>
<tr>
<td>T1/2 (hours)</td>
<td>15.2</td>
<td>9.2</td>
<td>25.1</td>
</tr>
<tr>
<td>MRT (hours)</td>
<td>18.3</td>
<td>11.9</td>
<td>28</td>
</tr>
<tr>
<td>CL/F (mL/min/kg)</td>
<td>405</td>
<td>270</td>
<td>600</td>
</tr>
<tr>
<td>Vd/F (mL/kg)</td>
<td>8851</td>
<td>4730</td>
<td>16550</td>
</tr>
</tbody>
</table>

AUC = area under the curve; Cmax = maximum serum drug concentration; Tmax = time to maximum serum drug concentration; t1/2 = elimination half-life; MRT = mean resonance time; CL/F = ratio of apparent oral clearance; Vd/F = ratio of apparent oral volume of distribution; CI = Confidence Interval (95%).
Figure 8.1. Serum equine cannabinoid concentrations (CBD and Δ9 THC) with corresponding standard deviations over the time course of the study (n=13). Data is reflected as the geometric mean and the 95% Confidence Interval. Accompanying pharmacokinetic data is found in Table 8.1.
During the course of the study, no horse demonstrated sedation, ataxia, or depressed response to auditory or touch stimuli. There was not a significant change from baseline levels of heart and respiration rates. No substantive lowering of the head to the ground occurred in any animal throughout the course of the study. All values for sedation may be reviewed in Table 8.2; Figure 8.2. There was no evidence of withdrawal response to pressure placed on the dorsal aspect of the mid-cannon bone or along the epaxial muscles at any of the time points throughout the course of the study.
Table 8.2. Evaluation of sedation for horses (n=13) over the first 24 hours after administration.

<table>
<thead>
<tr>
<th>Examination</th>
<th>Heart Rate (bpm)</th>
<th>STD</th>
<th>Respiration Rate (bpm)</th>
<th>STD</th>
<th>Lower Lip Height (inches)</th>
<th>STD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial</td>
<td>49</td>
<td>16</td>
<td>20</td>
<td>5</td>
<td>125</td>
<td>8</td>
</tr>
<tr>
<td>1 hour</td>
<td>45</td>
<td>13</td>
<td>20</td>
<td>3</td>
<td>125</td>
<td>8</td>
</tr>
<tr>
<td>6 hour</td>
<td>42</td>
<td>5</td>
<td>19</td>
<td>4</td>
<td>124</td>
<td>7</td>
</tr>
<tr>
<td>12 hour</td>
<td>42</td>
<td>4</td>
<td>17</td>
<td>3</td>
<td>126</td>
<td>10</td>
</tr>
<tr>
<td>24 hour</td>
<td>43</td>
<td>4</td>
<td>17</td>
<td>3</td>
<td>128</td>
<td>7</td>
</tr>
</tbody>
</table>

Heart Rate bpm = beats per minute; Respiration Rate bpm = breaths per minute; STD = standard deviation
Figure 8.2. Evaluation of sedation and serum CBD concentration for horses (n=13) over the first 24 hours after administration in graphical form.
Discussion

Pain management in the equine patient is a major concern to owners and veterinarians as it impacts the animals’ quality of life. The first line of defense for pain management in the equine patient is the use of NSAIDs, such as phenylbutazone, or more recently COX-2 selective products such as firocoxib. Despite their improved safety, use of newer NSAIDs, including the coxibs, are potentially associated with life threatening adverse drug events. Because their use inhibits prostaglandin production, a decrease in gastrointestinal mucosal blood flow, mucous production, and increased hydrochloric acid secretion can result in gastric and intestinal ulceration. Adequate blood flow to the gastric mucosa is critical for preventing ischemia and subsequent hypoxia induced-cellular acidosis and release of enzymes which may damage the cell membrane leading to necrosis (Videla R.). Diarrhea secondary to recommended, overdose, or chronic use of NSAIDs has also been well documented experimentally and retrospectively. Other side effects implicated in the use of NSAIDs include renal papillary necrosis (Chapman).

The mechanism by which Δ9 THC behaves within the human body was developed in parallel with the discovery of the opioid receptor, and led to the discovery and identification of endogenous cannabinoid ligands and their respective endocannabinoid receptors (Di Marzo; Di Marzo V.; Hosking R.D.). Similar to opioids, endogenous endocannabinoid ligands are capable of acting as agonists or antagonists on their corresponding receptors (Di Marzo). Activation of CB1R receptors causes inhibition of voltage-activated calcium channels, reducing the release of excitatory (acetylcholine) and inhibitory (GABA) neurotransmitters. Clinically, this produces a variety of clinical effects, including inhibition of nociception (sensation and pain), decreased gastrointestinal and cardiovascular function, and anxiety (Pinto L.).
Pharmacokinetic evaluation of the cannabinoids is challenging for many different reasons including low analyte concentrations, rapid and extensive metabolism, and differentiation of the cannabinoids from normal matrix of the animal (Huestis). In people, oral administration of the Δ9 THC and CBD has been shown to be highly variable with peak maximal serum drug concentrations ranging from 60 minutes to six hours with high inter and intra subject variability. Also, Δ9 THC oral bioavailability has been reported to be highly variable at 4-20%. Vehicles of administration of the Δ9 THC may also affect absorption with evidence glycocholate and sesame oil based medium resulting in increased absorption. In this study, it appears that horses also reach maximal serum drug concentrations between 1.9 and 4.3 hours, which is similar to what has been reported in dogs (Badowski; Conte R.; Gamble L.J.; Grotenhermen; Huestis; Punyamurthula N.S.).

Many studies have investigated the metabolism of cannabinoids in human hepatocytes, liver microsomes, or the fungus Cunninghamella elegans. Using these studies, it was determined that the cannabinoids undergo extensive first pass metabolism where cytochrome P450 enzymes (CYP2C9, 2C19, and 3A4) are the primary mediators of the metabolic reaction. In horses, the CYP3A subfamily, coded by six functional and one pseudo gene, contains significantly more members than people. Each metabolic reaction is specific for the particular cannabinoids as well as the species to which the product is administered. In a comparative study evaluating human-horse sequence analysis, the four genes of the human CYP3A family correspond to seven potential closely linked genes responsible for cannabinoid metabolism (D. S. Schmitz A.; Z. J. Schmitz A.).

Based on the results of the current study, it appears that the dose of the CBD administered transmucosally is absorbed by the equine patient with high variability with a
prolonged half-life (15 hours). These results are consistent with what has been described in both rodent as well as human species. The low detectable levels of both CBD and Δ9 THC as well large volume of distribution appreciated in this study is indicative most likely due to the low dose administered as well as distribution of the cannabinoids to the adipose tissue of the equine patients. In further work, care should be taken when increasing the dose administered to the horse due to the long half-life. As with firocoxib administration, the canine dose is 5 mg/kg, whereas the corresponding equine maintenance dose is 0.1 mg/kg. It is this 50-fold difference in dose that allows once a day dosing in horses, facilitating owner compliance, as well as providing longer pain relief.

In both Gamble and Bartner’s pharmacokinetic studies, dogs were administered CBD infused oil dosed orally at 2, 8, 10, and 20 mg/kg with a corresponding maximum CBD concentrations at: 102.3 ng/mL, 590.8 ng/mL, 649.43, and 903.69 ng/mL, respectively (Barton M.H.; Gamble L.J.). In this study, horses received a dose of (0.1 mg/kg) with a Cmax of 27.2 (13.8-53.8) ng/mL. Using the data collected from dogs, and assuming linear and stationary kinetics, the current data set has the potential to be extrapolated to higher doses in future studies such as 2 mg/kg to parallel the canine studies.

The assay for this study was designed to look only for CBD and Δ9 THC. However, in the absence of no evidence of marked pharmacodynamics responses, this study can conclude at least at the concentrations of CBD achieved in this study, there is no evidence of abnormal physiologic responses. For further work, developers may consider also screening for the major active metabolites of Δ9 THC since there was evidence of this particular cannabinoid in the serum collected.
Cannabinoids have a combination of stimulant and depressive effects on the central nervous system with clinical effects of euphoria, talkativeness, increased perception of external stimulation, dizziness, and sedation. Phytocannabinoids have also been shown to protect neurons from toxic stimuli or prevent degeneration through ligand reactions with the CB receptors or mediating innate antioxidant properties on the central nervous system (Hill 2012). Cannabidiol (CBD) has shown to have a positive effect on attenuating psychotic, anxious, and depressive behaviors (Boisselier, 2017).

Based on the wide dispersion of the endocannabinoid receptors, applications for pain management may be expanded to both lameness and visceral studies. However, since the endocannabinoid receptors are closely related and function similarly to the opioids, caution should be used when treating patients at high dose. Clinical signs were associated with CBD concentrations ranging from 10-10,000 ng/mL (Samara E.). Any further studies should include a dose titration evaluation so as not to put patients at further risk.

Investigation into alternative products for effective management of orthopedic or soft tissue pain with minimal side effects and ease of administration is needed. While a cannabinoid product is more appealing than pure marijuana as an analgesic, data supporting scientific evaluation of these products is essential to determine the efficacy, safety, and quality assurance such that there is scientific justification for its use. Another consideration is the status of CBD in terms of state and federal DEA regulations. The legalization of industrial hemp may ultimately result in CBD products for medical use in animals, including horses. However, realistic application of this product in clinical use may be limited in horses because of the very large dose to be administered unless a different formulation is created with a higher CBD concentration. That being said, owners are able to order CBD products readily on the internet and have them
directly shipped to their home. A final consideration regarding the use of these products is the quality of formulations in the absence of regulations that mandate pre-market assessment of labeled content. Not all products are accurately labeled, and thus may contain less CBD than labeled, as well as inappropriate concentrations of Δ9 THC. This may be problematic both for assessment of efficacy and safety, but also for horses entering competitive events. Most recently, racing associations as well as USEF and FEI have banned the use of cannabinoid products in competitive animals.
Potential Therapeutic Targets of Cannabinoids

The primary drive of evaluating cannabinoids in the equine patient has been to treat pain and inflammation. However, the cannabinoids are being evaluated in many areas of pathology in human medicine that warrant review and potential evaluation for the equine market.

Central Nervous System

Use of cannabis for hyperexcitability has been documented as far back as to the Arabic scholar al-Mayusi in 1100 AD and again in the 15 century when the historian Ibn al-Bardri recorded that the cannabis "cured the epileptic son of the caliph’s chamberlain completely” (W. C. Hill A.J.).

In the 1970s, the phytocannabinoids were evaluated for their effects on seizure states using the electroshock model (MES) in hum. At that time, the studies revealed that the potency of the phytocannabinoids were as follows Δ9 THC>CBD>CBN. Although Δ9 THC was found to be the most potent, its effects on hyperexcitability disorders can be unpredictable and has been shown to have evidence of contradictory central excitement or pro-convulsant effects. CBD was also evaluated in a subset of animals using the MES, audiogenic, cobalt, picrotoxin, 3-mercaptopropionic acid, isonicotinic acid, bicuculine, hydrazine, strychnine, pentylenetetrazole (PTZ), pilocarpine, and penicillin induced seizures in murine species model for seizure generation (J. N. Hill A.J.). Authors concluded that CBD had the greatest protective index when compared to the traditional antiepileptic drug phenobarbital. When administered at a dose of >100 mg/kg CBD was effective as a nontherapeutic agent; however, when administered in combination, there was evidence of differential effects. CBD enhanced the anticonvulsant effects of phenytoin or phenobarbital but decreased the effects of chlordiazepoxide, clonazepam, trimethadione, or ethosuximide (W. C. Hill A.J.).
The contribution of CBD to treating epilepsy has not been fully elucidated and much of that is due to the poorly understood mechanism of action of CBD within the central nervous system. However, the anticonvulsant effects of CBD has been primarily isolated to the neuronal CB1R targets, resulting in alterations of glutamate release. Hill reported that CBD and CGB are sodium channel blockers at micromolar concentrations in human and murine neurons and recombinant cells; however, in their model, these effects did not relate to anticonvulsant activity (2014). Authors have also hypothesized that the overall mechanism of action of CBD in seizure control may involve a more complex system of second messengers that suppress neuroinflammation and peripheral inflammatory factors (Jones N.A.; Reddy).

In humans, there is growing evidence to support that endocannabinoids as well as the cannabinoid receptors may play a crucial role in pathology associated with patients affected by epilepsy, multiple sclerosis (MS), Alzheimer’s, Parkinson’s, or amyotrophic lateral sclerosis. In each of these neurologic pathologies, there is evidence of hyper active glial cells as well as infiltration of peripheral blood leukocytes (W. C. Hill A.J.; P. M.-R. Mechoulam R.).

Multiple sclerosis (MS), Alzheimer’s disease (AD), and Parkinson’s disease (PD) all have distinct pathologies; however, they all exhibit two similar clinical signs of inflammation and neurodegeneration. Neuroinflammation has been characterized by the activation of microglia and release of inflammatory agents and has now been determined to be a significant cause of neurodegeneration. In disease states such as AD and PD, neurodegeneration is characterized by the progressive loss of viable neurons within one or more regions of the CNS leading to specific deficits that increase in severity as the disorder progresses. In patients suffering from the autoimmune disease MS, the neurodegeneration component of the disease becomes more profound as the clinical signs become more apparent. Nabilone, a Δ9 THC
analog available in Switzerland, the United Kingdom, and Canada is labeled for use for treatment of chemotherapy induced nausea and vomiting; however, case reports are present with its use for treating spasticity in patients with MS.

There is currently very little human data available for phytocannabinoid use in neurodegenerative disorders; however, increasing amount of preclinical evaluations have shown promise that CBD may be able modulate immune cell activity in the CNS and limit oxidative stress creating in a neuroprotective effect (W. C. Hill A.J.; P. M.-R. Mechoulam R.). Sativex, the licensed formulation containing a combination of Δ9 THC and CBD, has been shown to decrease the symptoms associated with MS. For instance, Mechoulam (2002) reported that both natural and synthetic CBD suppress the production of TNF by LPS activated mouse macrophages (P. L. Mechoulam R.).

Cancer

The application of cannabinoids in the field of cancer management is restricted palliative treatment of nausea and vomiting caused by chemotherapeutic administration. The first placebo controlled study demonstrating efficacy of Δ9 THC for the treatment of chemotherapy induced nausea and vomiting was published in 1975. In humans, there are three cannabinoid agonists currently available on the market: dronabinol, nabilone, and cannabis medicinal extract. Dronabinol, a synthetically manufactured Schedule III Δ9 THC molecule is available in the United States as an appetite stimulant in patients with HIV or for chemotherapy induced nausea and vomiting. With positive response from this application, pre-clinical studies have been initiated to evaluate various effects of both Δ9 THC and CBD on various cancers. However, pharmacodynamic response to oral Δ9 THC administration is highly variable depending on the
route administered, the product used if administered orally (capsule vs. solution), as well as high intra-subject variability (Badowski; Boisselier R.L.; P. M.-R. Mechoulam R.).

Ocular

As discussed previously, the endocannabinoid system is present in both the anterior and posterior ocular tissue, including the retina. Cannabinoid products applied to topically to the produces several clinical effects including hyperemia, reduced tear production as well as intraocular pressure.

As with any translational medicine approach, careful consideration of implementation of each of these pathologies is warranted prior to use.
Chapter 9. Conclusion Chapter and Potential Therapeutic Topics

“Courage is not the absence of fear,
But rather the assessment that something is more important than fear”

– Franklin D. Roosevelt

Within the pages of this dissertation, the anatomic configuration as well as function of each of the organs within the equine gastrointestinal tract and their contributing factors to the digestion and absorption of a drug have been discussed. The gastrointestinal tract is unique in that it serves as a protective barrier from the external environment while also serving to facilitate the absorption of nutrients from the ingested food particulate. No matter if the substance is nutritional, supportive, or a drug, if administered orally, the molecule must be processed by the gastrointestinal tract prior to absorption into the blood stream. In so doing, the molecule must be able to withstand the intraluminal gastrointestinal environment (Florence).

Novel Development - Peritonitis Model

Thirteen adult healthy horses (geldings and mares), weighing approximately 900-1,300 lbs. (409-590 kg) were selected for use in this study. Horses were assigned to one of the treatment groups: Abdominocentesis only (n=1), 500 mL of balanced crystalloid solution (n=1), 500 mL balanced crystalloid solution containing 50 mL heparin sodium citrate infusion (n=2), autologous plasma infusion with 50 mL of heparin sodium citrate (n=1), autologous whole blood with 50 mL heparin sodium citrate (n=2), or 500 mL autologous whole blood without anti-coagulant (n=6). Horses were monitored with physical examinations, urine/fecal output, and
water/food consumption three times daily during the study. At days 1 through 5, post treatment, abdominal ultrasounds were performed to evaluate peritoneal fluid accumulation, gastrointestinal motility and intestinal wall thickness. Abdominal examination *per rectum* were performed daily to detect changes within the abdominal cavity. Peritoneal fluid and whole blood were also collected for a complete blood count and serum biochemistry profile in order to assess evidence of systemic response to peritoneal inflammation.

In this study, horses developed evidence of a mild, transitory inflammatory response after infusion of whole blood into the abdomen; however, levels of both nucleated cell count and total protein did not reach acceptable levels to be classified as clinicopathological peritonitis. Despite this, patients treated with whole blood showed evidence of peritoneal inflammation on ultrasonographic evaluation with decreased motility, thickened loops of small intestine, and increased/alterations of the peritoneal fluid character. Subjectively, examinations also confirmed decreased motility as increased turgidity of the wall of the large colon was appreciated during abdominal examinations *per rectum*.

Despite there not being a statistical difference between groups, the whole blood infusions (with and without the anticoagulant present) did appear to be more likely to initiate a response than the other treatments. Based on the horse’s tolerability to the various treatment modalities, further studies should be considered using larger volumes of blood to further evaluate this aseptic model of peritonitis. Increasing the infusion volume to one liter of blood should be evaluated. Also, walking or lunging the horses intermittently after infusion to increase exposure of the infused blood to the visceral structures of the gastrointestinal tract. Further studies should also monitor peritoneal pH as well as peripheral and peritoneal D-Dimer, glucose, and lactose levels as these have become valuable diagnostic aids in assessing systemic disease in the equine.
patient. In septic peritonitis, a peritoneal glucose of >50 mg/dL or peritoneal pH 7.2 with a peritoneal glucose <30 mg/dL can be highly suggestive of septic peritonitis (Auer J.A.; M. L. Delgado M.A.; M. L. Delgado M.A.).

Once the intraperitoneal fluid infusion volume has been determined to be injected to produce a reliable and predictable response in the equine peritoneum, this method should be fully validated prior to implementation and use for evaluation of drug movement, accumulation, clearance, or efficacy.

*Impact of Route and Volume on Drug Absorption in the Equine Patient*

Currently, there is not a “standard of care” for evaluating drug movement in the equine patient. Pharmacokinetic studies evaluating oral administration in horses most commonly involve administration of either a paste or liquid formulation. However, when these are unavailable, a solid dosing form of the drug (tablet or capsule) is crushed or opened and administered as a powder one of several ways: spread over grain, dissolved in a small volume of water and then administered in a syringe, or as a large volume solution via nasogastric tube.

Pharmacologically, multiple factors can affect a drug’s ability to be absorbed. In people, studies have shown the volume in which a drug is administered markedly impacts the rate (time to maximum drug concentration) and extent that it reaches systemic circulation (maximum plasma drug concentration, area under the curve, and bioavailability) (Neirinck E.). Depending on the characteristic of the drug, absorption may also be affected by the presence or absence of food in the stomach and small intestine.

Determining effects of oral drug administration has been key in developing appropriate models that predict drug concentrations in animals and people. The effects of food, drug coating,
and how the drug is administered are the cornerstones in evaluating and modeling drug movement (Mizuta H.). In the horse, oral administration either in a clinical setting or as part of research studies often varies depending on the drug, the investigator, or the circumstances under which the drug is administered.

The goal of this chapter was to investigate the impact of: route, volume, and fasting versus fed state on orally administered acetaminophen using six healthy adult horses, randomized, cross over design. All six horses received a 20 mg/kg dose of acetaminophen using two different oral routes of administration (nasogastric versus syringe), two different volumes (100 vs 1500 mL), and in the fed versus fasted state.

Administering the acetaminophen directly through a nasogastric tube with 100 mL water showed a significant increase in drug absorption over syringe administration with 100 mL. This increase in absorption and is most likely due to bypassing the issues associated with oral product administration such as product loss by delayed swallowing. Though clinically this would not be possible, in the academic arena where drug movement is often studied, this would be the most direct method of assessing drug movement without the compounding issues of administration.

Similar to people, the effect of volume of administration also affects the extent to which a drug may be absorbed as was illustrated with the comparison of NGT 100 mL vs. 1.5L. In future endeavors where drug movement is being evaluated, it would be prudent to take this into account when planning the amount of volume to be used during administration.

Animals that were non-fasted had a statistically significant increased AUC and C_{max}, both indicating that the effects of food being present in the stomach or small intestine greatly affects the absorption of drug into the blood stream. Depending on the drug structure, this may be due
to binding of the drug in food material, alteration of intraluminal pH, or decreased gastrointestinal motility and exposure of the drug to the blood stream.

In conclusion, investigators were able to establish that for the most accurate determination of oral drug absorption in the equine: animals should be fasted for eight hours prior to study initiation and administered via a nasogastric tube with the formulation (tablet or capsule) dissolved in 1.5L of water.

*Formulation Effect on Drug Absorption*

Depending on drug administration, there are often multiple steps required prior to reaching the target tissue for treating pathologies. The first step along this path is absorption of the formulation itself. Dosage forms are necessary because they: protect the drug substance from environmental influences (humidity and oxygen) or gastric acid degradation, conceal the bitter, salty or offensive taste or odor, or provide a rate controlled release from the products (Ansel). Many factors effect an active ingredient’s ability to be absorbed in a patient’s body. How an active ingredient is formulated, meaning how the drug is prepared for commercialization, takes three important factors into account: disintegration, dissolution, and diffusion. Each of these factors directly influence how the matrix is broken down and the active ingredient becomes liberated in order to be available to absorb into the patient’s body.

Dissolution of a drug from its formulation is often the slowest process of drug absorption and the rate is greatly affected by the pH of the environment within the lumen of the gastrointestinal tract. The pH of the ingesta is important to consider as most drug formulations are weak acids or bases and the aqueous solubility of these compounds are influenced by the rate of dissolution from the dosage form. Drugs that are acidic in nature are more readily dissolved
in the basic environment of the small intestine in comparison to the acid environment of the stomach. In contrast, drugs that have a basic pH will dissolve more readily in gastric fluid. A variety of preparations using binding agents, disintegrants, various salts or esters influence where the formulation is degraded and dissolved in the gastrointestinal tract. Use of polymers may also be used to coat granules or tablets that are designed to dissolve at a specific desired pH, which ultimately protects the drug from degradation in unwanted pH’s that will maximize absorption profile for the drug (Ansel; Boothe; Florence; Riviere).

The purpose of this study was to compare the bioavailability (degree and rate of absorption) of firocoxib formulated in a paste designed for horses to a chewable tablet formulated for dogs as well as evaluate therapeutic levels with clinical response. Horses (n=8) received a single loading dose of firocoxib (0.3 mg/kg) as an oral paste, chew, or intravenously in a randomized, triple cross-over study.

In contrast to horses, the elimination half-life of firocoxib in dogs is only eight hours. The longer half-life in horses impacts therapeutic use of firocoxib in several ways. First, it allows once a day dosing in horses, facilitating owner compliance, as well as providing longer pain relief. Second, the longer half-live firocoxib results in a 50-fold oral dose differential between the two species: horses are dosed at 0.1 mg/kg/day compared to 5 mg/kg/day in dogs. It is this 50-fold difference in dose that has led equine practitioners to administer the canine preparation rather than the approved horse product to equine patients. Third, the longer t_{1/2} in horses also results in different times to steady-state between the species. In dogs, firocoxib does not reach a true steady-state when using the labeled dosing interval. However, in horses, with a 40-hour half-life, drug concentrations in horses will minimally fluctuate during a 24-hour dosing interval. Furthermore, because little drug is eliminated during each interval, drug will
accumulate with each subsequent dose until steady-state is reached. Thus, the full effect of the
drug in horses will not be realized until three to five drug half-lives – or approximately five to
seven days – have lapsed once a dosing regimen is implemented. This delay to steady-state
necessitates a loading dose (0.3 mg/kg) in horses if a rapid onset in effect is desired. By
administering an initial loading dose, the patient reaches therapeutic drug levels after the first
dose and a clinical response is appreciated within the first 24 hours of treatment

This study confirmed that despite the different formulations available for firocoxib,
one administered at the same mg/kg dose, they are similarly bioavailable, and based on the
clinical samples collected, are capable of controlling both soft tissue and orthopedic pain.
This study also highlights the importance of fully evaluating each active ingredient with a full
pharmacokinetic profile in each intended species and not translating from one species to the
other without careful analysis.

Comparison of Oral to Rectal Administration

Treatment and management of severe brain injuries in horses is expensive, labor
intensive and frequently results in a grave to guarded prognosis. For immediate intervention,
diazepam and midazolam have been employed in both foals and adult equine patients. Single
seizure episode control with diazepam is effective, relatively inexpensive, and simple; however,
recurrent seizures become more difficult to manage. For long term seizure control, phenobarbital
and potassium bromide have been the drugs of choice to manage long term seizures in horses or
foals. Recently, levetiracetam has been used for seizure control in the equine patient. Serum
levetiracetam concentrations achieved are generally within the published therapeutic ranges for
dogs and cats, however, as in other species, the drug has a short half-life of six hours in horses.
This short half-life would require frequent administration which is labor intensive, as well as cost prohibitive for long term management (Cesar).

In seizing or obtunded horses, rectal administration of a drug may be necessary due to altered mentation and safety concerns (Feary D.J.). Drawbacks of rectal administration include interruption of absorption due to defecation, patient acceptability, or binding of the drug formulation to feces present within the rectum (A.G. De Bower). Ensuring that a product is capable of oral absorption after rectal administration is key to determining use in the clinical setting. The objectives of this study were to describe the disposition and time course of drug concentrations of a new antiepileptic zonisamide when administered either orally or per rectum in the healthy horse.

In this dissertation, a chapter described the disposition and time course of drug concentrations of zonisamide when administered either orally or per rectum in the healthy horse. Eight healthy adult horses were used in a randomized, crossover study under fasted conditions. Horses received zonisamide orally via nasogastric tube (20 mg/kg, PO), and per rectum (PR, 40 mg/kg) via a Foley catheter. Whole blood was collected intermittently for 72 hours post administration. Zonisamide (20 mg/kg PO) maintains serum concentrations in the human therapeutic range for 13 hours in healthy horses and might be effective for treatment of seizures. In contrast, zonisamide was not consistently detected after 40 mg/kg after rectal administration, which does not support use of this current dosing form in this route.

In both routes of administration, the serum concentrations were lower than what was expected in patients where the capsule was administered in an intact fashion, as has been studied in people and small animals (Boothe D.M.). One of the limitations in this study as well as in equine practice is the need to alter dosage forms in order to treat the patient. Further evaluation
may need to be done to look at methods to administer the whole capsules to horses in order to achieve a more accurate indication of serum drug concentrations.

Absorption of a rectal drug formulation is dependent on many factors. First, the molecular size of the drug as well as partitioning of the drug between the delivered formulation and the rectal fluid is of key importance. Several dosage forms are available for rectal delivery of drugs: suppositories (emulsion or suspension), gelatin capsules (solutions and suspensions) and enemas which are quantified by macro (100 mL) and micro (1 to 20 mL). Formulations that are aqueous or alcoholic solutions have a greater chance of being absorbed more quickly than tablet or paste formulations. The use of surfactants may also alter drug absorption. (A.G. De Bower; H. D.-E. Corveleyn S.). In equine practice, most of the formulations used are a suspension or paste which is created by dissolving the oral product (veterinary or human) in a variable amount of water (A.G. De Bower).

Inactivation of drug formulations by binding to fecal material has been suggested as a potential cause for reduced bioavailability. In a study evaluating rectal administration of an omeprazole paste, all horses defecated within the first two hours of treatment and there was macroscopic binding of the paste evident on the fecal piles. These effects as well as a small amount of drug dispensed into the rectum (5 mL) could have had a greater effect on drug absorption (Rand C. Stanley).

Despite having a low sample size (n=4) dosed zonisamide at 20 mg/kg appears to reach published human therapeutic levels and as such, might be considered as a possible alternative for treating epilepsy in the equine patient. None of the horses experienced any adverse events during the course of the pharmacokinetics studies as well as all maintained complete blood counts and serum chemistry profiles within clinically normal limits. Since zonisamide was well
received in healthy adult horses, it should be a consideration for use in equine patients with seizure activity as well as serve for pilot data for use in foals.

In further work, this zonisamide should be administered at 20 mg/kg in a paste formulation (to simulate what is done in clinical practice) and compare it to nasogastric administration. Due to zonisamide’s unique capabilities, there is potential for it to be evaluated as a therapeutic agent in neuropathic pain conditions affecting the equine patient in further clinical trials.

Further Advances in Equine Pain Management

In the 1970s, Sir William Paton began the study of the pharmacologic actions of cannabis and the cannabinoids as possible analgesic and sedative agents. Originally, thoughts were that the cannabinoids were similar in mechanism of action as to the general anesthetics and movement within the cellular membranes were determined by the chemical size and shape of the molecule. However, it was later determined that the clinical effects seen on affecting pain management were due to interaction with the CB1R and CB2R (Di Marzo).

As discussed earlier, CB1R are most densely present in the brain – hippocampus, cerebellum and striatum. However, there are several areas which could provide targets through which cannabinoids could modulate pain including the periaqueductal grey (PAG), rostral ventral medulla, superficial layers of the spinal dorsal horn as well as the dorsal root ganglion. The endocannabinoid system has also been identified in the ventral, posterior later nucleus of the thalamus which is the termination zone of the spinothalamic tract which is the major source of ascending nociceptive information to the brain (de Vries M.; Hohmann A.G.).

The capacity for cannabinoids to control pain is among the most studied responses and have been noted to be effective in both acute (phasic) and chronic (tonic) pain (Izzo A.A.) Activation
of centrally located CB₁R receptors present in the dorsal horn, lateral funiculus, and Lamina X have been specifically shown to suppress the nociceptive neurons after mechanical, thermal, as well as chemical stimulation (Hohmann A.G.; Izzo A.A.; Rice). Peripherally, CB₂R receptors, and to a much lesser extent CB₁R, have been effective in modulating the inflammatory response as well as tissue and nerve injury (Hohmann A.G.; Rand C.). CB₂R, present on both mast cells and leukocytes, play multiple key roles in the modulation of the local inflammatory response including preventing mast cell degranulation, diminishing neutrophil migration, and decreasing the release of nitric oxide from macrophages (Rice).

Cannabinoid use has been best prescribed for controlling neuropathic pain. Among these, Δ⁹ THC is the most understood as it is the main property of psychogenic producing behavior and pharmacological activity against pain (Grotenhermen; Di Marzo V.). Secondary to nerve injury, cannabinoid induced antinociception is more effective in alleviating pain than opioid drugs by suppressing wind up and noxious stimulus induced central sensitization (Hohmann A.G.; MacPherson). The mechanism of action is hypothesized to be due to loss of opioid receptors along the traumatized nerve tissue being either removed or compromised secondary to the injury, whereas CB₁R remain intact (Bridges D.; Rice). Recently, studies of the interactions between the cannabinoid and the opioid systems indicates that co-administration of two agents may produce favorable synergistic effects, and may offer a new treatment strategy for multi-modal analgesia (de Vries M.; MacPherson; Ripamonti C.).

Preliminary studies of ajulemic acid (CT-3) in rats have shown that they have anti-inflammatory activity similar to that of NSAIDs, without the gastrointestinal adverse effects, even at supratherapeutic dosages (Burns T.L.). Accordingly, hemp-based products show promise as either sole or combination analgesia. Studies have found that Δ⁹ THC: CBD extract
and Δ9-THC alone were effective in the management of pain resistant to strong opioid use in humans (Boisselier R.L.). Sativex (approximately a 1:1 mixture of Δ9 THC:CBD) was the first medicine derived from the whole cannabis plant licensed to treat pain and spasticity in multiple sclerosis (MS) patients without the negative side effects associated with Δ9-THC monotherapy. With this combination, it was found that CBD most likely inhibited the metabolism of Δ9 THC to the more psychoactive metabolite 11-OH-Δ9 THC (W. C. Hill A.J.).

Recent findings have also suggested that NSAIDs may also owe some of their therapeutic success to their interaction with the endocannabinoid system either by inactivation of proteins or by encouraging biosynthesis. Rofenicoxib, a cyclooxygenase 2 (COX-2) selective nonsteroidal anti-inflammatory, synergizes with anandamide (the endogenous agonist of CB1R and CB2R) in a positive feedback loop to further elevate levels of anandamide as well as other analgesic fatty acid ethanolamide levels (Di Marzo V.). Interestingly, after oral administration of CBD in a murine model for rheumatoid arthritis, researchers saw a diminished interferon gamma (IFN-γ), decreased release of tumor necrosis factor alpha (TNF-α), and decreased nitrous oxide (NO) (P. M.-R. Mechoulam R.; Malfait A.M.).

CBD also works as a potent anti-oxidative agent showing greater protective nature against glutamate neurotoxicity than either ascorbate (Vitamin C) or α tocopherol (Vitamin E) (P. M.-R. Mechoulam R.). These anti-oxidative effects may have explained why CBD was successful in correcting hypermotility in mice with no effects on the control population (Capasso R.). On a smaller scale, CBD has been shown to stimulate mesenchymal stem cells responsible for bone formation and fracture healing while also controlling bone resorption (Izzo A.A.).

Recent legalization of marijuana or hemp for medicinal use has been accompanied by increased interest in the implications for veterinary medicine. A supplement comprised of non-
psychotropic cannabinoids is being marketed specifically for canine and feline patients for diverse medical indications. Dietary supplements, including hemp-based products, undergo no premarket approval for quality, safety, or efficacy. Demonstrating the transmucosal disposition of this product should be beneficial for a wide variety of equine patients experiencing visceral (diarrhea, colic, enteritis, and pleuropneumonia) and/or musculoskeletal pain (osteoarthritis, lameness associated with soft tissue injury, or laminitis).

To describe the disposition and time course of drug concentrations of CBD and Δ9 THC when administered transmucosally to healthy horses. Thirteen healthy adult horses under fasted conditions horses were administered a cannabinoid oil (0.1 mg/kg). Whole blood was collected intermittently for 72 hours post administration. Pharmacodynamic variables were evaluated for indication of sedation over the course of 24 hours after administration. All animals appeared to tolerate the cannabinoid well at the dose administered. After transmucosal administration, \( C_{max} \) was 27.2 (13 - 53.9) ng/mL at \( T_{max} \): 2.9 (1.9 - 4.3) hours. MRT and disappearance half-life were 18 hours (11-94 - 28) and 15 hours (9 - 25), respectively. AUC was 247.1 (166.1 – 367.8) ng/mL/hour. Cannabinoid oil (0.1 mg/kg) was well tolerated for administration to horses; however, the dose appears to be too low to evaluate pharmacodynamics effects. However, initial pilot data using oral administration of a cannabinoid “cookie” was well tolerated at 14 mg/kg twice daily for 7 days.

In further work, transmucosal oil should be considered the formulation for use and administration when evaluating effects in the equine patient. Preliminary work has been provided within the pages of this dissertation that would allow further researchers to explore many avenues of cannabinoid effects on the equine patient, including but not limited to managing visceral and somatic pain signaling. However, in order to successfully treat the patient
as well as meet the needs of the pharmacologist, manufacturers of the cannabinoid oil would need to be able to increase the concentration to levels that would not prevent dosing to be cumbersome for the veterinarian or the client. Due to the longer half-life in the horses, the concentration increase in the formulation should be titrated to effect in further studies such that the horses are not put at risk. Also of note is careful advisement to clients of the products that they are administering. Since there is not an oversight of the manufacturing of these products currently, each product that is on the market is not the same quality or content as the other. Veterinarians should seek to know the product being administered to their patients as well as have further analysis done to ensure the composition of the product being administered.
References


